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ABSTRACT  
The thesis work deals with the development of chitosan (CS) based composite scaffold matrices with 
improved material and osteogenic differentiation property for bone tissue engineering. Pure CS and CS/ β-
TCP composite scaffolds reinforced with micro and nano sized β-TCP with different CS:β-TCP ratios 
were successfully prepared by freeze gelation method and characterized for morphological, structural, 
mechanical, swelling, wettability and degradation. Pure CS and composite scaffolds possess 
interconnected open pore microstructure with desired pore size and porosity. The compressive strength of 
CS scaffold was remarkably increased by the incorporation of micro and nano sized β-TCP. However, the 
highest compressive strength of 2.67±0.21 MPa was achieved with CS/nano β-TCP composite scaffold at 
optimal CS:β-TCP ratio of 60:40. The scaffold also exhibited favourable biodegradation and improved 
bioactivity. The biocompatibility of the scaffold is confirmed by in-vitro cell culture study using human 
mesenchymal stem cells (hMSCs) seeded on the scaffold. Conjugation with fibrin is shown to be 
beneficial for improving cellular affinity of the scaffold which is evident by the enhanced cell attachment 
(FE-SEM), metabolic activity (MTT assay), proliferation (DNA quantification) and osteogenic 
differentiation (ALP), bio-mineralization, total calcium content and expression of osteogenic specific 
genes (semi quantitative RT-PCR) of seeded hMSCs. CS/nano β-TCP scaffold was cross-linked with 
genipin (GN) and sodium tri poly phosphate (TPP) with the aim of controlling rapid degradation rate of 
CS scaffold and improving mechanical strength. Thus the developed GN cross-linked CS/nano β-TCP 
composite scaffold has shown favourable degradation (8%) and higher compressive strength (2.78±0.11) 
than the scaffold cross-linked with TPP. CS/nano β-TCP/GN scaffold was further coated with fibrin 
thereby a significant improvement of cellular responses such as cell attachment, proliferation, metabolic 
activity and osteogenic differentiation was achieved. The enhanced osteogenic differentiation ability of 
the fibrin coated scaffold was further evident by Semi Quantitative RT-PCR study that has revealed up 
regulation in the expression of osteogenic specific genes like collagen 1 (COL1), osteocalcein (OC), bone 
sialo protein (BSP), osteonectin (ON), β-actin and ALP.  In-vivo biocompatibility of the CS/nano β-
TCP/GN/F composite scaffold was confirmed by animal testing using mice model. All together, the study 
has demonstrated that the developed CS composite scaffolds in particular CS/nano β-TCP/GN/F can be 
used as potential artificial ECM (extra cellular matrix) for various non-load bearing bone tissue 
engineering applications.  
 
Key words: Chitosan, bio-ceramic, beta-tricalcium phosphate, scaffold, compressive strength, 
genipin, tripolyphosphate, fibrin, hMSCs, bone tissue engineering, osteogenesis 
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1.1 Background and significance of study 
Bone tissue defects and diseases due to the consequence of trauma, injury, infections and 
degenerative bone loss are of major concern in the field of human health [1]. Every year more 
than 1 million cases of bone injuries is reported to occur in USA alone and an alarming 
increase in number of bone injuries is expected to continue around the globe, which leads to 
high demand for bone substitutes [2]. The current clinical option for repairing bone defects 
and diseases is bone grafting which is classified as autografts and allografts [3]. Failure rates 
in these techniques are attributed to several reasons like disease transfer, immune rejection 
and donor crisis [4-5]. This has prompted a lot of research interest among the scientific 
community for an alternative  solution [6]. In this context, bone tissue engineering has 
emerged as an alternative strategy to repair and/or replace diseased and/or damaged bone 
tissue through the development of a biologically active substitute so called tissue engineered 
scaffold that offers complete recovery of original state and bone tissue function [7]. The 
development of three dimensional porous scaffold matrices from a variety of biocompatible 
polymers with a desired set of properties such as optimum degradation rate, bio-resorbable, 
non immunogenic, interconnected pores with optimum porosity, high mechanical strength and 
biocompatibility is a key challenge for the success of bone tissue engineering. Furthermore, 
scaffold must facilitate bone formation by stimulating cell adhesion, proliferation and 
regulating osteogenic differentiation of host cells [2, 8-9]. The component of natural bone 
matrix is the combination of organic, inorganic materials and a variety of proteins, the main 
type of which is collagen and apatite as biological mineral [8]. To meet these requirements, a 
lot of research interest has been generated in recent years to explore potential biopolymers 
and their composites to develop a suitable scaffold material for bone tissue regeneration. 
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Chitosan, a natural biopolymer is considered as an ideal biomaterial due to its excellent 
biocompatibility, abundant availability, intrinsic antibacterial property and biodegradability 
[9-10]. The ability of CS to bind with growth factors makes it a competent candidate for 
scaffold material [11]. Chitosan can be easily molded into different forms such as porous 3D 
structures [12], gels [13], thin films [14], membranes [15] and fibers [16] which are 
favourable for bone cell growth. However, CS has several drawbacks which limit its use as 
scaffold material particularly for bone tissue engineering. The major limitations are lack of 
sufficient mechanical strength, cell binding ability, rapid degradation and deficient of 
bioactive cell signalling molecules which are vital for bone tissue regeneration [12, 18-19]. 
Besides material and biological properties, fabrication of 3D porous scaffold is another 
important aspect that needs to be considered. In this context, freeze-gelation is one of the 
scaffold fabrication techniques which is very simple, time and energy saving [17]. Hence the 
present research focuses on the development of CS based 3D composite matrices by freeze-
gelation method to mimic the unique hierarchical architecture of bone matrix by addressing 
the above three major issues that limit the use of CS in bone tissue engineering.  
1.2 Tissue regeneration strategies 
Tissue Engineering (TE) applies biological, chemical, and engineering principles towards the 
repair, regeneration or restoration of living tissues using biomaterials, cells, and growth 
factors such as basic fibroblast growth factor (bFGF), vascular endothelial growth factor 
(VEGF) and platelet derived growth factor (PDGF) alone or in combination [18]. Usage of 
tissue engineering triad is considered as an excellent strategy for existing bone tissue related 
defects by using stem cells and bioactive molecules onto scaffold matrix [19]. TE approaches 
were classified based on triad components, either used individually or in combination [20]  as 
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(i) cell based therapies, (ii) inducing tissue regeneration by soluble bioactive factors and (iii) 
employing artificial extracellular matrix system namely scaffold. 
1.3 Applications of tissue engineering 
Tissue engineering aims at repairing damaged or diseased tissues and organs by offering long 
term cure with low cost. A new era has already begun in the field of medicine with the aim of 
solving bone tissue related defects by using the advancement of tissue engineering strategies 
[21]. The important applications of tissue engineering include cartilage [24-26], bone [11, 22-
24] skin [27-30], cardiovascular [20, 25], ligament [32-34], tendon [26-27], neural [37-39], 
liver [40-42] and musculo-skeletal [43-45] related diseases. 
1.4 Tissue engineered scaffold 
A scaffold is a temporary matrix which aids in the proliferation of cells until they attain the 
ability to support themselves. Scaffolds hence degrade after a certain period of time 
permitting the formation of new tissue. 
1.4.1 Properties of scaffold 
Structural property 
Pore size: Scaffold should have interconnected network of pores and desired pore size for 
proper diffusion of nutrients and exchange of metabolic wastes thus facilitates the cells to 
grow, proliferate and differentiate into specific lineage [28-29]. The pore size varies 
depending on specific tissue engineering applications such as bone tissue (50-300 µm), 
cartilage tissue regeneration (150-300 µm) [8, 30-31]. 
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Porosity: Scaffold should have optimum porosity to facilitate nutrient diffusion and allow cell 
migration. It should not be highly porous which ultimately decreases the mechanical strength 
of the scaffold [32-33]. 
Mechanical property: 
Scaffold must possess mechanical strength that matches with the target tissue to avoid shear 
stress at the site of implantation [34-35]. The scaffold should be finely tuned for lineage 
specific differentiation [36]. 
Biodegradability:  
The scaffold must be biodegradable. The rate of degradation should match with the rate of 
new tissue formation without release of any toxic by products. Furthermore, scaffold should 
not solubilise rapidly during tissue regeneration process [14, 37].  
 
Bioactivity: 
 Scaffold should form and deposit apatite crystals in both in-vitro and in-vivo environments 
[38-39]. 
 
Surface property 
Hydrophilicity: Hydrophilicity is the ability of getting wet by a biomaterial which plays a 
crucial role in governing cell responses especially cell attachment, cell growth and 
proliferation. Reports suggest higher hydrophilic surfaces of scaffold matrices are responsible 
for improved cellular attachment where as relatively hydrophobic surfaces are essential for 
improved protein adsorption [36, 40]. 
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Biocompatibility:  
Scaffold material and its degraded products should not be toxic and non-immunogenic in both 
in-vitro as well as in-vivo conditions [21]. 
 
 
Tissue inductive property:  
The scaffold should promote cell attachment, spreading, migration, proliferation and 
differentiation of particular phenotypic tissue as needed [21]. For example, scaffold must have 
osteoinductive and osteoconductive property essential for bone tissue engineering. 
Osteoinduction is the ability to attract the osteoprogenitor cells to the bone healing site in 
order to undergo differentiation [32]. Unfortunately lack of such osteoinduction property is 
found in majority of the natural polymers [11]. Therefore it is preferable to choose a scaffold 
system with innate osteoinductive properties for better performance at the healing site.  
1.4.2 Biomaterials for scaffold development 
In order to achieve desired cell growth and proliferation, the artificial extracellular matrix 
(ECM) i.e. scaffold is a prerequisite for any tissue engineering application including bone 
tissue regeneration [41]. Scaffolds should provide required structural support to the host bone 
cells and facilitate cell adhesion, spreading, proliferation and finally osteogenic differentiation 
[21]. Designing of a temporary scaffold matrix with a desired set of properties such as 
optimum degradation rate, bio-resorbable, non immunogenic, interconnected pores and 
optimum porosity, high mechanical strength and biocompatibility is one of the most 
challenging tasks in the area of bone tissue engineering [5]. In this context, biopolymers are 
considered as ideal biomaterial for scaffold development and they are classified as natural and 
synthetic polymers. 
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1.4.2.1 Natural polymers 
Natural polymers are obtained from natural sources such as animal (chitosan-crustacean 
shells) or vegetal (cellulose-plants) and have been reported to create a better environment for 
cell growth, spreading and proliferation [42]. Scaffolds from natural polymers have been 
extensively studied in the last decade. Collagen [43], chitosan [44], gelatin [45] and silk 
fibroin [46] are found to be important polymers for various tissue engineering applications. 
The degradation products from these natural polymers do not offer any apparent immune 
reactions. Further, Majority of these polymers are hydrophilic which makes them suitable for 
cell culture studies [2]. However, in most of the cases, single polymer does not possess all the 
desired characteristics of tissue engineered scaffold. Natural polymers lack shape retention 
ability due to excess swelling and poor mechanical strength that restrict their use in bone 
tissue engineering applications [47]. 
1.4.2.2 Synthetic polymers 
Synthetic polymers have increased applications as they are well defined with reproducible 
mechanical and physical properties such as tensile strength, elastic modulus and degradation 
rate [48]. Typical biodegradable synthetic polymers for biomedical use are hydrophobic 
polyesters such as poly lactic acid (PLA) [49], poly lactic glycolic acid (PLGA) [50], poly 
glycolic-co-lactic acid (PGLA), poly3 hydroxy butyrate (PHB),  poly 3 hydroxy valerate 
(PHV), poly ortho esters, poly α-hydroxyl acids, polycaprolactone (PCL) and poly urethane 
(PU) [51]. The major drawback of these synthetic polymers is their degradation products 
which are toxic and thus harmful to the cells. For example, PLGA and PGLA release lactic 
acid and glycolic acid which enter tri carboxylic acid cycle thus creating imbalance in cell 
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metabolism [32]. Further, these degradation products have been reported to cause 
inflammation at the site of implantation [19]. 
1.4.2.3 Ceramics 
Ceramics such as hydroxyapatite (HAp) [52], tri-calcium phosphate (TCP) [50, 53], biphasic 
calcium phosphate (BCP) [21] and wollastonite [54] have been studied to develop composite 
scaffolds for bone tissue regeneration. The composite scaffolds are characterized by high 
mechanical strength and enhanced osteogenic property. In bone tissue engineering, they 
exhibit chemical and structural similarity to the mineral phase of native bone and enhance 
osteoblast differentiation and proliferation [70-71]. The application of ceramics is common in 
dental [40], maxillofacial and orthopaedic surgery for filling and coating implant surface of 
host bone [55]. However, their brittleness and difficulty in remodelling limit their clinical 
application of scaffold based bone tissue regeneration. Though bio-ceramics are equally 
strong in their mechanical behaviour, they are deficient in supporting cell growth [52]. It is 
therefore interesting to note that the combination of biopolymer and bio-ceramic (polymer-
ceramic composites) can provide suitable platforms with enhanced cell supportive property 
and mechanical strength [72-74] for bone tissue regeneration. 
1.4.2.4 Composites 
Composite materials can be defined as a material composed of two or more distinct phases 
such as metallic, ceramic and polymeric, which are separated by an interface [56]. By taking 
advantage of this combining concept, many researchers have given efforts in developing 
composite materials for tissue engineering to enhance mechanical properties and cellular 
function. Generally, polymers are known to be flexible and exhibit lack of mechanical 
strength and stiffness [57]. However, polymers are simple to mold and can easily form 
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complex structures, while ceramics are stiff and brittle [9]. Composites aim to combine the 
desired properties of both materials to enhance tissue reconstruction. For example, a natural 
polymer chitosan is a known for its excellent biocompatibility but lacks sufficient mechanical 
strength in order to use in bone tissue regeneration [47]. Similarly, a robust biopolymer, silk 
fibroin, though mechanically stable, lacks hydrophilic property. Considering these, polymer 
composite or polymer blend biomaterials, have been developed to combine the desired 
characteristics of both polymer and/or bio-ceramic to overcome the drawbacks of individual 
polymer or ceramic [29]. Fabrication of such composite scaffolds is one of the  promising 
efforts towards successful bone tissue regeneration [58].  
1.4.3 Scaffold fabrication techniques 
The search for an ideal biomaterial has been under progress since the conception of tissue 
engineering. Much significant development has been witnessed in recent years which include 
an assortment of scaffold fabrication techniques and various polymers. The potential for 
scaffolding techniques are still in their burgeoning stage and need to be established further to 
achieve excellence. Each method is unique in terms of its principle and working conditions. 
Depending upon the requirement and application, fabrication techniques differ. Various 
methods currently in use for scaffold fabrication include electrospinning, phase separation, 
solvent casting, particulate leaching, gas foaming, rapid prototyping etc [58-59] which are 
described below. 
1.4.3.1 Salt leaching 
Salt leaching developed by Mikos et al. in the year of 1994 [60], is relatively simple method 
used to develop porous scaffolds. This process involves the addition of soluble salt particles 
as porogen in polymer solution and casting into suitable molds [61-62]. After evaporation of 
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the solvent, the salt particles are removed by leaching thereby porous scaffolds are formed. 
The major drawbacks of this method are poor interconnectivity, lower mechanical strength, 
difficulty in controlling  porosity and usage of high toxic solvent [63]. However, by 
controlling the size of the salt particle, it is possible to tailor the properties of the resultant 
porous structure [64-65].  
1.4.3.2 Gas foaming 
Gas foaming is a unique method to produce porous matrices. This method can produce porous 
materials without the interference of any solvent [66]. Carbon dioxide is the most commonly 
used gaseous agent for the formation of porous foam. Polymer disks at their solid state are 
subjected to CO2 environment where gas bubbles are allowed to form in the polymer system, 
thereby creating porous sponges. The disadvantages of this method include need of 
specialized equipment to handle high pressure CO2 and the process is limited to very few 
polymers [61]. 
1.4.3.3 Thermally induced phase separation (TIPS)  
Thermally induced phase separation is defined as the separation of solid-liquid or liquid-
liquid phases which can be triggered by thermal changes [59]. In this method the temperature 
of the polymer solution is lowered to bring about phase separation thereby forming polymer-
rich and polymer-lean phases. Once the phase‐separated system is stabilized, the solvent‐rich 
phase is removed by sublimation using vacuum leaving behind the polymer as foam [67]. 
Polymer-solvent phase separation can be divided into liquid-liquid and solid-liquid phase 
separation. Phase separation, which avoids harsh chemical or thermal environments, has been 
utilized to incorporate small bioactive molecules into scaffolds [68]. The advantage of this 
method is that the scaffolds often have good mechanical property compared to salt leaching 
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technique [69]. The optimal pore size and  morphology can be achieved by a suitable choice 
of processing conditions such as quenching temperature, concentration, molecular weight of 
polymer, solvent/non-solvent composition and additives [70]. Though the process is simple 
and cost effective, the major limitation lies with precise control over pore size of developed 
scaffolds [59].   
Liquid– liquid phase separation 
Phase separation occurs in a liquid-liquid solution by decreasing temperature to an upper 
critical solution temperature. The addition of a non-solvent to the polymer solution may 
induce liquid-liquid phase separation thus forming polymer rich and polymer lean phases 
[71]. The scaffolds prepared by this method offer open pore structure after the removal of 
excessive solvent.  
Solid-liquid phase separation 
Solid-liquid phase separation occurs when the temperature is lowered to freeze a polymer 
solution and the solvent in the system forms crystals and polymer is separated from the 
solvent crystallization front [72]. This process takes place by a nucleation and growth 
mechanism. Interconnected pores are generated after the removal of solvent crystals by 
sublimation or solvent exchange [73]. Thus porous structures can be formed by freezing 
polymer solution, followed by solvent removal by either freeze drying or freeze-gelation [74], 
which are described below.  
(i) Freeze-drying: Freeze-drying works on the principle of thermally induced phase 
separation. During this process, the phase-separated mixture is maintained at low 
temperatures and subjected to a high vacuum to sublime the solvent [75]. Pores are generated 
by the removal of ice crystals of solvent formed within the polymer solution. These solvent 
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crystals serve as porogen whose size can be easily controlled by adjusting freezing 
temperature and concentration of the polymer solution [72]. The main drawbacks of freeze 
drying include scaffolds with low mechanical strength, smaller pore size and difficulty in 
complete removal of the residual solvent [76]. 
(ii) Freeze-gelation: Freeze-gelation is a unique method of scaffold fabrication, which 
involves the principle of thermally induced phase separation. Problems encountered with the 
freeze drying process are destruction of pores in scaffold and formation of surface skin which 
are overcome by freeze-gelation method [77]. The main advantage of freeze-gelation process 
is its simplicity. The frozen polymer solution is immersed in a gelation environment at a 
temperature lower than the freezing point of polymer solution [78]. In this technique, since 
the polymer matrix becomes gel before the drying stage, the porous structure is retained 
without freeze-drying. The formation of ice crystals within the solution occurs at 273 K, but 
gelation does not occur until the temperature reaches a few degrees below freezing (~270 K). 
After freezing, the gel is warmed to melt the ice crystals and then dried. This causes a 
relatively high degree of continuous porosity with pores duplicating the morphology and 
dimension of the ice crystals formed during the freezing process [15]. This method overcomes 
the limitations of freeze drying and sol-gel processing. It permits the formation of low-cost, 
crack-free, essentially zero-shrinkage scaffolds [79]. Freeze-gelation has been used in wide 
areas of tissue engineering applications by using natural, synthetic polymers and their 
composites such as CS [78], silk [17], CS/β-TCP [10], CS/PGA [68] and CS/alginate/carboxy 
methyl cellulose [74]. 
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1.4.3.4 Electrospinning  
Electrospinning is a method to generate nanofibers from various biomaterials. Electrospinning 
is a widely used technique that utilizes electric field to facilitate the formation of polymer 
deposits over a suitable collector [50, 100-102]. The polymer solution is induced using a 
strong electric potential due to which it acquires an imbalanced charge. After a critical voltage 
is attained, surface tension of the polymer solution is overcome by the charge imbalance 
leading to an electrically charged jet. This jet is focussed towards a target which is grounded. 
After solvent evaporation, nanofibers are deposited over the collector. Process parameters that 
make the formation of ideal nanofibers include concentration of the polymer solution, applied 
voltage, tip to collector distance etc [43]. Different natural and synthetic polymers were used 
to fabricate nanofibers  for various applications such as wound healing [103-107], bone [108-
110], skin [80-81], cartilage regeneration [82] and drug delivery applications [83-84]. The 
main disadvantages of electrospinning include high energy requirement and high cost. Low 
pore size of the developed scaffolds further limit the cellular infiltration inside the fibers [34]. 
1.4.3.5 Rapid prototyping 
Rapid prototyping (RP) also known as solid free-form fabrication (SFF) is one of the most 
appropriate methods to fabricate complex porous 3D structures [85]. It works on the principle 
of building 3D models using layer by layer methodology [86]. RP (SFF) refers to a group of 
techniques that will manufacture scaffolds based on computer aided design (CAD) data.  
Various rapid prototyping methods are stereo-lithography, fused deposition modelling, 
selective laser sintering and 3D printing [87]. RP was used to make bone grafts with complex 
geometry  and interconnected networks to mimic micro environment of natural bone [88]. 
Furthermore, this method overcomes the disadvantages of conventional fabrication techniques 
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such as freeze drying and salt leaching by developing scaffolds with complex geometries. The 
major limitations of this method are the use of expensive machinery and difficulty in 
operating the instrument [89].  
1.5 Stem cells for tissue engineering 
Stem cells are one of the constituents of tissue engineering triad and play a major role in 
success of an implant. Multilineage differentiation property of mesenchymal stem cells 
(MSCs) makes them potential cell source for tissue regeneration applications [90]. The 
various sources of MSCs include placenta, umbilical cord blood (UCB), blood, adipose tissue 
and bone marrow. Ease of handling and considering it as cheaper hospital waste product, 
UCB is considered as one of the promising sources for the isolation of MSCs [91-92]. Stem 
cells and their usage for curing tissue related defects are expected to continue as a foremost 
area of development for successful tissue engineering applications.  
1.5.1 Embryonic stem cells 
Embryonic stem cells (ESC) originate from the inner cell mass of blastocyst from which 
embryo derives. These cells are isolated and cultured in media from the past 2 decades and 
able to differentiate to all somatic cell types. The unique properties of embryonic stem cells 
include their self renewal property and capacity to differentiate via precursor cells. ESC has 
the  differentiation ability to adipocytes [93], chondrocytes [94], neuron [95], hepatocytes [96] 
and osteocytes [97-98]. However, immunological incompatibility and uncontrolled 
proliferation which leads to teratomas and teratocarcinomas are the limitation of using ESC. 
Further, the major issue with the usage of ESCs is ethical conflicts between the researchers 
and patients continue to exist [99]  
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1.5.2 Adult stem cells 
An adult stem cell belongs to the category of undifferentiated cells found amid differentiated 
cells in tissues or organs. Adult stem cells are considered as the most potential cell source for 
tissue engineering. These cells can be found in bone marrow [100], periosteum [101], muscle 
[102-103], fat [93] and skin [45]. Presence of osteogenic precursors in bone marrow makes it 
a special choice for bone tissue engineering applications. The prime role of ASC is to 
maintain and repair the tissue in which it is found. Furthermore, on in-vivo implantation, these 
cells exhibit immunosuppressive ability which makes them a suitable candidate for allogenic 
transplantation [104].  
1.5.3 Mesenchymal stem cells (MSCs) 
Mesenchymal stem cells (MSCs) also known as somatic cells are undifferentiated and present 
in any tissue or organ. These cells are of mesodermal origin and develop into various 
connective tissue types like blood, muscle, bone, cartilage, tendon, and ligament. These cells 
have the capacity of self renewal and can differentiate into specialized cell types. MSCs can 
be easily isolated, cultured and expanded under in-vitro conditions. MSCs, under culture 
conditions possess morphology similar to fibroblasts and exhibit good affinity to the tissue 
culture substrate; So, MSCs are good choice for tissue engineering applications including cell 
based therapies. There are several reports on the in-vitro culture of MSCs and their  
differentiation  into dermal, musculo-skeletal [105], adipogenic [106], bone [107] , cartilage 
[108], tendon [109], and ligament [110] tissue. 
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1.6 Role of signalling molecules in tissue regeneration 
Signalling molecules also known as growth factors which control a variety of cellular 
responses through specific binding of transmembrane receptors on target cells [111]. The 
method of binding results into translation of a specific protein kinases which further activates 
cascade of both intra and extracellular events [112]. The various growth factors which reside 
in the ECM of bone are transforming growth factor-β (β-TGF), insulin-like growth factor 
(IGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and bone 
morphogenic protein (BMP). The specific role of these growth factors is given in Table 1.1. 
Table 1.1: Growth factors and their specific function 
S. N. Growth factor Forms Role/function 
1 TGF-β1 TGF-β1 
TGF-β2 
TGF-β3 
Haematopoiesis, formation of skin, mammary 
glands, wound healing, stimulates collagen, ALP, 
osteonectin, synthesis and angiogenesis [113]. 
Decreases osteocalcin synthesis [114]. 
2 IGF IGF-I 
IGF-II 
Osteoclast formation[115]. 
3 PDGF PDGF-AA 
PDGF-BB 
PDGF-AB 
Increases collagen and non collagenous protein 
production and helps in fracture healing [116]. 
4 FGF FGF Shows dose dependent action; elicit or inhibits 
bone repair [19].  
5 BMP/OP BMP-2 
BMP-7 
Healing in long and non union bones [117-118].  
 
1.7 Bone 
Bone is a form of mineralized tissue which is highly vascularised and ultimately provides a 
skeletal support to the body, including protection of various internal organs [32, 59]. So any 
major defects in its structure affects entire body functionality and thus lifestyle too [21]. Bone 
regeneration has many intricate factors which include mimicking the microenvironment of 
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natural bone. Though it has intrinsic ability to regenerate to certain extent, larger defects make 
healing improper and thus may start damaging themselves in the long run [119].  
1.7.1 Structure and composition of bone 
Bone comprises of a variety of cells with specific functions and an extra cellular matrix 
(ECM). Collagen I is the major component of bone which occupies 95% of bone ECM. 
Proteoglycans and non-collagenous proteins contribute only 5% [120]. Glycosaminoglycan 
[GAG] is an example of proteoglycans which is found in bone and cartilage. Bone can form 
and deposit calcium phosphate salts in the matrix which provides rigidity and strength to bone 
[98]. The composition of bone is given in Table 1.2.  
Table 1.2: Composition of bone 
S.NO Component      Percent (wt %) 
1 Hydroxy apatite 69 
2 
 
Organic matrix 
(i) Collagen [Organic matter] 
(ii) Other organic matter 
22 
90-96% of organic matrix 
4-10% of organic matrix 
3 Water 9 
 
1.7.2 Types of bone 
Bones are classified into two categories namely cortical (hard) and cancellous/trabecular bone 
(spongy). The typical cortical bone is the outer layers of most of the bones and occupies 
various long bones with 80-90% mineralization [121]. It provides mechanical strength to the 
entire skeleton. Cancellous bone consist of 15-20% minerals and occupies the interior of 
bones [122]. The cancellous bone is full of vasculature and hence metabolic actions are taken 
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care by it. The mineral containing fibers are arranged into lamellar sheets which are arranged 
in concentric rings forming an osteon [123]. 
1.7.3 Types of bone cells 
There are three types of cells that contribute to bone formation such as osteoblasts: bone-
forming cells, osteoclasts: resorb or break down bone and osteocytes: mature bone cells. The 
various types of bone cells and their functions are represented in Table 1.3.  
Table 1.3: Types of bone cells and their function 
 
 
1.7.4 Mechanism of bone healing  
The native architecture of damaged bone is restored by regeneration of normal cell population 
rather by repair of injured area as it occurs in other connective tissues [124]. The healing 
mechanism can be classified as immediate bleeding and blood clotting, which provides the 
basic platform for inflammation [125]. The neo bone produced thus replaces the blood clot 
with soft callus (fibrous tissue and cartilage) which is later on replaced by hard callus. Finally 
the tissues become compact and thus remodelling occurs [126].  
1.8 Chitosan as ideal polymer for tissue regeneration 
Chitosan, obtained by partial deacetylation of chitin, is a polysaccharide which is available 
abundantly in nature after cellulose [9]. The basic unit of CS is 2-amino-2-deoxy-D-glucose 
with β→1-4 glucosidic linkages. CS is insoluble in water but soluble in dilute aqueous 
CELL TYPE MORPHOLOGY FUNCTION 
Osteoblasts Cuboidal in shape; located at the 
bone surface with their precursors 
Synthesis and regulation of 
bone ECM deposition 
Osteocytes 
 
Stellate shaped Calcification of osteoid 
matrix 
Osteoclasts Multinucleated cells Bone resorption 
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solutions. The most commonly used organic solvents are acetic acid and formic acid. The 
unique properties of CS make it an excellent biomaterial in many fields of tissue engineering. 
Low cost, wound healing, minimal immunogenicity [3], antimicrobial activity [127], 
biocompatibility and ability to adsorb proteins grab the attention of researchers towards CS in 
various tissue engineering applications [44, 128]. Positive charge of CS in aqueous acidic 
conditions attracts negatively charged plasma proteins which lead to thrombus formation and 
blood coagulation during the process of wound healing [11, 38]. Ability of CS to bind with 
sialic acid in phospholipids restricts the metabolism of microorganisms which is responsible 
for its antimicrobial activity [129]. One of the most promising features of CS include its 
flexibility to mold into different forms (porous 3D scaffolds, fibers, thin films) to be used in 
tissue engineering applications with different pore size [130]. Most importantly, chitosan, 
possess relatively better mechanical strength when compared to other natural polymers [11]. 
However, CS lacks some specific aspects that are important in tissue engineering. For 
example, poor mechanical strength of CS scaffolds makes it unsuitable particularly for bone 
tissue engineering applications [56]. CS is deficient in bioactive signal molecules which help 
in cell attachment, spreading, growth, differentiation and proliferation [131]. Nevertheless, 
incorporation of bio-ceramic particles and signalling molecules into it surpasses the 
mentioned limitations. 
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1.9 Future prospects of tissue engineering  
Tissue engineering is an offset of regenerative medicine that can cater to the need of millions 
of patients worldwide suffering from various tissue diseases. Though tissue engineering is 
promising as an exciting industry with a potential market, it is still facing numerous 
challenges like the establishment of a quality control program that can ensure the safety of the 
ultimate tissue engineered bone or other implant [32, 121]. Recently, efforts to address these 
issues are on track and this technology is expected to have a major boom in cell based 
remedies. The FDA has already initiated some regulatory efforts and guidelines related to 
certain tissue engineered bone implants. In the forthcoming years, these guidelines are 
expected to be standardized that will ensure the safety of these marketed implants [33]. Thus, 
this promising wing of future medicine will enable to enlighten lives of needful patients and 
prevail as an alternative to traditional bone and other grafting methodologies. 
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1.10 Thesis Outline 
The whole thesis work has been organized in six chapters as follows: Chapter 1- includes 
general introduction and significance of the research work. Chapter 2- presents literature 
review including concepts and fundamental understanding of recent advancement in chitosan 
based tissue engineering and possible improvement in potency of current implantable chitosan 
biopolymers in bone tissue repair. It has also been discussed, the need and possible ways to 
improve the material and bio-relevant properties of CS scaffold to make it more effective as 
bone tissue engineering scaffold materials. Chapter 3- presents scope and objective of the 
study. Chapter 4- presents materials and methods adopted for the preparation of CS and CS 
based composite scaffolds and their physical, chemical and biological characterisation. 
Chapter 5- describes the results and discussion of experimental work which is sub-divided 
into the following parts: Part I reports the development of CS/β-TCP composite scaffolds and 
their characterization including the investigation on the effects of micro and nano β-TCP on 
various scaffold properties and their comparison. Part II deals with the development of fibrin 
conjugated CS/nano β-TCP composite scaffolds and their characterization. Part III describes 
the development and characterization of genipin (GN) and tripolyphosphate (TPP) cross-
linked CS/nano β-TCP composite scaffolds. Part IV presents the further improvement of the 
cell supportive property of GN cross-linked CS/nano β-TCP composite scaffolds by fibrin 
coating. Chapter 6 includes a brief summary and conclusion of the thesis work along with 
suggested future study.  
 
 Literature Review 
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2.1 Current status of bone tissue diseases and defects 
Bone defects and diseases because of the consequence of trauma, injury and infections are of 
major concern in the field of health sector [2]. It is estimated that more than 50% of all 
osteoporotic hip fractures will occur in Asia alone by the year 2050 [132]. In India, the 
number of osteoporosis patients alone has been reported  in the order of 26 million till 2003 
and expected to increase to 46 million by 2023 [133]. Surgical reconstruction, transplantation 
(auto and allografts), drug therapy, artificial prostheses and medical devices which are current 
clinical treatment options for various tissue related disorders including bone tissue [134]. 
These treatment options have disadvantages such as severe pain, risk of infections, hematoma, 
immune rejection, donor site morbidity, transmission of viral (HIV, hepatitis-B) and prion 
proteins [135]. In this context, in recent years bone tissue engineering has emerged as an 
appropriate strategy to repair and/or replace damaged and/or diseased bone tissue defects.  
2.2 Challenges and prospects of bone tissue engineering  
Bone tissue engineering uses a temporary porous structure known as scaffold. The design and 
development of 3D scaffold matrix from a variety of biocompatible polymers with desired 
tailor properties is the key challenge for the success of tissue engineered bone grafts. 
Scaffolds provide suitable platform for the seeded cells and fill the defect and helps in 
forming a new tissue [136]. 
2.3 Ideal biomaterials for bone tissue engineering 
The ideal biomaterial for bone tissue engineering should have specific characteristics such as 
providing a momentary mechanical support to the affected area, should possess porous 
interconnecting architecture for allowing vascularization and bone in-growth. Further, the 
biomaterial should be biocompatible with appropriate surface chemistry in order to permit cell 
adhesion and provide sufficient integration with host bone tissue [137]. Furthermore, a 
biomaterial should encourage migration of bone cell into the scaffold, should help in 
promoting osteogenic differentiation, osseointegration and degrade in a controlled manner to 
facilitate load transfer to developing bone [138]. 
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2.3.1 Polymer/polymer blend and polymer/ceramic composites  
It is evident that a single biomaterial does not possess all the desired properties and thus there 
is need for the development of a polymer blend and/or composite material with an appropriate 
composition from a variety of biopolymers and other biomaterial [30]. Various research 
groups have attempted to combine natural polymers with some other natural or synthetic 
polymers for achieving better results in terms of compressive modulus, surface property such 
as wettability and  biocompatibility  [139-140]. Natural or biological polymers namely 
chitosan, silk fibroin, alginate, fibrin, agarose, gelatin, hyaluronan etc possess superior 
biocompatibility and are thus utilized in various tissue engineering applications. Synthetic 
polymers containing aliphatic polyesters are easily degradable within the biological and the 
degradation products are adsorbed in the metabolic pathway. However, these synthetic 
materials are chemically and biologically inert and thus require optimum surface modification 
with ECM mimicking molecules such as RGD and also osteoconductive moieties like bio-
ceramics. Micro and nano sized bio ceramics incorporated in natural biopolymers are 
considered as a promising option in developing scaffolds with desired mechanical property 
for bone tissue regeneration [141]. Polymer ceramic composites consist of two or more 
components where ceramic particles are distributed homogenously in polymer matrix [9]. In 
this regard, few researchers adopted biomimetic approaches to enhance the mechanical 
properties of polymeric scaffolds. In such studies, researchers used Collagen type I [142], 
type III and glycosaminoglycans (GAGs) as an organic phase and nano Hydroxyapatite 
(nHAp) as inorganic phase [18]. 
2.4 Surface modification 
Surface properties of a biomaterial determine its efficacy in cellular binding. Scaffold material 
can be improved by modifying their surfaces chemically or physically, and a variety of such 
surface modified scaffolds have been used for investigating cellular behaviour [63]. 
Modification of biomaterials and understanding of cell behaviour have made it clinically 
possible to replace or reconstruct damaged host cells and tissues [51]. As far as there is 
advancement in biomaterial research, new biomaterials and novelty in their usage will 
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continue to emerge. CS has been used with surface of various prosthetic materials used for 
bone tissue engineering applications. Availability of free NH2 and OH groups makes CS more 
special and ease in modification with wide range of applications [11]. Titanium (Ti) surfaces 
were coated with CS by using silane glutaraldehyde chemistry and an enhanced cellular 
responses of osteoblast like cells have been observed [143]. CS also has been modified for 
improving its physico-chemical, biological and degradation properties by cross linking and 
grafting with cell adhesive peptides by using carbodimide chemistry [19, 97, 170]. 
2.5 Role of chitosan scaffold matrices in tissue regeneration 
Pore size and porosity, biodegradability, mechanical strength and immunogenicity and 
porosity are the important characteristics of an ideal scaffold for various tissue engineering 
applications. Chitosan, a linear polysaccharide consisting of repeating units of D-glucosamine 
and N-acetyl-D-glucosamine linked by β-1,4 glycosidic bonds obtained from deacetylation of 
chitin present in shells of crustaceans and molluscs [12]. Tissue engineering approaches for 
bone repair with different forms of CS namely films [14], membranes [15, 144], fibers [145], 
3D matrices [38] and sponges [146] has been reported. CS has better mechanical and 
biological properties as compared to other natural polymers. However, CS has limitations like 
low mechanical strength [10], rapid biodegradability [16] and low bioactivity etc., in order to 
use as scaffold material for bone tissue regeneration.  
2.5.1 Chitosan based composite scaffolds in tissue regeneration  
Published reports have shown enhanced mechanical and biocompatible properties of ceramic 
reinforced chitosan based composite scaffolds along with the decelerated degradation rate 
[147]. Calcium phosphate ceramics (CPC) are widely used as fillers to overcome the 
mechanical inferiority of polymeric scaffolds [148]. CPC interacts with the body fluids to 
form apatite on its surfaces that offers bone healing due to osteoconduction [149]. The 
uniform surface morphology of CPC is a vital factor which promotes cell proliferation and 
differentiation. Hydroxyapatite (HAp), beta-tricalcium phosphate (β-TCP), octa calcium 
phosphates (OCP) and biphasic calcium phosphates (BCP) are the major constituents which 
fall under calcium phosphate ceramics [150]. These biomaterials can be manufactured in 
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various forms such as blocks, powders and coatings [151]. Published reports on β-TCP 
confirm its excellent biocompatibility, osteoconductivity and favours cell growth, 
proliferation and differentiation of MSCs [4, 152]. Optimal resorption, high bone bonding 
ability and degradation similar to natural bone makes β-TCP a suitable scaffold candidate for 
bone tissue regeneration than HAp [55]. Furthermore, HAp degrades slowly and thus remains 
for a long time once implanted in critical size bone defect [53]. With rapid advances in 
nanotechnology, nano-structured biomaterials gained high importance due to their high 
surface area and excellent bioactivity. Nano-sized bio-ceramics are the most promising 
because of their structural similarity to inorganic phase (HAp) of the bone [153]. Enhanced 
cell migration, proliferation and differentiation of seeded cells has been reported by 
incorporating nano sized ceramic particles like HAp and bi-phasic calcium phosphate (BCP) 
[120, 154]. Thein et al. reported the reinforcement of nano HAp particles into CS matrix not 
only increased the mechanical strength but also decreased degradation rate by 10%. 
Furthermore, MC3T3 cell proliferation in the composite scaffolds was increased by 1.5 times 
when compared to pure CS scaffold [38]. Incorporation of β-TCP in CS-gelatin composite 
system has produced scaffolds with higher mechanical property and better biocompatibility. 
The maximum compressive strength obtained was 0.8 MPa with an average pore diameter of 
337μm [53]. In another study, introduction of β-TCP in poly (L- lactic acid)/chitosan/gelatin 
scaffold matrix has enhanced the osteogenic differentiation potential of bone marrow 
mesenchymal stem cells was increased in the above mentioned composite scaffold due to 
osteo-inductive nature of β-TCP [4] Stiffness of polymeric matrices has also been increased 
by various physical and chemical cross linking agents such as Ultra Violet rays [155], 
glutaraldehyde (GLT) [127], carbodimide [156], genipin (GN) [145] and tripolyphosphate 
(TPP) [16]. Furthermore, cross-linking has been reported to have a direct influence on 
degradation rate of polymeric matrices. Lee et al. developed glutaraldehyde cross-linked 
gelatin/chitosan porous 3D scaffold with tunable compressive moduli and surface roughness 
for bone tissue regeneration [45]. Reis et al. has improvised physico-chemical properties of 
chitosan based scaffold by cross-linking with genipin by freeze drying. The pore size of 
genipin cross-linked composite scaffolds has been increased which shows direct effect on cell 
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growth, proliferation and differentiation for cartilage tissue engineering [28]. Dhara et al. 
reported a significant increase in MG63 cellular responses, osteoblastic differentiation and 
compressive strength (~3MPa) on chitosan-TPP sodium tripolyphosphate (TPP) cross-linked 
3D nanofibrous scaffolds [16]. Though composites overcome mechanical limitations, still 
challenge exists in designing a scaffold which mimics the host tissue [49]. Furthermore, 
among the biomaterials used for producing 3D scaffolds, chitosan seems to be an attractive 
option [11]. However, the major drawback of chitosan is lack of cell binding molecules like 
RGD (Arginine-Glycine-Aspartic acid) to attract more number of cells on its surface [157]. 
Surface modification of chitosan scaffolds with RGD peptide has been reported to improve 
cell adhesive property of seeded MSCs. In this context, efforts have been given by Tsai et al. 
to immobilize RGD peptide on CS based 3D porous scaffold to further improve the 
biocompatibility of CS. They reported an increase in cell attachment and cell number of 
seeded rat osteosarcoma cells [155]. Sheikh et al. has reported the role of fibrin in improving 
cell binding ability of polymers [158]. He et al. reported that having numerous cell binding 
sites on fibrin makes it a special in overcoming the cell seeding defects and thus promoting 
excellent tissue growth [159]. Gray et al. has proved the importance of fibrin in various tissue 
engineering applications [160]. Yilgor et al. incorporated BMP-2 and BMP-7 signalling 
molecules into chitosan/poly lactic acid-co-glycolic acid (PLGA) composite scaffold and 
noticed increased levels of cell number and thus ALP activity which confirms the osteogenic 
lineage commitment of rat bone marrow mesenchymal stem cells [117]. Yamada et al. and 
Tholpady et al. investigated the effect of fibrin by culturing MSCs on 3D scaffold and 
reported an increased cell adhesion, proliferation and thus better osteogenic differentiation 
ability [131, 161]. Table 2.1 depicts the various CS based composite scaffolds with improved 
properties reported so far. 
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Table 2.1: Chitosan based composite scaffolds with enhanced properties 
Composite Out come Reference 
CS/nano Hap 
 
Increased mechanical strength, 
superior cell attachment, high 
proliferation of MC3T3 cells 
Han et al [101].  
CS/ALRGDN-peptide  
 
Promoted  biocompatibility Huang et al [51]  
CS/Gelatin/β-TCP  Increased osteoblast attachment and  
proliferation 
Mohammadi et al [4] 
CS/Alginate/Carboxy methyl 
cellulose 
Increased  compressive modulus  Yuan et al [74].  
CS/RGD/ UV cross-linking Increased proliferation [GAG and 
DNA] 
Tsai et al. [158] 
 
CS/HAp nanofibers Increased interconnected  
architecture of scaffold 
Frohbergh et al [145] 
CS/SF Controlled bio-degradation rate Bharadwaj et al [17] 
CS/nHAp 
 
Increased mechanical strength Thein-Han et al [38] 
CS/Bioactive glass  
 
Increased mechanical strength, cell 
attachment 
Fu, Q et al [121].  
CS/PLGA 
. 
 
Increased stiffness of scaffold, 
Biocompatibility 
Jiang et al [29] 
CS/PLA Increased compressive strength 
Neutralize the acidity of PLA 
degradation products 
Van de Witte et al 
[69]  
 
CS/gelatin/TCP/Glutraldehyde  
 
Increased cell spreading 
 
 
Yin et al [53] 
CS/Bioglass Increased mechanical property and 
decreased inflammatory actions of 
bio glass. 
 
Chen et al [162].  
 
CS/BMP Increased porous morphology,  
cell viability and controlled release 
of FGF 
Luca et al [163].  
CS/wollastonite Increased mechanical strength and 
bioactivity 
Li Zhao et al [54].  
CS/HAp/collagen I Controlled pore size and 
biodegradation  
Pallela et al [44] 
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CS/alginate Increased ligament and tendon 
growth  
Majima et al [164] 
CS/PLAGA/Fibrin Increased mechanical strength, 
Osteoblast cell proliferation 
Mol  et al [20] 
CS/Fibroin Enhanced stiffness and 
biocompatibility 
She et al [70].  
CS/Ca3P04 Increase in cell attachment, 
proliferation and phenotypic 
expression of osteoblastic markers 
Lin et al [165].  
 
Beside material properties, another challenging aspect that needs to be focussed is the 
fabrication of scaffolds using a simple and cost effective method. Freeze-gelation is one of the 
scaffold developmental techniques which is very simple, time and energy saving [17]. The 
amount of residual solvent and formation of surface skin is limited which helps in better 
growth of cells cultured on these freeze-gellled scaffolds [76]. Furthermore, the scaffolds 
developed by this method possess an interconnected porous network with better mechanical 
properties [77]. Earlier research suggests the usage of this method to develop 3D scaffolds 
from various biopolymers like collagen [166], carboxy methyl cellulose [74], poly (d,l-lactic-
co-glycolic acid) [76], chitosan [78], pectin [79] and silk fibroin [17]. CS can be easily 
modified in combination with other materials to achieve required mechanical and surface 
properties of scaffold [167]. Chitosan has been utilized as promising biomaterial with a wide 
range of processability and applications as illustrated in Figure 2.1 and Table 2.2 
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Figure 2.1: Chitosan for different tissue engineering applications 
 
CS scaffolds in various forms such as 3D porous, fibrous, films etc developed for tissue 
engineering application is listed in Table 2.2 
Table 2.2: Various forms of CS in tissue engineering applications 
 
Chitosan Fabrication method TE application References 
 
3D scaffolds 
 
Freeze drying 
 
 
Freeze-gelation 
 
Salt leaching 
Tendon tissue engineering 
Skin tissue engineering 
 
Bone tissue engineering 
 
Ligament tissue engineering 
Majima et al [164]  
Bagnaninchi et al [168] 
Adekogbe et al [169]  
Hsieh et al [78] 
 
Funakoshi et al [170] 
Fibers  Electrospinning 
 
Wound dressings 
 
 
Bone tissue engineering 
 
Cartilage tissue engineering 
Zhou et al [171]. 
Tuzlakoglu et al[172] . 
 
Frohbergh et al [145] 
 
Subramanian et al [127] 
Films Salt leaching 
Lyophilization 
Connective tissue 
Bone repair 
Wound dressing/skin repair 
Yoon et al [61] 
Wang et al [173] 
Zhou et al [157] 
Zhou et al [171] 
Hydrogel Sol–gel transition  
 
Cartilage tissue Engineering 
Bone tissue engineering 
Drury et al [174]  
Luca et al [163]  
Sponges Freeze drying 
 
Wound dressings 
Bone tissue engineering 
Cartilage tissue engineering 
Denkbas et al [175] 
Seol et al[176]  
Silva et al [146] 
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2.6 Applications of CS in tissue engineering  
2.6.1 Skin/wound healing 
Research groups Zhou et al. and Lee et al. have reported the in-vitro dermal fibroblasts 
spreading and proliferation on 3D CS/gelatin scaffold and CS/PVA nanofibrous membranes 
[45, 171]. Bharadwaj et al. reported excellent cell viability of human keratinocytes on 3D 
CS/silk fibroin  freeze-gelled composite scaffolds [17].  In another study, Denkbas et al. 
developed norflaxin loaded CS sponges for enhanced skin wound healing effects [175]. The 
enhanced tensile strength of CS nanofibers containing HAp particles was reported by 
Frohbergh et al [145]. Furthermore, wound healing ability of composite nanofibers was found 
to increase as compared to pure CS nanofibers. Adekogbe et al. developed dimethyl 3,3-
dithio-propionimidate (DTBP) dihydrochloride cross-linked 3D chitosan scaffolds for skin 
tissue engineering by freeze drying [169]. The cross-linking with DTBP has remarkably 
increased the tensile strength from 20 ± 6 KPa to 160 ± 12 KPa which is suitable for skin 
tissue engineering applications. 
2.6.2 Cartilage 
Application of CS based 3D scaffolds for cartilage tissue engineering was reported by Silva et 
al [146] and Krampera et al [177] by freeze drying. Subramanian et.al reported the effect of 
cross-linking on stiffness of CS matrix and chondrocyte viability and proliferation [127]. 
Tortelli et al cultured human mesenchymal stem cells (MSCs) on 3D chitosan scaffolds and 
allowed them to differentiate into chondrocytes. They reported an enhanced expression of 
collagen type II and GAG [97]. CS sponges were prepared by Nettles et al using freeze drying 
and noticeable differences were reported in chondrocyte proliferation and differentiation in 28 
days of incubation in chondrogenic media [167]. Malafaya et al developed an innovative route 
for processing CS particles into agglomerated 3D scaffolds for osteochondral defects by using 
adipose tissue derived stem cells [178]. Cytotoxicity studies reported the biocompatible nature 
of CS agglomerates. In a similar study conducted by Li et al. reported that the CS/alginate 
scaffolds has shown excellent adhesion, proliferation and enhanced differentiation of HTB-94 
cells to chondrocytes in 3 weeks of incubation time [30]. 
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2.6.3 Bone 
Tissue engineering strategy to repair damaged bone tissue with different morphologies using 
chitosan based scaffolds in various forms have been reported by Hsieh et al [78], Tuzlakoglu 
et al [172], Zhou et al [171], Luca et al [163], Seol et al [176], Li et al [40]. Initial effort was 
dealt with CS hydrogels by Yamamoto et al [13] and Drury et al [174]. CS membranes were 
successfully prepared by Liao et al [179] and Orrego et al  [15] for bone regeneration. 
However, in the last decade, due to technological advances, many methods have been 
reported to develop 3D porous CS based scaffolds and seeded with MSCs for the repair of 
bone defects. Laurencein et al and Reis et al reported the usage of CS in bone tissue 
engineering applications. CS/PLAGA composite scaffolds were prepared with enhanced 
compressive moduli for bone tissue engineering. Osteoblasts like cells were seeded on 
composite scaffolds and found the enhanced cellular responses in terms of cell number, 
proliferation and differentiation over composite scaffolds as compared to pure CS scaffolds 
[29, 172]. CS was processed into films [14] and electrospun to form fibrous scaffolds [34] or 
a 3-D porous scaffold by freeze-gelation [17] and freeze drying [180]. Introduction of RGD 
peptide sequence and growth factors such as BMP-2 and VEGF was reported to enhance 
surface properties for cellular activities [188, 204]. CS scaffolds were UV cross-linked to 
immobilize RGD cell signalling peptide for improving cell binding affinity of CS scaffolds. 
MC3T3 cells were seeded to evaluate the biocompatibility of these scaffolds. They observed 
the enhanced adherent cells on RGD immobilized CS scaffolds. Furthermore, enhanced 
mineralized matrix is also observed as compared to scaffolds without RGD [155]. Injectable 
BMP-2 loaded CS hydrogels have been reported to induce osteogenesis in-vitro and in-vivo 
bone formation [181]. CS based composites have been reported to outperform in-vivo bone 
growth than commercially available synthetic polymers. Reports demonstrate the successful 
differentiation of MSCs into osteogenic lineages grown over CS/nano-hydroxyapatite. 
CS/PCL composite 3D scaffolds which were observed to promote osteogenesis at both non-
load bearing [182] and load-bearing [157] sites implanted in small animal (nude mice) 
models. Angiogenic activity associated with the external implant surface was clearly 
observed. Further, lymphocyte proliferation assays and low antibody responses indicated a 
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very low immune rejection of CS-PCL composite scaffolds [183]. Li et al. reported the 
biocompatible nature of CS/alginate scaffold system by culturing MG63 osteoblast-like cells. 
Furthermore, an enhanced cell proliferation, matrix deposition and higher levels of osteogenic 
gene expression were reported [30]. Interconnectivity between pores of these scaffolds has 
increased neo vascularisation as revealed by in-vivo tests in mice for 12 weeks and thus useful 
for both bone and cartilage load bearing defects. CS/Poly-L-lysine films were developed by 
Zhenhaun et al which supported the growth, proliferation and differentiation of MC3T3-E1 
osteoblast like cells. RT-PCR analysis proved the increased expression of osteoblast related 
specific genes osteocalcin (OC) on composite films as compared to pure CS films [184]. 
 2.6.4 Ligament/tendon 
The flexibility of chitosan into controllable physical forms makes it promising for ligament 
and tendon tissue engineering. CS fibers resemble the collagen fibers present in ligaments 
and tendons. Ceramic reinforced chitosan nano fibers possess better mechanical properties 
and larger surface area for cell attachment and ECM secretion. CS fibers has been 
investigated for proliferation and differentiation of MSCs towards ligament tissue, 
expression of ligament-specific markers (collagen type I, collagen type III) and cellular 
response for mechanical stimulus [189, 194]. HAp coated chitosan nanofibers have been 
reported to restore the mechanical strength without influencing in vitro cytotoxic effects and 
in vivo inflammatory response for ligament tissue engineering [185]. RGD coated CS matrix 
showed enhanced ECM production and increased expression of Collagen type I as compared 
to unmodified CS fibers [164]. 
2.6.5 Other tissues 
Studies of Jiankang et al. have reported that CS and other synthetic polymer conjugates 
support the attachment and proliferation of hepatocytes [186]. Feng et al reported that cells 
cultured on nanofibrous galactosylated CS are able to detoxify ammonia by increasing urea 
synthesis [96]. CS has also been demonstrated to support the growth and proliferation of 
schwann cells for nerve tissue engineering [95]. Masuko et al. have developed Arginine, 
Glycine-Aspartic acid-Serine-Glycine-Glyicine-Cystine (RGDSGGC) peptide conjugated CS 
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scaffolds and reported an increase in chondrocyte and fibroblast adhesion, proliferation on 
RGDSGGC conjugated CS scaffolds due to RGD cell recognition peptide as  compared to 
pure CS scaffolds [187]. Shao et al. have shown elevated levels of collagen I, II, aggrecanin 
annulus fibrosus (AF) cells seeded on CS alginate hybrid scaffolds thus proved the 
potentiality of CS in intervertebral disc tissue engineering applications [188]. Akman et al 
evaluated the role of CS in periodontal tissue engineering by fabricating bFGF loaded 
CS/HAp composite scaffold. Peridontal ligament cells and cementoblasts were seeded and 
found that they were spreading and proliferating on scaffold surface which were revealed by 
confocal microscopy and cell viability assays [181]. Zhao et al. explored the usage of CS in 
liver tissue engineering by developing CS/TiO2 composite scaffolds. Hepatic immortal cell 
lines (HL-7702) were found to restore their long term viability along with albumin secretion 
and synthesis of urea which indicated the potentiality of CS/TiO2 scaffolds for liver tissue 
engineering [189]. 
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In recent years, bone tissue engineering has been emerged as the most promising technique 
for the treatment of bone tissue defects and diseases through the development of a 
biologically active 3D artificial extracellular matrix so called tissue engineered scaffold. The 
design and fabrication of such 3D porous scaffolds with a desired set of properties is a key 
challenge.  Among the various biopolymers explored for tissue engineering applications, 
chitosan is considered as one of the potential candidates owing to its biocompatibility, 
biodegradability and wound healing properties [57]. However, chitosan lacks desired 
mechanical strength, bioactivity, degradation and cell binding ability which limits its use in 
bone tissue engineering. Therefore, the present research focuses on the development of a 
novel chitosan based composite porous scaffold for bone tissue engineering application by 
solving the various limitations associated with chitosan.  
The specific objectives of this research work are: 
 
i. To develop chitosan-bio-ceramic composite scaffolds with improved bioactivity and 
mechanical property 
ii. To improve the cell supportive property of  the developed composite scaffolds by 
conjugation with bioactive  molecule 
iii. To develop cross-linked composite scaffolds with controlled biodegradation property 
iv. To study physico-chemical and mechanical properties of the scaffolds 
v. To assess biocompatibility and osteogenic potentiality of the developed composite 
scaffolds  
 
The scope of the research work is enumerated as follows- 
1. Preparation of Chitosan/bio-ceramic based composite scaffolds  
Chitosan is an attractive biopolymer for tissue engineering applications. However, chitosan 
lacks in sufficient mechanical strength and bioactivity that limit its use particularly in bone 
tissue engineering. In this phase of research work, efforts will be given to develop composite 
scaffolds with improved mechanical and bioactive property by incorporating β-TCP into CS. 
It is further evident that the use of particles at nano size is better than micro one. Therefore, 
the effect of nano and micro sized β-TCP on the properties of the developed CS composite 
scaffolds will be evaluated to achieve potential tissue engineered scaffold. 
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2. Characterization of scaffolds 
It is utmost important to assess surface, mechanical and biological properties of the scaffold to 
confirm their suitability for bone tissue regeneration. Morphological, structural, pore size, 
hydrophilicity, porosity, compressive strength, biodegradability, swelling behaviour and 
bioactivity of the developed scaffolds will be characterized. The cell supportive property in 
terms of cell attachment, cell proliferation, metabolic activity and osteogenic differentiation 
potential will be evaluated. 
3. Development of fibrin conjugated Chitosan/β-TCP composite scaffolds 
It is evident from literature that CS lacks in cell signalling molecules representing its lower 
cell supportive property. Hence, the cell binding affinity of the developed CS/β-TCP 
composite scaffold will be improved by surface modification with fibrin as bioactive 
molecule. The developed fibrin conjugated composite scaffold will be characterised as 
mentioned above. 
4. Development of cross-linked Chitosan/β-TCP scaffolds  
The rapid degradation of chitosan is another important factor that needs to be addressed to 
match between the degradation and the rate of new tissue formation. Though an improved 
degradation is expected by the addition of bio-ceramic, still challenge will remain for further 
improvement of this property to achieve desirable degradation level. In this context, the fast 
degradation of the developed scaffolds will be reduced by cross-linking with suitable cross 
linking agent. The modified scaffold will be characterised for its physico-chemical, 
mechanical and biological properties.  
5. Development of fibrin coated cross-linked Chitosan/β-TCP composite scaffolds  
To make the developed cross-linked chitosan/β-TCP composite scaffold more effective 
towards bone tissue regeneration, the cell supportive property will be improved by surface 
coating with fibrin. The developed scaffolds will be evaluated for their in-vitro 
biocompatibility in terms of cell attachment, spreading, proliferation and differentiation etc 
and in-vivo animal testing. 
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4. 1 Materials  
4.1.1 Preparation of scaffold  
Chitosan of medium molecular weight-190kD and degree of deacetylation 90% was 
purchased from Marine chemicals, India. Micro and nano sized β-tricalcium phosphate [Ca3 
(PO4)2 with >98%, β-phase, fibrinogen, prothrombin N,N-(3-dimethylaminopropyl)-N′-ethyl 
carbodimide (EDC), N hydroxysuccinimide (NHS), 2-(N morpholino) ethanesulfonic acid 
(MES), lysozyme, genipin, NaCl, KCl, CaCl2, MgCl2, K2HPO4, NaHCO3, Na2SO4 and sodium 
tripolyphosphate (TPP) were procured from Sigma Aldrich (USA). Sodium hydroxide 
(NaOH), di sodium hydrogen phosphate (Na2HPO4), glycine, ethanol (C2H5OH) and acetic 
acid were obtained from Merck India Ltd.  
4.1.2 Cell culture study 
Dulbecco’s modified eagle medium (DMEM) from Gibco (BRL, USA) and (Hyclone FBS, 
USA), penicillin-streptomycin solution, fetal bovine serum (Hi-FBS), Dulbecco’s phosphate 
buffered saline (DPBS), Collagenase type I and 0.25% Trypsin/EDTA solutions were 
obtained from Gibco (BRL, USA). Para formaldehyde and MSCs qualified Fetal bovine 
serum (FBS) were purchased from (Hyclone FBS, USA). Quant-it Pico Green dsDNA reagent 
kit and TRIzol were procured from Invitrogen, USA. Ascorbic acid, β-glycero-phosphate, 
Triton X, Calcein-AM, Ethediumhomodimer, Quanti chrome calcium and ALP assay kits 
were purchased from Bioassay Systems, USA. Phalloidin-Alexa Fluor 488 conjugate, Hoescht 
dyes were purchased from Invitrogen, USA. MTT assay reagent, Commassie blue G-250 are 
from Hi-Media labs, India. Growth factors EGF and bFGF,  BD FACS lysis buffer, CD 34-
FITC, CD 29-FITC, CD44-FITC, CD45- FITC, CD73- FITC, CD90- FITC, CD105- FITC 
and HLA-DR- FITC were purchased from Becton Dickenson, San Jose, CA. Dexamethasone 
(DEX), staurosporine, α-MEM, L-glutamine, L-ascorbate, β-glycerophosphate (βGP), 
protease XIV, bovine serum albumin (BSA), Alizarin red S, propidium iodide, Osmium 
tetroxide, tris-buffer, Mg acetate and 1, 9-dimethylmethylene blue (DMMB) were from 
Sigma-Aldrich (St Louis, MO, USA). Primers used for PCR were purchased from Sigma 
Aldrich and cDNA synthesis kit from Fermentas.  All the tissue culture plastic wares were 
purchased from BD falcon and RNase was purchased from MP Biomedicals, USA. 
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4.2 Characterization of β-TCP powder 
4.2.1 Morphology: FE-SEM was used to observe the morphology of both sized β-TCP 
4.2.2 Average particle size crystallite size: Average particle size was measured by DLS 
(Dynamic Light Scattering) method  
4.2.3 Specific surface area: BET was used to calculate the surface area of both micro and 
nano sized β-TCP. 
4.2.4 Crystallite size: Crystallite size of β-TCP particles was calculated by “Tiny tools” 
(online tool) using the following equation. 1/20.94 / cospD    . Dp = crystallite size, β = 
line broadening in radius, θ is the Bragg angle and wavelength (λ=1.54056 A0).  Peak length 
and peak position are obtained from X’pert high score.  
 
4.3 Preparation of scaffolds 
4.3.1 Preparation of CS scaffolds  
Chitosan scaffolds were prepared by following the procedure reported elsewhere [17]. Briefly, 
CS was dissolved in aqueous acetic acid (0.1M) solution to form 2.5 wt% of polymer 
solution. The prepared polymer solution was poured into petridishes and kept at -20°C for 6 
hr. The frozen petri dishes containing chitosan solution was immersed in a gelation medium 
consisting of pre cooled (-20ºC) NaOH: EtOH of 70:30(v/v) solutions. The petridishes were 
frozen at -20°C for 6 hr. The petridishes were removed from the gelation medium and dried in 
a vaccum drier [Labtech, Daihan LabtechCo.Ltd] for 6-8 hrs at 40°C. Finally the scaffold was 
rinsed thoroughly with phosphate buffer saline (PBS) and deionised water thrice followed by 
drying. The scaffolds were cut into specific dimensions and made ready for different 
characterization techniques. 
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4.3.2 Preparation of CS/β-TCP composite scaffolds 
Beta tri calcium phosphate powder in micro and nano size (0.1, 0.2, 0.3, 0.4, and 0.5 wt %) 
was dispersed in deionised water for 5 min hr by ultrasonication. The dispersed particles were 
added to the chitosan solution drop by drop and allowed to stir overnight until homogeneity is 
achieved [38]. After this, exactly same method of the preparation of CS scaffold was 
followed. The obtained composite scaffolds were cut into specific dimensions and made ready 
for different characterization techniques. The schematic representation of the preparation of 
CS/β-TCP composite scaffolds is depicted in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Schematic representation for the preparation of CS/β-TCP scaffolds by freeze-
gelation method 
 
4.3.3 Development of fibrin conjugated CS/nano β-TCP composite scaffolds 
Fibrin was conjugated to CS/nano β-TCP composite scaffolds by following the protocol 
reported earlier [190]. Briefly, CS/nano β-TCP composite freeze-gellled scaffolds were cross-
linked with N,N-(3-dimethylaminopropyl)-N′-ethyl-carbodimide(EDC),N hydroxysuccinimide 
(NHS) solution at 105°C for 24 hrs. After washing with double-distilled water for 3 times (10 
min each), the scaffolds were dried to obtain EDC/NHS-treated CS/nano β-TCP composite 
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scaffolds. The scaffolds were then sterilized in 75% ethanol overnight followed by a PBS 
wash. 50 μL of fibrinogen (80 mg/ml) and thrombin (600 U/ml) solutions were spread on the 
surface of the CS/nano β-TCP scaffolds and kept for incubation at 37°C for 30 min till fibrin 
forms on the surface of CS/nano β-TCP composite scaffolds. 
4.3.4 Development of cross-linked CS/nano β-TCP composite scaffolds 
Different concentrations of genipin (GN) and sodium tripolyphosphate (TPP) in the range of 
0.01-0.20 % (w/v) were added to CS/nano β-TCP composite solutions. The mixture was then  
stirred for 2 hrs and poured into petri-dishes according to the protocol followed earlier [78]. 
Cross-linked CS/nano β-TCP composite scaffolds were obtained by following the same 
protocol used for CS and CS/β-TCP composite scaffolds. The scaffolds were immersed in a 
standard glycine solution to remove the traces of unreacted cross-linking agents. Finally 
scaffolds were neutralized by 0.1 M Na2HPO4 rinsed with deionised water, dried and 
preserved for further experiments [191]. 
4.3.5 Development of fibrin coated GN cross-linked CS/nano β-TCP composite scaffolds 
 
Genipin cross-linked CS/nano β-TCP composite scaffolds were coated with fibrin by 
following the protocol reported elsewhere [192]. Briefly, 1 ml of fibrinogen solution (2 wt%) 
was added in a test tube containing genipin cross-linked CS/nano β-TCP composite scaffolds 
and dried in a dessicator by applying vacuum. 1 ml of thrombin solution was added to the 
above dried sample in a test tube and incubated by using vacuum drier at 37° C for 12 hrs till 
fibrin forms on the scaffold.   
4.4 Characterization of scaffolds 
4.4.1 Rheological behaviour 
The viscosity of pure CS and CS/β-TCP composite solutions was analyzed by rotational cone 
(diameter = 30 mm; angle = 5.4°) and plate viscometer [Bohlin Visco-88, Malvern, UK]. A 
constant gap of 0.15 mm was maintained between cone and the plate throughout the study. 
The variable shear rate applied was in the range of 20 to 100 sec
-1
 in 16 min. All the samples 
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were analysed at room temperature. The data has been analyzed with Bohlin visco-8 software 
using cross model [193]. 
4.4.2 Morphological study  
Scanning Electron Microscopy (SEM) was performed using a JEOL-JSM 6480 LV to observe 
the morphology of developed pure CS and CS based composite scaffolds. The traces of 
moisture present in the scaffolds were removed by drying in a vacuum drier for 2 hrs at 40°C. 
Platinum coating was done prior to imaging. A minimum of 25 pores were considered for 
calculating the pore size of the developed scaffolds by using Image J (USA) software.  
4.4.3 Porosity measurement 
The porosity of developed scaffolds was measured by Mercury intrusion porosimeter 
[Poremaster-33, Quantachrome, USA].The bulk density of samples was calculated by 
equation, . /B D D W S  , where D = dry weight, S = suspended Weight, W = soaked 
Weight.  The percentage porosity was calculated from intrusion data. For all types of 
scaffolds, experiments were carried out in triplicates. The porosity was measured using 
Washburn equation: (1/ )4 (cos )D P   which is based on the relationship between the 
applied pressure and the pore diameter into which mercury intrudes. The various parameters 
of the equation are: D is the pore diameter,   is surface tension of mercury, φ is the contact 
angle between mercury and the pore wall P is the applied pressure [128]. 
4.4.4 Phase analysis  
Phase analysis of developed CS and CS based composite scaffolds was performed by X-ray 
Diffractometer [PANalytical, X’pertPhilips,USA] using Cu-Kα radiation (λ= 0.1542 A°) in a 
step-scan mode in the 2θ range of 10-80° with a scanning speed of  2° per min [194]. The 
operating conditions were 30 kV and 30 mA.  
4.4.5 Functional analysis  
Fourier transform infrared spectroscopy (FTIR) was performed to evaluate the structural 
property and functional groups of the developed CS and CS based composite scaffolds by 
using an Infra red Microscope [Shimadzu AIM-8800, Japan]. Hydraulic press was used to 
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pelletize the scaffold samples by mixing them with dry KBr powder. The mixture was pressed 
into transparent disks and used for IR analysis. The machine was operated in transmittance 
mode by using the range 500 to 4000cm
-1
 with a resolution of 8cm
-1
 [30]. 
4.4.6 Contact angle measurement  
The contact angle of the developed pure CS and CS based composite scaffolds (films) was 
measured by a contact angle meter K100MK3 tensiometer (KrussGmbH, Hamburg, 
Germany). Films of width (15mm), height (10mm) and thickness (1mm) were used for 
analysis. Water was used as the solvent for accomplishing the measurements. All the samples 
were analyzed at room temperature in triplicates [184]. 
4.4.7 Mechanical strength 
Compressive tests of the prepared CS and CS based composite scaffolds were carried out by 
Universal testing machine (H10 KS Tinius Olsen USA).  Cylindrical samples with a diameter 
of 10 mm and thickness of 15 mm were used for analysis. Compression test was performed 
with a crosshead speed of 1 mm/min with a load cell of 1000N. Each scaffold sample was 
tested in triplicate. Compressive strength was calculated by using the formula max /S F A , 
where Fmax represents the force applied and A is the cross sectional area of the sample [191]. 
Similarly, compressive strength of (cross-linked scaffolds) in wet condition is also measured 
by following the procedure reported elsewhere [16]. Briefly, the scaffolds were immersed in 
PBS for 30 min and similar process was repeated as mentioned above. 
4.4.8 Swelling behaviour  
Swelling behavior of the developed CS and CS based composite scaffolds was evaluated 
using deionised water at room temperature until they reach equilibrium at different time 
intervals (1 h, 3 hrs, 5 hrs, 7 hrs, 24 hrs and 42 hrs). The weight of the scaffold samples before 
immersion in water is DRYwt and after immersion at particular time point is denoted as 
WETwt. The following formula (Mathtype 5.0) was used to determine % swelling of scaffold 
[16]. 
% ( ) / 100wt wt wtSwelling WET DRY DRY                ................... (1) 
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4.4.9 In-vitro biodegradation study  
In-vitro biodegradation study of the developed CS and CS based composite scaffolds was 
performed by soaking them in PBS containing 500 µg ml
-1 
of lysozyme. The initial dry weight 
of the scaffold samples were weighed and noted as WI. The soaking time of the samples was 
1,7,14 and 28 days. The samples were removed at regular time intervals and freeze dried 
before calculating the final weight, WF.  The remaining weight % (WR) was calculated 
according to the formula given below. All the experiments were performed in triplicates [38].  
              % 100 [( ) / 100]o t oWeight remaining W W W            .................... (2) 
4.4.10 Bioactivity  
SBF was prepared according to the previous reports by adding NaCl (7.995 g), KCl (0.224 g), 
CaCl2·2H2O (0.368 g), MgCl2·6H2O (0.305 g), K2HPO4 (0.174 g), NaHCO3 (0.349 g), and 
Na2SO4·10H2O (0.161 g) to 1 L of distilled water in the same order as mentioned [195]. The 
final pH of the solution was maintained at 7.4 by the addition of Tris/HCl. In order to assess 
the bioactivity of developed scaffolds in-vitro, the samples were incubated in the prepared 
SBF. 1.5 g of the sample was placed in SBF (20 ml) and incubated at 37°C for 1, 7, 14, 21 
days. After each time point of soaking, scaffolds were taken out from SBF, rinsed with 
distilled water and the moisture was removed with tissue paper. Finally the samples were 
vacuum dried at room temperature to remove the traces of moisture present in them. SEM was 
used to observe the crystals formed on the scaffold surface. Morphology and elemental 
analysis of the scaffolds were done using SEM and EDX facilities [191]. 
 
4.5 In-vitro cell study 
4.5.1 Isolation and culture of MSCs 
Umbilical Cord Blood was collected from the Ispat General Hospital, Rourkela, India with 
prior consent of the patient. Mononuclear cells (MNCs) were isolated in our stem cell lab by 
Ficoll Hypaque technique described in literature [196]. The isolated MNCs were cultured in 
Dulbecco’s Modified Eagle Medium adjunct with 10% fetal bovine serum, 1% non-essential 
amino acid, 1% 200mM L-glutamine, 2% 1M HEPES [4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid )] buffer, 0.150 gms/liter L-ascorbic acid, 100U/ml penicillin 
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and 0.1 mg/ml streptomycin [expansion medium].  The cell culture conditions were 37
 0
C, 5% 
CO2 with 80% relative humidity. Based on the unique adherent property, MSCs were 
separated from non-adherent cells in culture flasks and non adherent cells were discarded. The 
adherent cells consisting of MSCs were washed thoroughly with D-PBS/EDTA and 
supplemented with freshly prepared expansion medium. The cells were cultured upto 4
th
 
passage by changing the media twice in a week.  
4.5.2 Characterization of MSCs 
Fluorescence activated cell sorting (FACS ARIA III; BD Biosciences) was used to sort the 
MSCs from the cultured MNCs. CD90 FITC-, CD73- FITC, CD105- FITC, CD44-FITC, 
CD45 FITC, HLA-DR FITC and CD34 FITC (BD Pharmingen, San Jose, CA make) were 
used for sorting.  CD44, CD90, CD73 and CD105 were used as positive markers. Further 
culturing of sorted MSCs was done in DMEM by changing media twice in a week. Fibroblast 
like morphology of cultured cells indicates the presence of mesenchymal stem cells. 
4.5.3 Cell seeding and culture 
Scaffolds (10x10x1.5 mm) were sterilized prior to cell seeding by soaking in 70% ethanol and 
10 U/ml penicillin solution for 2 hrs followed by sterile PBS wash. Cells from 4
th
 passage 
were seeded on sterilized scaffolds with a seeding density of  5 × 10
6 
cells/ml by static method 
[197]. The cell seeded scaffolds were incubated in culture medium with a media change for 
every 3 days.  
 
4.5.4 Cell morphology and cell attachment  
Human mesenchymal stem cell (hMSCs) seeded CS and CS based composite scaffolds were 
cross-linked with 4% paraformaldehyde in phosphate buffered saline (PBS). 2% (v/v) 
gluteraldehyde was used for fixing the cells and the samples were rinsed with wash buffer. 
Osmium tetroxide (1%) was added to the samples and kept aside for 30 min. Then the 
samples were rinsed with wash buffer for five times and dehydrated with series of ethanol 
gradations (50, 70, 80, 95 and 100%) for 10 min each [128]. Finally the samples were air 
dried at 37°C and sputter coated with gold, platinum for 30 sec prior to imaging. 
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(Quorumtech, Q150RES, Czech Republic). Images were taken by SEM [JEOL-JSM 6480 
LV], SEM [Tescan Vega-3, SBU-USA] and Field Emission Scanning Electron Microscopy 
(FE-SEM) [Nova SEM-Czech Republic] in high vacuum at 30 kV. 
4.5.5 Metabolic activity  
4.5.5.1 MTT assay 
The metabolic activity of hMSCs cultured on CS and CS based composite scaffolds was 
evaluated quantitatively by MTT [3-(4, 5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide] 
assay [198]. Fresh media was supplemented to the cells consisting of 100μl MTT solution 
(diluted in 1:10 PBS). Then the cells were incubated at 37°C for 4 hrs 0.5 ml DMSO was 
added and centrifuged at 1000 rpm for 5 min.  The optical density (O.D) of intense pink 
colored formazan derivative was measured using a spectrophotometric plate reader (2030 
multi label reader Victor X3, Perklin Elmer, USA) at 595 nm. 
4.5.6 Cell proliferation study 
4.5.6.1 Fluorescence Microscopy  
CS and CS based composite scaffolds with a dimension of 1cm×0.5cm×1mm were used for 
fluorescent imaging. Cell (hMSCs) seeded scaffolds were cultured for predetermined time 
periods, collected on a clean microscopic slide and finally mounted with glycerol: PBS (1:1 
ratio). Fluorescent microscope [Carl Zeiss E600, Wavelength= 450 nm] was used for imaging 
using a green filter at wavelength 490 nm [199].  
4.5.6.2 Alamar blue assay 
Proliferation of hMSCs on the developed scaffolds was checked by Alamar blue dye 
reduction assay at specific time intervals of 3, 5 and 7 days of culture. The colour change of 
alamar blue dye can be attributed to the reduction of dye by mitochondrial enzymes. 100 µL 
of Alamar blue was added to the scaffolds in 1 ml of the media and incubated for 5 h at 37ºC.  
The absorbance was measured at 570 nm using a multi plate reader and proliferation was 
calculated according to manufacturer’s protocol [200]. 
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4.5.6.3 DNA quantification assay  
Proliferation of hMSCs on CS and CS based composite scaffolds was also studied by DNA 
quantification assay. Cell scaffold constructs from each predetermined time period of culture 
(3, 7, 14 and 21 days) were collected and washed with serum free DMEM to remove the 
traces of serum components. Finally the constructs were washed with PBS and cells were 
lysed using 0.4 mL of Lysis buffer containing 10 mM tris and 2% triton for 1 hr. Quant-it 
PicoGreen reagent was used according to the manufacturer’s protocol. Briefly, 100 µL of 
Quant-it PicoGreen reagent was added to 100 µL of sonicated cell lysate and incubated at 
room temperature for 10 min. The fluorescence was measured with a spectrofluorometric 
plate reader (LS 55, Perklin Elmer, USA) at excitation and emission wave lengths of 528 nm 
and 485 nm respectively. The readings were correlated with the number of cells using a 
calibration curve constructed with hMSCs of known concentration [201].  
4.5.7 Cell distribution and cytoskeletal organization  
Cell distribution and cytoskeletal organisation on cell seeded scaffolds were analyzed by 
confocal laser scanning microscopy using Hoescht and Alexa Floor 488 Phalloidin according 
to the protocol followed elsewhere [202]. Briefly, cell scaffold constructs after 14 days of 
culture were fixed with 4% paraformaldehyde for 1 min followed by Hoescht nuclear staining 
for 1 min. Prior to stain F–actin, the cell seeded scaffold constructs were fixed with 3.7% 
paraformaldehyde for 10 min followed by permeabilization with Triton-X for 5 min and then 
blocked with PBS containing 1% Bovine Serum Albumin for 30 min. Finally, the constructs 
were stained with Phalloidin conjugated to Alexa Floor and the samples were examined by 
confocal laser scanning microscope (CLSM Leica SP8 inverted microscope, Germany 
equipped with HeNe 633 nm laser) at excitation wavelength of 488 nm and 633 nm. Images 
were collected in z-stack mode with optical sectioning at 0.2 µm and converted to 3D images 
in Leica LAS AF lite software to visualise distribution of cells inside the scaffold. 
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4.5.8 Osteogenic differentiation potential 
4.5.8.1 Alkaline Phosphatase assay (ALP) 
Alkaline phosphatase (ALP) activity of hMSCs grown on CS and CS based composite 
scaffolds was performed to assess the osteogenic differentiation ability by using Quanti 
Chrom Alkaline Phosphatase Assay Kit according to manufacturer’s protocol. In brief, the 
scaffolds cultured in osteogenic differentiation medium for 3, 7, 14 and 28 days were 
collected and washed with PBS. The cells were treated with 1% Triton X-100  for 60 min and 
centrifuged at 10,000 rpm at 4˚C for 15 min.190 µL of working solution having 10 mM p-
nitro phenyl phosphate and 5mM magnesium acetate was added to the 10 µL cell lysate and 
incubated for 4 min at 37°C. The absorbance was measured at 405 nm with a micro plate 
reader at time zero and after 4 min. ALPase activity was calculated according to the equation 
given below and the measured ALPase activity was normalized to DNA content [201]. 
24 0
[( ) / ( ) 808]t t calibrator ddH OA A A A                                         ............................ (3) 
4.5.8.2 Measurement of total calcium content  
Total calcium content of hMSCs cultured on CS and CS based composite scaffolds was 
measured by QuantiChrom Calcium Assay according to manufacturers’ protocol. Briefly, 0.2 
ml of 2M HCl was added to 0.2 ml aliquot of sonicated cell lysate to dissolve the calcium 
content of mineralized matrix. 5 μL of cell lysate was added to 200 μL of working solution 
and incubated for 3 min at 27ºC. The absorbance was measured at 612 nm with a micro plate 
reader. The measured absorbance was correlated to equivalent amounts of Ca
+2
 using a 
standard calibration curve of CaCl2 solution of known concentration ranging from zero to 200 
µg/mL [201]. The scaffold without cells was used as control. The calculated Ca content of 
control (time zero) was deducted from the amount of total Ca content obtained at 
predetermined time points. 
4.5.8.3 In-vitro biomineralization (Alizarin red assay) 
Alizarin red assay was used to quantify the mineralization of hMSCs on the CS based 
composite scaffolds. hMSCs seeded scaffolds were washed with PBS and fixed with 4% 
paraformaldehyde for 20 min. The scaffolds were then washed thoroughly with distilled 
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water. 400 μL of Alizarin red stain (40 mM pH 4.1) was added and the samples were 
incubated at room temperature for 10 min. Images were taken using optical microscope. In 
order to determine the mineralization, alizarin red stains were removed from the scaffolds by 
treating with 500 μL of cetylpyridinium chloride for 1 hr. 300 μL of the extract was collected 
and O.D was measured at 540 nm using 2030 multi label reader Victor X3, Perklin Elmer, 
USA [203]. The scaffold without cells was used as control.  
4.5.8.4 Estimation of GAG (Glycosamino glycan) 
The amount of intracellular GAG secreted by the MSCs cultured on developed scaffolds was 
evaluated by GAG assay using 1, 9-dimethylmethylene blue (DMMB) in a microplate reader. 
The intracellular GAG was removed from the cells by digestion with papain solution (125 
μg/mL of papain, 5 mM L-cystein, 100 mM Na2HPO4, 5 mM EDTA) at pH 6.8, 60°C for 16 
hrs and analyzed using a microplate reader.  Then, the absorbance of the GAG-DMMB 
complexes was measured at 525 nm [204].  
4.5.8.5 Expression of osteogenic specific genes  
Semi-quantitative RT-PCR was performed to assess the expression of osteoblast related 
markers at mRNA level for cells cultured for 28 days. Primer sequences used for the study are 
shown in Table 4.1. For RT-PCR analysis, the total cellular RNA from osteoblasts 
(differentiated from hMSCs) was extracted by TRIzol. Synthesis of cDNA was carried out 
using first strand cDNA synthesis kit following the manufacturer’s protocol. The synthesized 
cDNA was used as a template for the semi-quantitative RT-PCR following the procedure 
followed elsewhere [205]. The β-actin gene was used as a housekeeping gene for normalizing 
mRNA level of ALP, OC, ON, BSP and Col-1 gene. The PCR reaction mixture consists of 1X 
PCR buffer, 50 mM mgCl2, 10 mM dNTPs, 0.2 µM of each primer, 1U Taq polymerase and 
autoclaved water. PCR chain reactions were performed at 94°C for 2 min, 35 cycles at 96°C 
for 30s, 55–63°C for 45s, and 72°C for 45s and 72°C for 10 min. Finally, the amplified DNA 
fragments (PCR products) were subjected to electrophoresis on 1.5% agarose gel and the band 
intensity was analysed using Image J software for evaluating the relative expression of 
selected genes (BioRad, USA). 
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Table 4.1: RT-PCR Primers used for expression of osteogenic specific genes 
Gene Direction  Primer sequence  
β-actin Forward 
Reverse 
5
1
- TCTACAATGAGCTGCGTGTG-3
1 
5
1
- CAACTAAGTCATAGTCCGCC-3
1 
Bone Sialo protein (BSP) Forward 
Reverse  
5
1
- CTTACCGAGCTTATGAGGATGAATA-3
1 
5
1
- ATTGGGAAGCAGAAAGATTAGATG-3
1 
Osteonectin (ON) Forward 
Reverse  
5
1
- CAC TGG CGC TGC AACAAG A-3
1 
5
1
- CAT TCC GGA GCT CAGCAG AAT-3
1 
Alkaline phosphatase (ALP) 
 
Forward 
Reverse 
5
1
- GGG GGT GGC CGG AAATAC AT-3
1 
5
1
- GGG GGC CAG ACC AAAGAT AG-3
1 
Osteocalcin (OC) Forward 
Reverse 
5
1
- CCC AGG CGC TAC CTGTAT CAA-3
1 
5
1
- GGT CAG CCA ACT CGTCAC AGTC-3
1 
Collagen I (Col I) Forward 
Reverse 
5
1
- GGCAATAGCAGGTTCACGTACA -3
1 
5
1
- CGATAACAGTCTTGCCCCACTT-3
1 
 
4.6 In-vivo biocompatibility test in animal model 
The developed scaffolds have been transplanted under the skin of 4 to 6 weeks old mice as per 
procedure described previously with a slight modification [206]. In brief, intra-peritoneal 
injection of avertin (Tri-bromoethanol, 0.25 mg/g of body weight; 2-methyl-2-butanol, 0.16 
mL/g) was given to anesthetize the mice and the skin was sterilized with 70% (v/v) ethanol. 
Approximately ~1 cm linear incision was made on the back in the cervical region of NMRI-
nude mice and scaffolds have been implanted subcutaneously. Scaffolds of dimension 5 x 5 
cm
2 
have been transplanted into the surgically-created subcutaneous pouch and the incision 
was closed using nylon suture. The mice were monitored routinely for the skin and systemic 
diseases, if any. After one month, they were sacrificed by cervical dislocation and the 
scaffolds were explanted. Histological analysis was done with the skin around the site of 
transplantation [207]. The skin samples were fixed with 10% (v/v) neutral buffered formalin 
and dehydrated in ascending grades of 40%, 60%, 80%, 95% and 100% ethanol and then 
embedded in paraffin wax. 5 µm thick slices of specimens were made by microtome 
sectioning and examined histologically after hematoxylin and eosin staining [13, 208]. All the 
experiments were performed under the aseptic condition in compliance with the guidelines for 
care and use of animals in research and teaching, published by the Federation of Animal 
Science Societies (3rd Edition, 2000), and were approved by the Institutional Biosafety and 
Ethical Committee, University of Konkuk, South Korea.  Efforts were given to ameliorate the 
suffering of animals. 
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4.7 Statistical analysis 
Statistical differences were evaluated by the Tukey-Kramer test after one way analysis of 
variance at p < 0.05 by using online version of graphpad quick calc software. The statistical 
analysis data was expressed as mean ± standard deviation with n = 3. 
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From literature it is evident that chitosan (CS) is a potential scaffold material for tissue 
engineering applications because of its high biocompatibility, biodegradability, intrinsic anti 
bacterial property, renewability and bio-functionality [57]. However, CS lacks sufficient 
mechanical strength and bioactivity that limits its application in bone tissue engineering. 
Recent research, therefore, focuses on the improvement of mechanical strength and 
bioactivity of CS by adding bio-ceramics. Among bioactive ceramic materials, hydroxy 
apatite (HAp) [11, 20, 54, 149],  and beta tricalcium phosphate (β-TCP) [12, 73, 228] are 
attractive scaffold materials for bone tissue repair and regeneration due to their compatibility 
to natural bone tissue and excellent osteogenic property [209]. However, the limitation of 
HAp is that it is not degradable in physiological conditions and resides within the regenerated 
bone tissue [55]. The use of β-TCP is advantageous with respect to its biodegradability [50] 
and its osteoconductive as well as osteoinductive property instead of mainly osteoconductive 
property of HAp [210]. Development of 3D porous scaffolds that can resemble natural extra 
cellular matrix by suitable fabrication technique is another important aspect for tissue 
engineering applications [63]. These methods offer scaffolds with adequate pore size and 
porosity. In this context, freeze-gelation which works on the principle of phase separation 
offers a simple, low cost, easy to scale up, time and energy saving method for the fabrication 
of 3D porous scaffold that can mimic unique hierarchical architecture of bone matrix. [74, 76, 
78]. Keeping the above aspects in view, in this phase of thesis, efforts have been given to 
develop CS/β-TCP composite scaffolds by incorporating β-TCP as a bioactive material by 
freeze-gelation method. The effect of micro and nano size β-TCP on CS scaffold properties 
was investigated to achieve optimal mechanical strength of freeze-gelled scaffolds. The 
potentiality of the scaffold for bone tissue regeneration was evaluated by various physico-
chemical, mechanical and biological characterizations. Result and discussion of this research 
work is described in this chapter.  
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5.1.1. Characterization of β-TCP powder  
The commercially available β-TCP powder was characterised by standard methods and the 
results are presented here- 
The morphological features were observed by FE-SEM images as shown in figure 5.1. 
 
Figure 5.1:  FE-SEM images of micro and nano β-TCP  
The average particle size of β-TCP was measured by DLS method. The particle sizes are 
811nm and 82nm for micro β-TCP and nano β-TCP respectively.  
The average surface area of micro β-TCP and nano β-TCP was calculated by BET and the 
corresponding values are 1.24 m
2 
/gm and 6.67 m
2 
/gm. 
The crystallite size measured from XRD data are 142 nm and 13.9 nm of micro and nano β-
TCP particles respectively.    
 
5.1.2 Rheological behaviour of CS and CS/β-TCP composite solutions  
The flow behaviour of a polymer solution has been reported to depend on the composition and 
stability of the composite suspensions [211]. Viscosity was therefore analyzed for both 
polymer (CS) and polymer-ceramic solutions (CS/β-TCP) under varied shear stress. All the 
solutions have shown non-Newtonian behaviour with shear thinning property. Figure 5.2 
depicts the shear thinning ability of pure and composite [CS/micro β-TCP (80:20), CS/nano β-
TCP (80:20)] solutions. CS solution has shown lower viscosity (1.21 Pa s) in comparison to 
the composite solutions with varied micron (1.31-1.99 Pa s) and nano sized β-TCP content 
(1.25-1.36 Pa s). It is further observed that the increase in β-TCP content increases the 
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viscosity of CS/β-TCP composite solution in a linear fashion. The viscosity of all other 
solutions with different β-TCP ratios is shown in Table 5.1. As indicated, the decrease of 
particle size decreases the viscosity of suspension as reported earlier [250]. The homogeneity 
of composite solution is observed to be decreased as TCP concentration increases. As a result, 
the layers in the composite solutions begun to show restricted movement cumulating in 
increased viscosity. This alteration in viscosity has an impact on pore size of developed 
scaffolds as reported  earlier [53].  
 
Figure 5.2:  Rheological behaviour of CS, CS/micro β-TCP (80:20) and CS/nano β-TCP 
(80:20) composite solutions. All the solutions show non Newtonian behaviour with shear 
thinning property.  CS/micro β-TCP and CS/nano β-TCP scaffolds are represented as CS/µ 
β-TCP and CS/n β-TCP in the figure respectively. [Data with other ratio of CS and β-TCP 
are not shown] 
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Table 5.1: Viscosity of CS, composite scaffolds with varied content of β-TCP 
 
S.No Sample Viscosity (Pa s) 
1 CS 1.214 
2 CS/µ β-TCP (90:10) 1.317 
3 CS/µ β-TCP (80:20) 1.609 
4 CS/µ β-TCP (70:30) 1.722 
5 CS/µ β-TCP(60:40) 1.860 
6 CS/µ β-TCP(50:50) 1.991 
7 CS/n β-TCP (90:10) 1.256 
8 CS/n β-TCP (80:20) 1.277 
9 CS/n β-TCP (70:30) 1.313 
10 CS/n β-TCP (60:40) 1.342 
11 CS/n β-TCP (50:50) 1.368 
 
5.1.3 Preparation of scaffolds 
3D porous chitosan and its composite scaffolds with varying amount of micro and nano size 
β-TCP were prepared by freeze-gelation method. The scaffolds are shown in Figure 5.3. The 
scaffolds are designated as CS (pure chitosan), CS/micro β-TCP (composite scaffold with 
micro size β-TCP) and CS/n β-TCP (composite scaffold with nano size β-TCP). 
 
Figure 5.3 Developed pure CS scaffolds (a), CS/nano β-TCP composite scaffolds (b, c) and 
CS/micro β-TCP freeze-gelled composite scaffolds (d) 
 
 Results and Discussion 
    
52 
 
5.1.4 Morphology and pore size  
Adequate pore size and interconnectivity of pores in scaffolds are vital factors for the 
diffusion of oxygen and nutrients to the cells and foster transfer of metabolic wastes [102]. 
SEM images were taken to visualize these features. As observed, pure CS scaffold shows 
porous and excellent interconnected network of open pore microstructures [Figure 5.4-(a)] 
with a pore size range of 61-171 μm. Similar morphology and pore structure are also achieved 
with composite scaffolds. However, the pore diameter of CS scaffolds is found to decrease 
with increase in β-TCP content. This may be attributed to a slight increase in viscosity of 
composite solutions with increase in β-TCP content, which leads to restricted movement of 
ice crystal during freezing as reported earlier [54]. The ice crystal mobility responsible for 
pore diameter is reduced in high viscous solutions and hence a decrease in pore size of 
composite scaffolds is observed as compared to pure CS scaffolds. Similar observation of 
decrease in pore size was reported  earlier when β-TCP was incorporated in various weight 
ratios into CS/gelatin 3D composite matrices developed for bone tissue regeneration [53]. The 
other reason may be due to the loss of structural integrity of scaffolds at higher content of β-
TCP resulting in irregularity in the pores and thus decrease in pore size [54]. Similar findings 
related to decrease in pore size of CS scaffolds reported earlier by incorporating bio-ceramics 
such as HAp, β-TCP and wollastonite [54, 68-69]. As observed, β-TCP is found to be more or 
less uniformly distributed over the scaffold surface and on the pore walls. Figure 5.4 
illustrates that there is no significant difference observed between pore size of nano β-TCP 
and pure CS scaffolds. On the contrary, scaffolds with varied micro β-TCP composite 
scaffolds show smaller pore size in comparison to pure CS scaffolds as shown in Figure 5.4 
(b - f). The pore size range obtained with varied micro β-TCP content is 45-165 μm. 
However, after a certain limit of micro β-TCP content (>30% wt), the distribution of β-TCP is 
found to be non uniform due to the formation of agglomerates along the periphery of the 
pores as shown in Figure 5.4 (A-b) and Figure 5.4 (B) Whereas with CS/nano β-TCP 
composite scaffolds, the pores are found to be regular [Figure 5.4 (A - c) and Figure 5.4 (C)] 
and β-TCP is uniformly distributed over the entire scaffold surface and in the pore walls. The 
pore size range obtained with CS/nano β-TCP scaffold is 51-168 μm. The pore size range of 
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developed scaffolds with varied ratios of micro and nano β-TCP were measured and depicted 
in Table 5.2. Published reports suggest that the pore size of scaffolds should be in the range 
of 50-300 μm for bone tissue engineering applications and results obtained matches with the 
reported pore size range [134]. Thus the developed freeze-gelled CS and CS/β-TCP composite 
scaffolds have the required morphological necessity in terms of pore size and interconnecting 
pore networks for proper cell growth and proliferation of osteoblasts. 
Figure 5.4: SEM images of the prepared freeze-gelled scaffolds. Open porous 
microstructure with interconnectivity is evident in pure CS and CS/β-TCP composite 
scaffolds. Decrease in pore size of composite scaffolds with increase in β-TCP content is 
noticed 
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Figure 5.4 (A): SEM images of scaffolds at higher magnification. Pure CS scaffold (a); 
agglomerates of micro β-TCP are represented with white colour arrow marks (b); uniform 
distribution of nano β-TCP is represented with white colour arrow marks in (c) 
 
Figure 5.4 (B): SEM images of CS/β-TCP scaffolds at higher magnification. Agglomerates 
of micro β-TCP are represented with white colour arrow marks 
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Figure 5.4 (C): SEM images of CS/β-TCP scaffolds at higher magnification. Uniform 
distribution of nano β-TCP is represented with white colour arrow marks 
 
5.1.5 Porosity  
The porosity of scaffold is an important factor that decides not only the transport of nutrients 
required for cell growth but also cell infiltration and migration [5, 117]. Table 5.2 shows the 
% porosity of the developed scaffolds.  As indicated, the porosity of CS scaffold (86 ± 3.21) 
is decreased with increase in both nano and micro β-TCP content. The corresponding % 
porosity of CS/micro β-TCP and CS/nano β-TCP composite scaffolds are 80.7 ± 2.33 to 74.2 
± 5.2 and 84.6 ± 2.65 to 78.3 ± 2.9 respectively.  Furthermore, the decrease in porosity is 
slightly higher in case of scaffolds with micro β-TCP than scaffolds loaded with nano β-TCP. 
The overall trend of porosity is CS>nano β-TCP>micro β-TCP.  However, the porosity of the 
composite scaffolds is still high enough for bone tissue engineering applications. This 
phenomenon of decrease in porosity may be attributed to the gradual increase in the density of 
β-TCP in CS matrix as reported earlier [54]. The porosity result has followed the same trend 
as pore size and the result obtained in our study is in good agreement with the results reported 
earlier when wollastonite and HAp were used for the development of composite CS scaffolds 
[54, 119]. 
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5.1.6 Phase analysis  
X-ray diffraction pattern was used to analyze the phase changes, if any occured in CS based 
composite scaffolds. A broad dome shaped curve is shown with pure CS scaffold representing 
its amorphous nature as shown in Figure 5.5 [38], whereas in composite scaffolds, the CS 
peak is completely dominated by the incorporation of ceramic which is attributed to high 
crystalline nature of β-TCP [36]. The broad, dome-shaped and low-intensity peaks at 2θ = 
9.16° and 20.6° correspond to pure CS and that of β-TCP are at 2θ = 31.7°, 32.1° and 39.7° 
confirming the presence of β-TCP in the composite scaffold. Furthermore, the effect of nano 
β-TCP is higher in dominating the CS peaks at 2θ = 20.6° as compared to micro β-TCP.  
Diffractograms of composite scaffolds with varied ratios of micro and nano β-TCP are shown 
in Figure 5.6 (C-A and B). As indicated, no significant change in peak intensity of β-TCP is 
observed with varied size of β-TCP. Further, the crystallite size of β-TCP particles in micro 
and nano size in composite scaffold were calculated using XRD peaks of Figure 5.5 (B). The 
corresponding values are 30.8nm and 10.82nm respectively. Thus it is established that the 
increase in crystallinity of CS/β-TCP composite scaffold is due to β-TCP as indicated from 
Figure 5.5 and 5.6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 (A):  XRD pattern of pure CS, CS/micro β-TCP (90:10) and CS/nano β-TCP 
(90:10) composite scaffolds. Peaks at 2θ=9.16° and 20.6° denotes CS where as twin peaks at 
2θ=31.7° and 32.1° denote β-TCP. CS peak at 2θ= 20.6° is dominated by the incorporation 
of β-TCP 
 Results and Discussion 
    
57 
 
 
Figure 5.5 (B):   XRD pattern of CS/micro β-TCP and CS/nano β-TCP (90:10) composite 
scaffolds. Crystallite size of micro and nano β-TCP is 30.8nm and 10.82nm respectively 
 
 
      
 
 
Figure 5.6 (C): XRD patterns of freeze-gelled composite scaffolds consisting of varying 
ratios of chitosan and β-TCP. Extent of decrease in amorphous nature of CS with respect to 
size of β-TCP is well represented. Nano sized β-TCP has completely dominated the 
amorphous nature of CS indicating higher crystallinity to composite scaffolds as compared 
to scaffolds with micro β-TCP as denoted with black colour arrow marks. The XRD peaks 
of composite scaffolds are compared with XRD peaks of pure CS peaks 
 
A B 
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5.1.7 Functional analysis  
An infrared spectrum represents the characteristics of a material with absorption bands. Thus 
infrared spectroscopy can provide a positive identification of every different constituent 
present in the composite matrices [154]. FT-IR analysis of CS and CS/β-TCP composite 
scaffolds was therefore, done to evaluate the interaction between the individual components 
present in the scaffolds. The bands generated as a result of chemical interactions is shown in 
Figure 5.7. Pure CS scaffold shows bands around 897 and 1154 cm
-1 
of assigned saccharide 
structure and the characteristic bands of N–H bending (amide-I) of CS is observed at 1560 
cm
-1 
[70]. The typical band range of tetrahedral anions is 790–1190 cm-1. Our analysis has 
demonstrated PO4
-3 
bands at 1040, 1122, 610, and 551 cm
–1
 fall within the reported range 
[211].
 
Reports suggest the shifting and formation of new bands due to the  interaction of 
ceramic material with the polymer functional groups [38]. The bands ranging from 1560-1587 
cm
-1
 N-H bending has been shifted to 1556-1573 cm
-1 
which may correspond to the 
interaction of β-TCP with CS. The bands around 1000-1300 cm-1 are due to the interaction of 
phosphate with oxygen and nitrogen of CS [130]. IR pattern of composite scaffolds with 
varying content of β-TCP are not shown as no significant variation between the obtained 
peaks is observed. 
 
Figure 5.7: FT-IR spectra of CS and composite scaffolds. Bands ranging from 1560-1587 
cm
-1
 corresponds to N-H bending has been shifted to 1556-1573 cm
-1 
due to the interaction 
of P=O with CS 
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5.1.8 Compressive strength 
The scaffolds must possess enough strength to withstand the force exerted by the neo tissue 
formed under in-vivo handling of implanted scaffold [212]. The stress strain curve and the 
corresponding compressive strength of the developed porous CS and CS/β-TCP composite 
scaffolds are shown in Figure 5.8 (a) and (b) respectively. It is clear from Figure 5.8 (b) 
that, the compressive strength (0.19 ± 0.05) of CS scaffold is remarkably increased with the 
addition of both types and content of β-TCP. The increase in compressive strength is due to 
reinforcing effect of bio-ceramic.  The enhanced mechanical strength of polymeric scaffolds 
by the  incorporation of bio-ceramic has also been reported earlier[162]. Further, the 
compressive strength of CS/micro β-TCP composite scaffolds is increased with increase in β-
TCP content which is due to the good dispersion of the ceramic material into the CS polymer 
matrix that helped the stress to spread over a larger area of the composite scaffold surface. 
However, a decline in compressive strength is observed when the β-TCP content was over 
30%. This decrease in compressive strength at higher β-TCP content is due to the 
agglomeration of β-TCP observed in CS matrix (Figure 5.5) that led the stress to be 
concentrated at the interface of the polymer-ceramics. When the particle size is in nano range, 
the reinforcement effect is found to be better in achieving higher compressive strength [213]. 
A linear relationship of compressive strength is observed with CS composites loaded with 
nano β-TCP (upto 40 wt%) and a slight decrease in compressive strength is observed with 
further increase in β-TCP content. This may be due to the decreased ability of scaffold to 
further reinforce the ceramic material into CS polymer matrix. More precisely, the 
compressive strength of scaffolds with nano β-TCP has been increased steadily upto 40% 
[CS/nano β-TCP 60:40-2.67 ± 0.21 MPa] and then a slight decrease in strength is observed 
[CS/nano β-TCP 50:50-2.55 ± 0.15 MPa] which represents the desired compressive strength of 
typical cancellous bone 2-10 MPa [214]. The compressive strength of all the developed 
scaffolds with varying micro and nano β-TCP content is depicted in Table 5.2. The high 
surface-to-volume ratio of nano size particle results in improved mechanical properties of bio-
ceramics as reported earlier with β-TCP, wollstonite, HAp and bioglass [4, 69, 149, 187]. A 
similar increase in compressive strength of CS gel and 3-D CS scaffolds has also been 
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reported and the strength was increased to 0.8 and 1.8 MPa respectively by incorporating β-
TCP [10, 53].  
 
Figure 5.8 (a):  Stress-Strain plot of CS and CS/β-TCP composite scaffolds 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 (b): Compressive strength of CS and CS/β-TCP composite scaffolds with 
different weight ratios of CS and β-TCP. Compressive strength of CS/ micro β-TCP 
composite scaffold increases with increase in β-TCP content upto 70:30 CS/ β-TCP ratio 
beyond which a decline trend is observed due to the agglomeration of β-TCP in the polymer 
matrix. Increase of nano β-TCP content has improved compressive strength of composite 
scaffold upto 40% 
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5.1.9 Swelling behaviour  
The swelling behaviour is one of the key factors of a scaffold determining its ability to qualify 
for in-vitro cell culture study. Swelling enables the cells to utilize the internal region of 
scaffolds upto maximum possible extent [234-235]. The trend obtained with swelling 
behaviour of CS and CS/β-TCP composite scaffolds is represented in Figure 5.9. The % 
swelling of all the developed scaffolds with varying β-TCP content is shown in Table 5.2. 
Among the developed scaffolds, pure CS scaffold shows a higher swelling percentage 
(~326%) than any of the CS/β-TCP composite scaffolds. The swelling ratio is observed to be 
decreased with increase in ceramic content. The decrease in  % swelling of composite 
scaffolds is caused by the incorporation of β-TCP in the polymer matrix which ultimately 
leads to a decrease in diffusion of water as reported earlier when HAp was used as filler in CS 
[54]. The composite scaffolds with nano β-TCP shows higher swelling rate (~190 to 275%) as 
compared to scaffolds loaded with micro β-TCP (~155 to 212%) which may be due to the 
difference in distribution ability of micro and nano sized filler [38]. The other reason for the 
difference in swelling behaviour of composite scaffolds is may be attributed to gradation in 
pore size and porosity [38]. 
 
Figure 5.9: Swelling behaviour of CS and CS/β-TCP composite scaffolds. Pure CS scaffold 
shows a higher swelling than composite scaffolds. The swelling ratio decreases with 
increase in ceramic content that implies that the ceramic content has a direct influence on 
the diffusion of water into the scaffold matrix 
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5.1.10 Measured contact angle  
The water contact angle is determined to assess the hydrophilicity characteristics of the  
scaffold surface which is important for various cellular responses as reported earlier [215].  
Therefore, the contact angle of the best composite scaffolds selected based on high 
mechanical strength was measured and compared with pure CS scaffold. There is no 
significant change in contact angle is observed between pure CS scaffold (51.2 ± 0.8°) and 
CS/nano β-TCP (60:40) [51.9 ± 1.1°] which represents their similar hydrophilic 
characteristics. However, a slightly lower hydrophilicity characteristic is shown by CS/micro 
β-TCP (70:30) [53.1 ± 0.5°] scaffold which may be attributed to micron size of the ceramic 
particle which restricted the flow of water through the scaffold architecture. Thus it has been 
demonstrated the superior surface property of CS composite reinforced with nano β-TCP is 
favourable for bone tissue engineering application than the composite made with micro sized 
β-TCP.  
5.1.11 In-vitro biodegradation study  
The degradation of scaffolds is one of the major goal of tissue engineering  research because 
of the self repairing ability of various tissues are different implying that scaffold should have 
corresponding degradation rates to facilitate new tissue synthesis [216]. So, adequate control 
over the rate of degradation plays a major role to be on par with the growth rate of neo tissue 
formed [74]. Therefore, biodegradation of the prepared CS and various CS/β-TCP composite 
scaffolds was studied in phosphate buffer saline containing Lysozyme for four weeks and 
compared with control. Biodegradation data is shown in Figure 5.10. The degradation rate of 
CS scaffold (31% of its initial weight) is observed to decrease with increase in micro and 
nano β-TCP content. Further, as β-TCP content increases, a decelerated degradation rate is 
observed upto 30 and 40 wt% of micro and nano β-TCP loading, beyond which a slight 
increase in degradation rate is found. Scaffolds with varied ratios of micro and nano sized β-
TCP have degraded to 25-30% and 16-24% of their initial weights respectively. However, the 
best result is achieved with CS/micro β-TCP (70:30) and CS/nano β-TCP (60:40) scaffolds as 
they degraded to 25% and 16% respectively. The difference in degradation rate is probably 
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due to the higher mechanical stability of nano β-TCP scaffolds as they are uniformly 
distributed throughout the matrix, resisting PBS seepage into the scaffold architecture. Similar 
trend in decreased degradation has been observed when nano HAp was incorporated in CS 
matrix as reported earlier [38]. The result further reveals that the addition of nano sized β-
TCP decelerated the rate of degradation of CS higher than scaffolds with micro β-TCP. Thus 
it has been demonstrated that the degradation rate of CS can be controlled by β-TCP content 
and use of nano β-TCP is more advantageous than micro size β-TCP as potential bio-ceramic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Observed degradation behaviour of CS and CS/β-TCP composite scaffolds by 
soaking in PBS for four weeks. The degradation rate of CS scaffold is decreased with 
increase in β-TCP content upto 30 and 40 wt% of micro and nano β-TCP loading, beyond 
which a slight increase in degradation rate is observed.  Further, nano β-TCP is superior in 
controlling degradation rate of CS than micro size β-TCP 
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Table 5.2: Pore size, porosity, compressive strength and % wt loss of pure CS and CS 
composite scaffolds with different size and ratios of β-TCP. 
 
Scaffold Type Pore size  
range (µm) 
%  Porosity Compressive 
Strength 
(MPa) 
% Mass loss 
[28 days] 
CS 61-171 86.9 ± 3.21 0.19 ± 0.05 31 
CS/µ β-TCP (90:10) 
55-165 80.7 ± 2.33 0.51 ± 0.09 29 
CS/µ β-TCP (80:20) 
53-161  79.3 ± 4.96 0.74 ± 0.08 27 
CS/µ β-TCP (70:30) 
51 -158 77.1 ± 3.21 1.52 ± 0.09 25 
CS/µ β-TCP (60:40) 
49-151 75.7 ± 6.1 1.39 ± 0.11 29 
CS/µ β-TCP (50:50) 
45-147 74.2 ± 5.2 1.12 ± 0.14 30 
CS/n β-TCP (90:10) 
59-168 84.6 ± 2.65 0.76 ± 0.17 24 
CS/n β -TCP (80:20) 
57-166 82.8 ± 3.43 1.21 ± 0.13 21 
CS/n β-TCP (70:30) 55-165 81.2 ± 2.87 1.82 ± 0.19 18 
CS/n β-TCP (60:40) 
55-162  80.1 ± 3.6 2.67 ± 0.21 16 
CS/n β-TCP (50:50) 
51-158  78.3 ± 2.9 2.55 ± 0.15 17 
 
5.1.12 Bioactivity  
Deposition of apatite crystals over the surface of a material assesses its osteogenic behaviour, 
which is one of the key aspects in the development of neo bone tissue [71, 227]. The 
developed composite scaffolds such as CS/micro β-TCP (70:30) and CS/nano β-TCP (60:40) 
were selected for this study because of their higher mechanical strength and favourable 
degradation rate. The pure CS scaffold was used as control. The result of bioactivity is shown 
in Figure 5.11 (a-f). The initiation of the formation of apatite layer on the surface of scaffolds 
was observed after 7 days of treatment (the image of 7
th
 day study is not shown in the figure 
as the apatite deposition was not much noticeable). The amount of apatite formed is gradually 
increased with time with varying degree of deposition on the different scaffolds as shown in 
SEM images (Figure 5.12).  The entire surface area of all the scaffolds is found to be covered 
with Ca and P minerals after 21days. Similar observation of apatite deposition over the entire 
surface of wollastonite loaded on CS scaffolds during 14-21 days of study has been reported 
earlier [54]. In the present study, the higher amount of apatite formation obtained with 
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CS/nano β-TCP may be due to the uniform distribution of nano sized bio-ceramic on the 
scaffold matrix that leads to an increased nucleation sites in CS. The other reason may be the 
higher density of nano sized β-TCP particles on the scaffold matrix which is responsible for 
higher amount of apatite formation on CS/nano β-TCP composite scaffold. The formation of 
white coloured globular entities on scaffold surface is confirmed by EDX and the chemical 
constituents are found to be Ca and P. Furthermore, XRD analysis revealed sharp 
characteristic peaks of formed globular structures at 2θ = 25.2º and 31.8º confirming the 
formation of hydroxy apatite (HAp). Thus it has been demonstrated that the bioactivity of CS 
scaffold can be enhanced by the incorporation of β-TCP. Furthermore, the use of nano size β-
TCP is advantageous than microsize particle achieving higher bioactivity.  
 
 
Figure 5.11: Apatite crystal formation on CS (control), CS/micro β-TCP (a & b) and CS/n 
β-TCP (b)] scaffolds upto 21days of treatment in SBF. EDX analysis shows the components 
of globular structures formed on the surface of developed scaffolds. Deposition of Ca and P 
indicates the constituents of HAp. Furthermore, the prominent peaks at 2θ=25.7º and 31.8º 
in XRD diagram confirm the formation of globular structures of HAp on the scaffold 
surface. Overall, the bioactivity of CS scaffold is shown to be remarkably enhanced by the 
incorporation of nano β-TCP 
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5.1.13 In-vitro cell study 
Among the various CS composite scaffolds prepared using micro and nano size β-TCP, 
CS/nano β-TCP (60:40) was found to be best followed by CS/micro β-TCP (70:30) in terms 
of various physico-chemical, degradation and mechanical properties. Therefore, these two 
composite scaffolds were selected for cell culture study and CS scaffold was used as control. 
 
5.1.13.1 Morphology of hMSCs 
Human mononuclear cells (hMNCs) were isolated from Umbilical Cord Blood by Ficoll 
Hypaque technique and cultured in Dulbecco’s Modified Eagle Medium supplemented with 
fetal bovine serum (FBS), penicillin and streptomycin. Cultured cells upto 4
th
 passage were 
used for cell culture study to assess the cell supportive property of the developed composite 
scaffold matrices. Morphological characterization of MSCs were assessed by phase contrast 
microscopy and illustrated in Figure 5.12. As seen in figure, cells are spherical during initial 
days of culture and have shown fibroblast like morphology at later time periods representing 
the cultured cells are mesenchymal stem cells. Further, the cultured cells attain confluence at 
14
th
 day as depicted in Figure 5.12 (f). 
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Figure 5.12: Morphological changes of hMSCs during 14 days of culture period observed 
under phase contrast microscope at magnification 50X and scale bar 100μm. Initially the 
cells are found to be spherical in shape and slowly changed to fibroblast like morphology 
 
5.1.13.2 Immunophenotypic characterization of hMSCs 
Besides morphology, immunophenotypic characterization of hMSCs was assessed by flow 
cytometry analysis and the results are shown in Figure 5.13. The positive expression of CD90 
(99.01%), CD73 (96.5%) and CD105 (95.5%) and negative expression of CD34 (1.0%), 
CD45 (0.5%), and HLA-DR (1.2%) signify that the cells are MSCs. 
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Figure 5.13: Flowcytometric analysis of cultured hMSCs. The positive expression of CD90 
(99.01%), CD73 (96.5%) and negative expression of CD105 (95.5%) CD34 (1.0%), CD45 
(0.5%), and HLA-DR (1.2%) confirm that the cells are MSCs 
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5.1.13.3 Cell morphology and cell attachment 
Cell morphology and cell attachment are the indicators of the affinity of seeded cells to the 
scaffold and hence are important aspect in forming a cell scaffold construct [30]. The 
attachment and morphological change of MSCs seeded on the various scaffolds are observed 
by SEM micrographs (Figure 5.14) during the 7 days of culture period. As indicated, on day 
3, the cells are shown to be spherical on pure chitosan, whereas MSCs started to elongate on 
CS/micro β-TCP scaffold. However, the cells are observed to attach and well spread on 
CS/nano β-TCP composite scaffold. Moreover, the number of cells is found to be relatively 
higher over CS/nano β-TCP scaffolds as observed on day 7 with spindle like morphology in 
comparison to CS and CS/micro β-TCP scaffolds. This confirms the higher compatibility of 
the scaffolds to the cells thus providing a suitable environment for attachment, spreading and 
proliferation of hMSCs. 
 
 
Figure 5.14:  SEM images of hMSCs seeded on CS (a, b) as control, CS/micro β-TCP (c, d) 
and CS/nano β-TCP (e, f) composite scaffolds representing the morphology, attachment and 
spreading of hMSCs on 3rd (a, c, e), and 7
th
 day (b, d, f) of culture. White arrow marks 
represent significant morphological changes of seeded hMSCs. Change in cell morphology 
from spherical to elongate is observed with increase in culture time.  However, better cell 
attachment and proliferation are depicted on CS/nano β-TCP scaffold 
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5.1.13.4 Metabolic activity by MTT assay 
Cell viability depends on scaffold architecture especially pore size, porosity and their 
interconnectivity [8]. Metabolic activity signifies the potentiality of cells to progress in the 
cell cycle [217]. The metabolic activity was also compared with the metabolic activity of 
hMSCs on pure CS scaffold as control. Figure 5.15 shows the relative cellular metabolic 
activity measured by MTT assay of hMSCs grown over the developed scaffolds during 3, 5 
and 7 days of culture. The number of cells is found to increase with culture time on all types 
of scaffolds with a varying rate of proliferation. However, the highest cellular metabolic 
activity is shown by CS/nano β-TCP composite matrix followed by CS/micro β-TCP and 
control. The corresponding O.D values are 0.614 ± 0.016 with CS/nano β-TCP, 0.52 ± 0.012 -
CS/micro β-TCP and 0.4 ± 0.018 - CS. The maximum compatibility for cells seeded on 
CS/nano β-TCP scaffold confirming its superiority over CS and CS/micro β-TCP scaffolds 
and this may be due to its increase in surface area and surface roughness of the scaffold which 
favour adherence of cells to a greater extent [218].  Further, it is reported that, nano crystalline 
calcium phosphate scaffolds enhance cell proliferation by releasing Ca and phosphate ions in 
the culture medium and similar result of enhanced metabolic activity of seeded cells on CS 
scaffolds reinforced with nano hydroxyapatite has also been reported earlier [18].  
 
Figure 5.15: Metabolic activity of hMSCs on CS (control), CS/micro β-TCP and CS/nano 
β-TCP scaffold after 3, 5 and 7 days of culture. Each point represents the mean ± SD (n= 
3), * and ** shows significant differences between groups at p> 0.05 and p<0.05 
respectively. The metabolic activity increases with culture time and the higher metabolic 
activity is shown by CS/nano β-TCP scaffold 
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5.1.13.5 hMSCs proliferation study  
The proliferation of MSCs seeded on CS/micro β-TCP and CS/nano β-TCP scaffolds was 
evaluated both qualitatively and quantitatively by fluorescence microscopy study and Alamar 
blue and DNA quantification assay respectively. 
 
(i) Fluorescence microscopy 
As mentioned, proliferation activity of hMSCs on scaffolds assessed qualitatively by the 
analysis of fluorescence microscopy images is shown in Figure 5.16 (a-f). The number of 
cells is observed to increase with respect to culture time on both the scaffolds with varying 
degree of proliferation. However, number of cells on CS/nano β-TCP scaffold is higher 
representing higher metabolic activity of hMSCs as compared to pure CS and CS/micro β-
TCP scaffolds. The increased cell proliferation on composite scaffold may be attributed to 
release of Ca and P ions in the culture medium by β-TCP which favoured the increased 
metabolic activity of seeded cells [50]. 
 
 
 
Figure 5.16: Cell distribution is visualized under fluorescent microscopy using FDA dye. 
Images were taken after 3
rd
 (a, c, e) and 7
th
 (b, d, f) days of MSCs culture on CS (a,b), 
CS/micro β-TCP (c, d) and CS/nano β-TCP (e, f) composite scaffolds. A significant increase 
in cell number is observed with time representing an increased proliferation rate. The 
highest metabolic activity is, however, achieved with CS/nano β-TCP composite scaffolds.  
Scale bar corresponds to 200 µm 
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(ii) Alamar blue assay 
Cell proliferation on scaffolds indicates their compatibility and represents appropriate 
behaviour towards hosting the seeded cells [184]. The proliferation of MSCs cultured on CS 
(control), and composite scaffolds upto 7 days of culture was evaluated by alamar blue assay, 
the result of which is shown in Figure 5.17. Alamar blue dye undergoes oxido-reduction 
reactions due to the action of mitochondrial enzymes present in the living cells and changes 
its colour according to the metabolic activity of the cells [17]. The greater reduction in the 
alamar blue dye indicates higher proliferation of hMSCs. Higher percentage reduction o dye 
with increase in culture time is observed with all the scaffolds. However, results of pure CS, 
CS/micro β-TCP and CS/nano β-TCP composite scaffolds showed a significant difference at p 
< 0.05. The higher percentage of alamar reduction than control observed with composite 
scaffolds is due to the presence of Ca ions in β-TCP which triggers the proliferation of seeded 
cells as compared to control. Furthermore, among the developed scaffolds, the highest 
reduction of dye is achieved with CS/nano β-TCP composite matrix.   This higher 
proliferation on CS/nano β-TCP scaffold may be attributed to the uniform distribution of nano 
β-TCP and no agglomerate formation in CS matrix which in turn allows uniform nutrient 
permeation through the scaffold architecture [120]. Our results are in good agreement with the 
previously published reports with keratinocyte proliferation observed on Silk Fibron/CS 
composite scaffolds [17, 152]. Thus, this study proves that, the particle size of bio-ceramic 
has a direct impact on scaffold biocompatibility and cell proliferation as reported earlier when 
CS scaffolds are incorporated with nano sized bioglass and HAp achieving  enhanced 
biocompatibility of CS matrix seeded with osteoblast like cell line MG 63 and MC3T3-E1 
respectively [54, 234].  
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Figure 5.17: Proliferation of hMSCs on CS (control), CS/micro β-TCP and CS/nano β-TCP 
scaffolds on 3, 5 and 7 days of culture. Each point represents the mean ± SD (n= 3) * and 
** shows significant differences between groups at p > 0.05 and p < 0.05 respectively 
 
(iii)  DNA quantification 
The proliferation of MSCs on the developed scaffolds was evaluated by DNA quantification 
assay. Figure 5.18 shows an increase in DNA content of MSCs with time as observed in all 
the developed scaffolds with varying degree of DNA content. The corresponding DNA 
contents of hMSCs cultured on control (CS), and CS/micro β-TCP composite scaffolds on 3 
to 21 days of culture are 75+11 ng/ml to 204±19 ng/ml, 89±9 ng/ml to 254±16 ng/ml and 
respectively. However, among the scaffolds developed under study, CS/nano β-TCP 
composite scaffold has shown the highest DNA content representing highest proliferation rate 
of MSCs. The DNA content of hMSCs cultured on CS/nano β-TCP composite scaffolds on 3 
to 21 days is 91±13 ng/ml to 289±22 ng/ml. Thus CS/nano β-TCP composite scaffold is 
proved to be superior over other CS scaffolds. 
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Figure 5.18: Cell proliferation represented in terms of DNA quantification on CS, 
CS/micro β-TCP, CS/nano β-TCP composite scaffolds observed during 21 days of culture. 
An increased trend in DNA content is observed on all the scaffolds with varying degree of 
DNA content. However, CS/nano β-TCP scaffold shows higher DNA content compared to 
other scaffolds. Each point represents the mean ± SD (n=3) * and ** represents p>0.05 and  
p < 0.05 respectively 
 
Therefore, qualitative and quantitative assessment of hMSCs proliferation demonstrates the 
biocompatibility of developed freeze-gelled scaffolds. 
5.1.13.6 Cytoskeletal organization 
 
Confocal laser microscopy was done to visualize the cell spreading, proliferation,  
development of F-actin and to understand the cell scaffold interactions [219]. Figure 5.19 
shows the distribution and morphology of MSCs cultured on CS/micro β-TCP and CS/nano β-
TCP scaffolds on 7
th
 day. Profuse cell growth is found on CS/nano β-TCP scaffolds compared 
to CS/micro β-TCP scaffolds. It is also observed from the figures that, more number of cells 
covered the scaffold surface on CS/nano β-TCP scaffolds with extensive developed actin 
indicating the enhanced spreading, proliferation. Furthermore, establishment of cell-cell 
interactions were also observed on CS/nano β-TCP composite scaffolds. 
Day 7 
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Figure 5.19: Cell distribution is visualized under confocal microscopy on CS/micro β-TCP 
and CS/nano β-TCP scaffolds. Few cells are spherical in shape as observed on CS/micro β-
TCP where as the cells are uniformly spread on CS/nano β-TCP scaffolds which confirms 
the superior biocompatibility of CS/nano β-TCP scaffolds.  Nuclei of the cells stained with 
Hoechst 33342 (blue) and actin filaments with phalloidin (green). Bar indicates 200µm.  
 
 
 
5.1.13.7 Osteogenic differentiation potential 
 
The osteogenic differentiation of MSCs over the scaffolds was evaluated by ALP activity and 
total calcium content which are described below. 
 
(i) ALP assay 
ALP activity is a critical tool for the assessment of cellular differentiation. The organic 
phosphate esters in the bone matrix are cleaved by ALP enzyme which enables the supply of 
free phosphate ions to the zones of mineral nucleation. ALP is an early marker which 
represents the differentiation and mineralization of the osteoblast phenotype [220]. ALP assay 
of hMSCs seeded scaffolds was done to evaluate the osteogenic potential of the scaffolds as 
shown in Figure 5.20. During initial days of incubation, an increase in ALP activity is evident 
upto 14 days since ALP is an early osteogenic marker. A decrease in ALP activity is noticed 
after 14 days of culture. Further, hMSCs cultured on CS/nano β-TCP expresses higher ALP 
activity than on control (CS) and CS/micro β-TCP composite scaffold.   A rapid increase in 
ALP expression is observed with all scaffolds from day 7 to day 14 (p < 0.05) with a variation 
in ALP activity. The ALPase activity of hMSCs cultured on control (CS) and CS/micro β-
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TCP composite scaffolds at 7 to 21 days is 1.1 ± 0.3 IU/µg to 2.81 ± 0.11 IU/µg and 1.75 ± 
0.29 IU/µg, to 3.25 ± 0.17 IU/µg respectively. ALPase activity of hMSCs cultured on 
CS/nano β-TCP composite scaffolds at 7 to 21 days is 2.96 ± 0.29 IU/µg, to 5.11 ± 0.17 
IU/µg. Thus enhanced ALP activity is noticed on CS/nano β-TCP composite scaffolds due to 
osteoinductive property of nano β-TCP which helped the differentiation of seeded hMSCs 
into osteoblasts to a greater extent than micro β-TCP [36]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20: Alkaline Phosphatase activity of CS, CS/micro β-TCP and CS/nano β-TCP 
composite scaffolds after 7, 14 and 21 days of cell seeding. Each point represents the mean 
± SD (n= 3) * and ** shows significant differences between groups at p >0.05 and p < 0.05 
respectively  
 
 
 
(ii) Total calcium content 
 
The total calcium content is the determination of the total mineral level present in the MSCs 
differentiated to osteogenic lineage [221]. Figure 5.21 shows the measured calcium content 
of hMSCs seeded scaffolds upto 21days of culture. An increase in calcium content is observed 
with increase with time representing an increased degree of mineralization on both CS/micro 
β-TCP and CS/nano β TCP scaffolds.  However, hMSCs seeded on CS/nano β-TCP scaffold 
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possessed higher (p < 0.05) calcium content (224-821 mg/mg DNA) than on pure CS (101-
512 mg/mg DNA) and CS/micro β-TCP composite scaffold (132-712 mg/mg DNA) as 
observed on day 21 of incubation. Higher mineralization activity of MSCs represents the 
superior osteogenic potential of CS/nano β-TCP scaffold in comparison to CS/micro β-TCP 
scaffold [201]. 
 
 
 
Figure 5.21: Total calcium content of CS, CS/micro β-TCP and CS/nano β-TCP composite 
scaffolds. Each point represents the mean ± SD (n= 3) * and ** denotes significant 
differences between groups at p > 0.05 and p < 0.05 respectively 
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PART-II 
Development of Fibrin Conjugated CS/nano 
β-TCP Composite Scaffolds  
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In the previous section, the limitation of low compressive strength and bioactivity of chitosan 
was addressed through the fabrication of CS/β-TCP composite scaffolds by reinforcing β-TCP 
with varying particle size. Among the various composite scaffolds, CS/nano β-TCP was found 
to be the most potential possessing high compressive strength, enhanced bioactivity and cell 
supportive property. It is further evident that CS lacks desired cell signalling molecules which 
are essential for cell attachment, growth, proliferation and differentiation and hence CS have 
less cellular affinity. The deficiency of cell affinity of CS scaffolds can be overcome by the 
incorporation of bioactive protein molecules [156]. In this context, Arginine-Glycine-Aspartic 
acid (RGD), a cell-binding peptide is most commonly used to enhance the cellular affinity of 
scaffold by improving its surface property [155]. Fibrin a biocompatible and biodegradable 
insoluble protein is reported to be a promising bioactive molecule for improving cell 
attachment, cell proliferation and extra cellular matrix formation in wound healing [158], due 
to the presence of numerous cell binding domains (RGD) in fibrin [20]. It is further reported 
that fibrin and its degradation products induce angiogenesis [222]. Fibrin plays important role 
in orthopaedic surgery to enhance osteogenesis and also act as angiogenic factor to increase 
cell retention thereby promotes early osteogenic differentiation of bone cells [161].  
 
Keeping the above aspect of fibrin in view, efforts have been given in this phase of research 
to investigate the effect of fibrin conjugation on the cell binding affinity of CS/nano β-TCP 
composite scaffold with the intention to achieve better cell attachment, proliferation and 
osteogenic differentiation of MSCs. A results and discussion on this study is described in this 
chapter. 
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5.2.1 Morphology and pore size 
 
SEM images as depicted in Figure 5.22 (A) reveal an open and interconnected porous 
network of the fibrin conjugated CS/nano β-TCP composite scaffolds. There is no significant 
difference in pore size range of CS/nano β-TCP due to fibrin conjugation. The pore size range 
of CS/nano β-TCP/F scaffold is 49-151 µm and is beneficial by allowing the diffusion of 
water soluble substances to the cells through the porous architecture of composite scaffolds 
[223]. The microstructure of developed fibrin conjugated scaffolds can play dual role by 
providing suitable porous platform to the cells and offers micro-channels for the efficient 
transport of nutrients from the media to the cultured cells. The micro channels formed on the 
scaffold surface is represented in Figure 5.22 (B).  Furthermore, the microstructure of fibrin 
conjugated scaffolds has become rough in nature which might have one of the reasons in 
enhanced cellular responses on fibrin conjugated scaffolds. A slight decrease (~15) in the pore 
size of CS/nano β-TCP/F composite scaffolds is observed which may be due to cross linking 
by EDS-NHS. The phenomenon of decrease in pore size has also been reported earlier when 
CS/collagen 3D matrices was cross-linked with carbodimide [224]. The obtained pore size 
range is adequate for hosting the seeded cells, cell adhesion to the inner surface and diffusion 
of nutrients through the scaffold. 
 
 
 
 
 
 
 
 
 
Figure 5.22 (A): Morphology of pure CS; fibrin conjugated and non conjugated CS/nano 
β-TCP composite at different magnifications. Fibrillar network like structure inside the 
pore walls of fibrin conjugated scaffolds is shown in white colored arrow marks (c, d) 
CS/n β-TCP/F 
Day 7 
()) 
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Figure 5.22 (B): FE-SEM images depicting the fibrillar structures of fibrin formed on the 
surface of composite scaffolds  
 
5.2.2 Porosity  
The porosity of the fibroin conjugated composite matrix was measured to assess any change 
has occurred in porosity due to conjugation of fibrin. A slight increase in porosity is obtained 
with the fibrin conjugated composite scaffold compared to non conjugated one and 
corresponding % porosity measured as 81.4 ± 4.1 and 80.1 ± 3.60. This slight increase in 
porosity may be as a result of reduced pore size caused by EDC-NHS cross-linking [78, 225]. 
Both conjugated and non conjugated scaffolds have shown decreased % porosities as 
compared to pure CS scaffold (86%) which may be due to the incorporation of β-TCP and 
EDC cross-linking. Similar trend of decrease in porosity was observed in study reported by 
Lein et.al where the porosity of gelatin scaffolds was increased due to cross-linking with 
genipin [226]. 
 
 
5.2.3 Phase analysis  
Figure 5.23 shows X-ray diffraction patterns of pure CS, fibrin conjugated and non 
conjugated CS/nano β-TCP composite scaffolds.  Fibrin being non crystalline in nature, it will 
not change the phase of the composite system with which it gets conjugated. So, the XRD 
pattern of composite scaffolds remains unaltered even after fibrin conjugation as shown in 
figure. Sharp peaks at 2θ = 31.7 and 32.1 confirm the presence of β-TCP in CS/nano β-TCP/F 
scaffolds similar to XRD pattern observed with CS/nano β-TCP [211]. As indicated in Figure 
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5.23, the intensity of peaks corresponding to CS is decreased due to the incorporation of nano 
β-TCP. Amorphous nature of CS is diminished in composite scaffolds. However, the decrease 
in the intensity of CS peak is higher in fibrin conjugated scaffolds attributed to cross-linking.  
Rafat et.al observed the similar increase in intensity of collagen/CS hydrogels when cross-
linked using carbodimide [224].  
 
 
Figure 5.23: XRD pattern of CS, CS/nano β-TCP and CS/nano β-TCP/F composite 
scaffolds. Pure CS has shown prominent peak at 2θ=9.16° & 20.6°; sharp peaks at 2θ = 
31.7 and 32.1° indicates the presence of β-TCP in the composite. * represents the decrease 
in intensity of CS peak at 2θ=20.6 ° 
 
5.2.4 Functional analysis  
Figure 5.25 illustrates the FTIR spectra generated with CS/nano β-TCP composite scaffolds 
with and without conjugation to assess any change in functional characteristics of the scaffold 
due to fibrin conjugation. Figure 5.24 illustrates the bands observed in the IR spectra for 
CS/nano β-TCP and CS/nano β-TCP/F scaffolds. Bands at 1040, 1122, 610, and 551 cm–1 
correspond to PO4
-3 of β-TCP [53].  It has been reported that shifting as well as generation of 
new peaks occur due to chemical interactions between individual components of composite 
scaffolds [227]. Nature of bonding between fibrin and chitosan caused by the cross-linking of 
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EDC, where carboxylic group of EDC bonded with amide groups of fibrin. The amide II and 
amide III absorption bands at 1550 and 1240 cm
-1 
belong to fibrin protein have been shifted to 
1577 cm
-1
 and 1251 cm
-1
. New bands at 751 cm
-1 
and 3540 cm
-1 
 is seen in both scaffolds 
which may be due to the interactions between PO4
-3 
with C=O of fibrin and N-H of CS 
respectively. These observations clearly indicate the interaction between –NH2 of fibrin with –
CH2 of chitosan and PO4
-3 of β-TCP. 
 
Figure 5.24: FT-IR pattern of CS/nano β-TCP and CS/nano β-TCP/F composite scaffolds 
5.2.5 Compressive strength  
Figure 5.25 depicts compressive strength of the developed fibrin cross-linked CS/nano β-TCP 
composite scaffold. There is no significant increase in compressive strength is observed due 
to fibrin conjugation. The similar compressive strength of conjugated and non-conjugated 
scaffold may be attributed to the non-homogenous crosslinking between EDC and chitosan 
that leads to propagation of crack within the scaffold. The mechanism of cross-linking 
between EDC with chitosan involves the reaction between amino and carboxylic groups.
 
The 
cross linking reaction between amino
 
groups of CS may not be homogenous and unevenly 
spread in the scaffold as reported elsewhere [78]. Some degree of uncross- linked CS is 
present in the scaffold which is well evident from the very less change in elastic modulus 
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(0.1MPa) calculated from stress strain plot. The developed crack due to non-uniform 
crosslinking might have propagated through the weakest link in the conjugated scaffold and 
therefore no significant change in compressive strength is obtained due to fibrin conjugation.  
Both conjugated (2.71 ± 0.14 MPa) and non-conjugated (2.67 ± 0.21 MPa) scaffolds possess 
higher compressive strength as compared to pure CS scaffold (0.19 MPa). The result is in 
good agreement with the published reports where the use of varied concentrations of EDC-
NHS has no effect on mechanical properties of freeze-gellled CS scaffolds [78].  
 
Figure 5.25: Compressive strength of CS, CS/nano β-TCP and CS/nano β-TCP/F 
composite scaffolds 
 
 
5.2.6 Measured contact angle  
From the assay result, a slight increase in measured contact angle is observed in case of 
CS/nano β-TCP conjugated with fibrin (53.1 ± 0.5°) representing a slightly lower 
hydrophilicity. No significant change is noticed between the contact angle of pure CS (51.2 ± 
0.8°) and CS/nano β-TCP composite scaffold (51.9 ± 1.1°). The slight increase in contact 
angle observed with fibrin conjugated scaffold may be explained as fibrin is a water insoluble 
protein (hydrophobic). Though fibrin conjugation has resulted a slight decrease in the 
hydrophilicity of CS composite scaffold, the presence of numerous cell binding domains like 
RGD peptides is expected to manifold its cell adhesive property as reported earlier [228]. 
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Most of the important protein- protein interactions occur between hydrophobic residues of 
proteins and thus increase of contact angle in a certain limit also might have favoured the 
enhanced protein-protein interactions resulting in improved cellular responses on fibrin 
conjugated scaffolds [51].  
 
 
5.2.7 Swelling behaviour 
Figure 5.26 shows the swelling of behavior of scaffolds during 48 hours of time. As observed 
in figure, during initial period (5-6 hrs) of the experiment, a rapid increase in swelling is 
prominent beyond which the scaffolds show a saturated swelling without any further change 
in % swelling. CS scaffold have shown the highest swelling (312% of its initial weight) than 
the other types of scaffolds. CS/β-TCP composite showed higher swelling (276% of initial 
weight) compared to the scaffolds with fibrin (243%). The decrease in swelling of fibrin 
conjugated scaffold may be attributed to the hydrophobic nature of fibrin which resisted the 
flow of water into the scaffold resulting in decreased swelling [229].  
 
 
 
 
 
 
 
 
 
Figure 5.26: Swelling behaviour of CS, CS/nano β-TCP and CS/nano β-TC/F composite 
scaffolds. CS/nano β-TCP scaffold shows a higher swelling than CS/nano β-TCP/F 
scaffold 
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5.2.8 In-vitro biodegradation study 
The scaffolds should preserve its structural and mechanical stability until the seeded cells 
secrete sufficient amount of ECM for their sustenance [56]. In this context,  degradation 
behaviour of the scaffold plays a vital role in the formation of neo tissue at the site of implant 
[135]. The in-vitro degradation pattern of the prepared fibrin conjugated scaffold (CS/nano β- 
TCP/F) is shown in Figure 5.27 and the degradation behaviour is also compared with the pure 
CS and CS/nano β-TCP composite scaffolds. The degradation pattern shows a favourable 
impact of fibrin conjugation achieving a slight decrease in degradation of conjugated scaffold 
(15%) than the non-conjugated one (16%). The reduced degradation in fibrin conjugated 
CS/nano β-TCP composite scaffold may be due to increase in intra and inter molecular 
hydrogen bonds that resulted in the increased compactness of scaffold matrix [230]. Both 
conjugated and non conjugated scaffolds have shown a decelerated degradation when 
compared to pure CS scaffold-31% (p < 0.05). Previous reports suggest that optimal 
degradation of scaffolds eases the longevity of scaffold implantation at tissue damaged site 
[231]. Dimethyl 3,3-dithio-propionimidate [DTBP] cross-linked CS scaffolds well maintained 
their structural integrity and degraded to 10% during 21 days of degradation [169]. Thus the 
prepared cross-linked CS/nano β-TCP/F composite scaffold is expected to provide adequate 
support to the growing cells for a certain longer period of time, which may be of a greater 
importance in in-vivo handling as the scaffolds will degrade in pace with neo tissue formation. 
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Figure 5.27: In-vitro degradation pattern of CS/nano β-TCP/F composite scaffold in PBS 
for 28 days treatment compared with pure CS and CS/nano β-TCP composite scaffolds. 
Significant difference in degradation noticed in pure CS and fibrin conjugated scaffolds 
where as slight difference in degradation rate is seen between CS/nano β-TCP and fibrin 
conjugated CS/nano β-TCP composite scaffolds 
 
5.2.9 Cell morphology and cell attachment  
Cell attachment and morphology of MSCs seeded on the scaffolds are visualized by FE-SEM 
images (Figure 5.28 a-f). On close observation, MSCs are found to attach and spread on the 
scaffold surface during the culture period.  On day 1, cells are found to be spherical in shape 
with distinct appearance [Figure 5.28 (a&b)]. The cells are well spread throughout the 
scaffold and colony formation is observed on day 7 and 14 as shown in Figure 5.28 (c-f). 
Furthermore, cells are found to attach on the surface and in the pores of scaffolds by filopodia 
like structures. The surface of CS/nano β-TCP scaffolds appear relatively smoother 
representing the less number of cells attached and proliferated. Whereas, the entire surface is 
covered with more number of cells attached and proliferated on CS/nano β-TCP/F scaffolds as 
compared to non conjugated scaffolds representing superior cytocompatibility of CS/nano β-
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TCP/F scaffolds. The presence of numerous cell binding domains (RGD) favoured the 
enhanced attachment and spreading of seeded hMSCs on CS/nano β-TCP/F scaffolds. 
 
 
 
Figure 5.28: FE-SEM images showing morphological changes an attachment of hMSCs on 
CS/nano β-TCP (a, c, e) and CS/nano β-TCP/F composite scaffolds (b, d, and f) during 14 
day culture period. Images depict the morphological changes of hMSCs. Spherical shape 
(a, b) on day 1, colonization (c, d) on day 7 and well spreading sheet like structures (e, f) on 
day 14 
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5.2.10 Metabolic activity by MTT assay  
The cellular viability in terms of metabolic activity of the MSCs seeded on the prepared 
scaffold was further evaluated quantitatively by MTT assay as shown in Figure 5.29. As 
indicated, an increase in O.D (optical density) with culture period is observed. The higher 
O.D value representing higher metabolic activity is obtained with CS/nano β-TCP/F (0.915 ± 
0.12) scaffolds as compared to control [CS (0.4 ± 0.018)] and CS/nano β-TCP (0.614 ± 0.016) 
after 7 days of culture. The increase in metabolic activity achieved with CS/nano β-TCP can 
be attributed to the presence of RGD sequences in fibrin which provides suitable cell 
recognition sites to attract more number of cells on the scaffold surface [232]. Thus, the fibrin 
conjugated scaffolds proved their superior biocompatibility over CS/nano β-TCP and CS 
scaffolds by MTT assay. 
 
 
Figure 5.29: MTT assay of hMSCs seeded on fibrin conjugated and non conjugated 
composite scaffolds on 3, 5 and 7 days of culture. Each point represents the mean ± SD 
(n=3) * and ** shows significant differences between groups at p >0.05 and p < 0.05. After 
7 days of incubation higher cell viability is achieved with CS/nano β-TCP/F composite 
scaffolds compared to pure CS as well as CS/nano β-TCP composite scaffolds 
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5.2.11 hMSCs proliferation 
(i) Fluorescence microscopy 
 
The proliferation of MSCs on the developed scaffolds was qualitatively assessed by the 
analysis of fluorescence microscopic images (Figure 5.30) during the 14 days of culture 
period. Figure 5.30 represents 7
th
 (a, c, e) and 14
th
 day (b, d, f), images of the relative cellular 
proliferation of MSCs grown over CS/nano β-TCP and CS/nano β-TCP/F composite 
scaffolds. Further, the number of cells on fibrin conjugated scaffold is observed to be higher 
as compared to non conjugated and pure CS scaffolds. 
 
 
 
Figure 5.30: Fluorescence images of hMSCs cultured on CS/nano β-TCP (a,b,c) and 
CS/nano β-TCP/F (d, e, f) scaffolds showing cell proliferation on day 3 (a, d); day 7 (b, e) 
and day 14 (c, f). Dense distribution of hMSCs is clearly seen on fibrin coated scaffolds 
compared to non fibrin coated scaffolds. Scale bar indicates 200µm  
 
(ii) DNA quantification assay: The proliferation of MSCs on the developed scaffolds was 
evaluated by DNA quantification assay. Figure 5.31 shows an increase in DNA content with 
time in all the developed scaffolds with a varying degree of DNA content. Among the 
scaffolds used under study, CS/nano β-TCP scaffolds conjugated with fibrin has shown 
highest DNA content representing an enhanced proliferation rate. The increase in proliferation 
rate achieved with CS/nano β-TCP/F is attributed to the presence of cell recognition binding 
sites or specific peptides like RGD on the surface of scaffold matrices enhance cell polymer 
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interactions as reported earlier [40]. The corresponding DNA content of  hMSCs cultured on 
CS/nano β-TCP/F composite scaffold for 3 to 21 days is 109 ± 12 ng/ml to 501 ± 24 followed 
by DNA content obtained with non conjugated composite matrix and pure CS scaffold. Thus 
the fibrin conjugated scaffolds is proved to mimic the native environment in a better way that 
results in the higher proliferation of hMSCs than other CS scaffolds. 
 
 
Figure 5.31: Cell proliferation represented in terms of DNA quantification on CS, CS/nano 
β-TCP and CS/nano β-TCP/F composite scaffolds upto 21 days of culture. An increased 
DNA content pattern is seen with all scaffolds with varying degree of DNA content. Fibrin 
conjugated scaffold has shown highest proliferation at any time point. Each point 
represents the mean ± SD (n=3) * and ** represents p>0.05 and p < 0.05respectively 
 
5.2.12 Cytoskeletal organization  
It is important to know the cell distribution in the inner sections of 3D scaffold for 
understanding the cell penetration which ultimately helps in tissue regeneration [233]. The 
cell infiltration and uniform distribution of hMSCs within the scaffold architecture was 
observed under confocal microscope. FITC conjugated Phalloidin and Hoescht dye was used 
to stain actin filaments and nuclei of cultured cells respectively. 3 dimensional confocal laser 
scanning microscopic (CLSM) images depict the cell penetration in 3D scaffold matrix upto a 
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depth of ~ 40 µm and 50 µm on CS/nano β-TCP and CS/nano β-TCP/F composite scaffolds 
respectively as shown in Figure 5.32 (b-d). On 14
th
 day of culture, number of viable cells 
observed is more on fibrin conjugated scaffolds than non fibrin conjugated scaffolds. [Figure 
5.32 (c)]  A similar observation in uniform distribution and enhanced infiltration of cells is 
reported earlier when alginate/micro β-TCP composite systems coated with fibrinogen [234].  
 
Figure 5.32: 3D laser scanning confocal images (Z stacks) of hMSC morphology after 14 
days of culture on CS/nano β-TCP (a, b) and CS/nano β-TCP/F composite scaffolds (c, d). 
Nuclei of the cells are stained with Hoechst 33342 (blue) and actin filaments with 
phalloidin (green). (b) and (d) represent z-stacks rotated in 3D space to depict cell 
infiltration into the porous architecture of CS/nano β-TCP and CS/nano β-TCP/F 
composite scaffolds respectively 
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5.2.13 Osteogenic differentiation potential  
(i) Alkaline phosphatase assay 
The osteogenic potential of hMSCs seeded scaffolds was evaluated by alkaline phosphatase 
assay as illustrated in Figure 5.33. ALP activity is found to increase steadily upto 14 days of 
culture. As observed, the slight decrease in ALPase activity after 14
th
 day of incubation 
indicates that cells have overcome the initial stage of osteogenic differentiation. Among the 
developed scaffolds, MSCs cultured on CS/nano β-TCP/F scaffold expresses higher ALP 
activity (P < 0.05) than cells grow on control (CS) and CS/nano β-TCP composite scaffold. A 
rapid increase in ALP expression is observed with all scaffolds from day 7 to day 14 (p< 0.05) 
with a variation in ALPase activity. However, higher ALP activity is achieved with fibrin 
conjugated scaffold. The corresponding value is 3.87 ± 0.32 IU/µg and 6.61 ± 0.11 IU/µg. 
Thus enhanced ALP activity is noticed on fibrin conjugated scaffolds which is due to 
osteoinductive property of fibrin and similar result was observed with fibrin coated PCL/HA 
composite system as reported earlier by Kang et al [235]. 
 
Figure 5.33: Alkaline Phosphatase activity of pure CS, fibrin conjugated and non 
conjugated CS/nano β-TCP composite matrices during after 21 days of culture. ALP 
activity increased upto 14 days of culture and then a slight decrease in ALP activity is 
observed.   Fibrin conjugated scaffold shows highest ALP activity. Each point represents 
the mean ± SD (n= 3) ** shows significant differences between groups at p < 0.05 
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(ii) In-vitro biomineralization  
Mineralization is a phenomenon in which calcium phosphate deposits on the surface of 
scaffolds and represent one of the evidences for cells to differentiate in to osteoblastic lineage 
[236]. Alizarin red assay was performed to assess the extent of matrix mineralization by 
MSCs differentiated on CS/nano β-TCP (with and without cells) and CS/n β-TCP/F 
composite scaffolds during 21days of incubation. As observed from Figure 5.34,  CS/nano β-
TCP/F scaffold has shown enhanced mineralization throughout incubation time
 
indicating 
greater osteogenic differentiation of hMSCs as compared to CS/nano β-TCP (with and 
without cells) composite scaffolds. Furthermore, mineralization of scaffolds is quantified by 
measuring the OD of the dye extracted from the stained nodules and the trend is shown in 
Figure 5.35.  Increase in OD value with respect to time is seen on both the scaffolds which 
indicate the differentiation of hMSCs on scaffolds under study. However, on day 21 
significant difference is observed in the measured optical density (O.D value) of fibrin 
conjugated scaffolds with other scaffolds. Alizarin staining results are in good accordance 
with the previous reports where RGD conjugated CS has shown greater mineralization 
compared to the unmodified CS scaffolds [40].  
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Figure 5.34: Optical microscopy images for CS/nano β-TCP (without cells: a), CS/nano β-
TCP (with cells: b) and CS/nano β-TCP/F (c, d) composite scaffolds. Intense red stains are 
observed on CS/nano β-TCP/F scaffolds on both 14 and 21 days (c, d) as compared to non 
conjugated scaffolds indicating enhanced mineralization on fibrin conjugated scaffolds 
 
 
 
Figure 5.35: Quantitative representation of mineral deposition on CS/nano β-TCP and 
CS/nano β-TCP/F composite scaffolds upto 21 days of incubation, ** represents p < 0.05 
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(iii) Expression of osteogenic specific genes 
Semi quantitative RT-PCR was performed to assess the expression of osteoblast related genes 
at mRNA level for MSCs cultured for three weeks. The mRNA expression of genes such as 
ON, ALP and OC are observed to be significantly higher in hMSCs cultured on CS/nano β-
TCP/F composite scaffold than non conjugated one as shown in Figure 5.36. The reason 
behind the increase in gene expression may be attributed to the synergic effect between β-
TCP and fibrin which helped in increased differentiation of seeded cells [4]. The obtained 
band intensities were further quantified to examine the increased level of gene expression. 
Figure 5.37 depicts the relative expression levels of the genes associated with osteogenic 
differentiation. Collagen type I and BSP are abundantly available proteins in bone ECM and 
deposited in the matrix during the maturation of osteoblasts as reported earlier [151]. Up-
regulation of collagen type I and BSP genes on non fibrin conjugated scaffolds may be due to 
positive effect created by β-TCP as reported earlier with osteogenic differentiation of adipose 
derived stem cells cultured on akermanite and β-TCP ceramics [237]. A statistical difference 
(p<0.05) was observed in the expression levels of specific genes on both CS/nano β-TCP and 
CS/nano β-TCP/F scaffolds. Similar increase in expression of osteoblast specific genes was 
observed with rabbit mesenchymal stem cells when seeded in fibrin coated β-TCP 3D 
scaffolds as reported earlier [194, 234]. 
 
 
 
 
 
 
Figure 5.36: Images of amplified cDNA products using specific osteogenic primers (BSP, 
ON, ALP, OC and Col-I) for hMSCs cultured on CS/n β-TCP and CS/n β-TCP/F freeze-
gelled composite scaffolds in osteogenic media for 21 days 
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Figure 5.37: Relative Expression of BSP (a), ON (b), ALP (c), OC (d) and Col I(e) on 
mRNA of MSCs cultured on CS/nano β-TCP and CS/nano β-TCP/F composite scaffolds 
for 28 days of incubation. Expression levels are normalized to β actin expression. ** 
Represents a statistical difference at p < 0.05  
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PART-III 
Development of Cross-linked CS/nano β-TCP 
Composite Scaffolds  
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In the last two phases of research work, attempt has been made to improve the mechanical 
strength, bioactivity and cell binding affinity of the CS scaffolds by the incorporation of β-
TCP as bioactive ceramic material and cross-linking with fibrin.  The rapid degradation of 
chitosan is another important aspect that needs to be addressed to achieve controlled 
degradation rate compatible with the rate of neo tissue formation [57].  To overcome such 
limitation, in last decade several approaches have been adopted by different researchers by 
incorporating bio-ceramics and cross-linking
 
agents [21]. In the previous section, though a 
slight improvement in degradation rate (slow degradation) is achieved by incorporating nano 
β-TCP, there is still need of controlling this degradation rate to a desirable level. This may be 
achieved by cross-linking scaffold with a suitable cross-linker. Glutaraldehyde is widely used 
as a cross-linking agent to reduce degradation of biopolymers, but the by-products of its 
degradation are shown to be harmful to cells [179]. As an alternative, the inorganic 
tripolyphosphate (TPP) has been used to cross-link collagen and reduce its degradation rate 
without harmful side effects [142]. Furthermore, the presence of phosphate moiety may be 
effective in promoting the growth of osteogenic cells [16]. Genipin (GN) a natural compound 
extracted from Gardenia fruits has been used as a cross-linking agent for synthesis of elastic 
gels in wound healing without causing any undesirable effects [130, 179]. Both these cross-
linkers are water soluble which are reported to be beneficial to crosslink polymeric matrices 
and proved to decelerate degradation rate as well as enhance mechanical properties of various 
polymeric matrices without any toxic or undesirable side effects [179, 238].  
The main aim of this part of thesis work was to prepare cross-linked composite scaffolds with 
controlled degradation rate, characterize their physicochemical and mechanical properties and 
investigate their in-vitro biological performance. The result and discussion of these studies are 
described in this chapter. 
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5.3.1 Development of GN and TPP cross-linked CS/nano β-TCP composite scaffolds 
Different batches of genipin and tripolyphosphate cross-linked freeze-gellled CS/nano β-TCP 
composite scaffolds were prepared. The different concentrations of cross-linking agents are in 
the range of 0.01 to 0.2% (w/v). The mechanism of GN cross- linking is put forward based on 
the published literature [239]. In brief, nucleophilic attack by amino groups of CS on olefenic 
carbon atom of GN results in dihydropyran ring opening of GN.  Another attack of secondary 
amino group of CS is on newly formed aldehydo groups of GN resulting in formation of 
cross-linked bridges [146]. TPP is an ionic cross-linker with negative charge which forms 
ionic linkages with amino groups of CS. Henceforth; it is expected to enhance the amphoteric 
nature of chitosan which ultimately results in better protein adhesion, followed by increased 
cellular responses [240-241]. 
 
5.3.2 Morphology and pore size 
SEM images of CS/nano β-TCP/GN and CS/nano β-TCP/TPP along with CS and CS/nano β-
TCP scaffolds for comparison are shown in Figure 5.38. All the developed scaffolds 
displayed interconnected honeycomb like microstructures with desired pore size suitable for 
bone tissue engineering applications. The concentration of the cross-linking agent is found to 
have a great influence on the pore size of the scaffold, trend being greater the concentration 
larger is the pore size. This phenomenon may be due to the fact that the pore structure is 
observed to be restrained from collapsing and thus results in an increase in pore size (Table 
5.3). The pore size of developed cross-linked scaffold is higher than the non cross-linked CS 
and CS/nano β-TCP composite scaffolds. However, the pore size range of GN cross-linked 
scaffolds is higher (57-199 µm) than TPP cross-linked scaffolds (55-186 µm). Similar results 
in increase in pore size of CS/collagen matrices were reported by cross-linking with amino 
acids [166]. It is further observed that the thickness of the pore walls has been increased due 
to cross-linking which is evident from Figure 5.38 (c-i). Thus, cross-linking has slightly 
increased the pore size of the developed scaffolds which meets the desired requirement for 
cell culture studies.  
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Figure 5.38: SEM images of cross-linked and non cross-linked composite and pure CS 
scaffolds. The developed scaffolds are highly porous and interconnected. Pore size of 
scaffold increases due to cross-linking and also increase in cross-linking agents. 
Furthermore, the increase in pore size of GN cross-linked scaffolds is higher than TPP 
cross-linked scaffolds. White colored arrow marks indicating thin (a-b) and thick (d-i) pore 
walls of non cross-linked and cross-linked scaffolds respectively  
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5.3.3 Porosity  
Table 5.3 shows the porosity results of the cross-linked scaffolds and its comparison with non 
cross-linked CS/β-TCP and pure CS scaffolds. Similar to pore size, the cross linking agents 
have an impact on porosity of the scaffolds. A decrease in % porosity is observed with cross-
linked scaffolds as compared to non cross-linked and pure CS scaffolds. The % porosity of 
GN cross-linked scaffolds is slightly lower than TPP cross linking. The % porosity of GN and 
TPP cross-linked scaffolds is in the range of 68 ± 2.1 to 76 ± 2.8 and 71 ± 1.9 to 78 ± 2.9 
respectively within the entire range of concentration (0.01- 0.2%).The decrease in porosity 
observed with increase in concentration is attributed to increase in pore size of cross-linked 
scaffolds as compared to non cross-linked scaffolds. For a given cross-linker, scaffold 
porosity decreased with increasing cross-linker concentration (Table 5.3). For example, as 
the TPP concentration was increased from 0.01 to 0.05, 0.10, 0.15 and 0.20, scaffold porosity 
decreased from 78 ± 2.9 to 76 ± 1.1, 75 ± 2.2, 73 ± 2.1 and 71 ± 1.9 respectively, whereas 
scaffold porosity decreased from 76 ± 2.8 to 74 ± 1.9, 73 ± 2.1, 70 ± 1.9 and 68 ± 2.1 for the 
same concentrations of GN.  From pore size and porosity results, it is observed that increase 
in pore size resulted in decrease in % porosity and our results correlates the published data 
where CS/collagen and CS matrices were cross-linked with glutaraldehyde and genipin 
respectively [191, 231].  
 
 
 
 
 
5.3.4 Phase analysis 
XRD was performed to assess any phase change occur due to cross-linking of the composite 
scaffolds and the pattern is shown in Figure 5.39. The scaffolds cross-linked with GN (0.1%) 
and TPP (0.1%) are shown to decrease the intensity of CS peak (amorphous nature) and its 
disappearance indicates further increase in crystallinity as shown in Figure. The effect of GN 
concentration on decreasing CS intensity is higher than TPP. XRD patterns of composite 
scaffolds with varying content of GN and TPP are not shown. Further, shift in the 2θ value of 
chitosan towards higher angle is evident indicating decrease in amorphous nature of CS.  
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Figure 5.39: XRD spectra of CS, CS/nano β-TCP, GN and TPP (0.1 %) cross-linked 
CS/nano β-TCP freeze-gelled composite scaffolds. Extent of decrease in the peak intensity 
of CS is greater in GN cross-linked scaffold as compared to TPP cross-linked scaffolds. 
Decrease in the intensity of CS peak (amorphous nature) and its disappearance indicates 
further increase in crystallinity of cross-linked scaffolds  
 
5.3.5 Functional analysis 
Figure 5.40 shows FT-IR spectra of cross-linked, non cross-linked CS/β-TCP composite and 
pure CS scaffolds.  In TPP cross-linked scaffolds, band  at 1200 cm–1 confirms the presence of 
PO4 [142], whereas, in case of GN cross-linked composite scaffold, noticeable shifts of band is 
observed in N-H bending of amide bond in the range 1570 cm
-1
 to 1550 cm
-1
 which may be 
attributed to the interaction of CS with GN. The absorbance in the range 1000-1300 cm
-1
 
bears some additional bands which probably due to the interaction of P=O of TPP with 
saccharide unit of CS. Roughly similar bands and intensities of cross-linked and non cross-
linked scaffolds are indicated by FTIR spectra and CS has presumably retained its molecular 
structure even after cross linking.  [242].  
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Figure 5.40:  FT-IR pattern of CS/nano β-TCP, GN and TPP (0.1 %) cross-linked CS/nano 
β-TCP composite scaffolds 
5.3.6 Compressive strength  
The compressive strength of all the prepared scaffolds with varied concentrations of GN and 
TPP along with non-cross-linked scaffold are shown in Table 5.3. The obtained stress strain 
plot is shown in Figure 5.41 (a). The compressive strength of CS/β-TCP scaffolds showed a 
bimodal trend with TPP/GN cross-linking, increasing slightly at low TPP or GN 
concentrations (0.01-0.1 %) but decreasing significantly at higher TPP or GN concentrations 
of 0.15 and  0.2 %  as shown in Figure 5.41 (b). For example, as the TPP concentration 
increased from 0.01 w/v to 0.05, 0.1, 0.15 and 0.2 w/v, the compressive strength of the 
scaffolds changed from 2.69 ± 0.17 MPa to 2.71 ± 0.11, 2.72 ± 0.11, 2.59 ± 0.19 and 2.34 ± 
0.15 MPa, respectively, for GN cross-linked scaffolds the compressive strength changed from 
2.69±0.11 MPa to 2.74 ± 0.13, 2.78 ± 0.14, 2.65 ± 0.17 and 2.49 ± 0.1 MPa (Table 5.3). The 
higher compressive strength achieved with cross-linked scaffolds is due to the bridge forming 
ability between the free amino groups of CS with the GN/TPP [142, 243]. At higher 
concentrations of TPP or GN ( > 0.1% ), cross linking occurs only with the free amino groups 
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present at the periphery of the polymer matrix, but the inner architecture of scaffold remains 
unexposed  resulting in decreased compressive strength at higher concentrations of cross-
linking agents [191]. The other reason behind the decrease in compressive strength may be 
due to drastic increase in pore size (~10 to 25 µm) of the cross-linked scaffolds when the 
cross-linker concentration reaches a threshold of 0.1% w/v. The corresponding compressive 
strength of GN cross-linked scaffold has shown a slightly higher compressive strength (2.78 ± 
0.14 MPa) over TPP cross-linked scaffold (2.72 ± 0.11MPa) at a threshold concentration of 
0.1%. The compressive strength of GN/TPP cross-linked scaffolds in wet condition were also 
measured and the compressive strength was drastically reduced in wet condition as shown in 
Table 5.3 . The decrease in compressive strength may be due to the increase in pore size as 
reported earlier [49].  Furthermore, the GN cross-linked scaffolds have shown higher 
compressive strength compared to TPP cross-linked scaffold. The maximum strength 
achieved with GN and TPP at 0.1% w/v is 0.572 ± 0.07 MPa and 0.438 ± 0.04MPa 
respectively which belong to the range [255]. 
 
Figure 5.41 (a): Stress strain plot of CS/nano β-TCP, CS/nano β-TCP/GN (0.1 % & 0.2 %) 
and CS/nano β-TCP/TPP (0.1 % & 0.2 %) composite scaffolds 
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Figure 5.41 (b): Compressive strength of GN and TPP cross-linked CS/β-TCP scaffolds as 
a function of cross-linker concentration. Compressive strength is increased with increase in 
concentration of cross-linking agent upto 0.1% beyond which, a decline in strength is 
observed. GN cross-linked scaffolds have shown higher compressive strength than TPP 
cross-linked scaffolds 
 
5.3.7 Measured contact angle  
Table.5.3 shows the values of measured contact angles for all the prepared scaffolds. The 
surface hydrophilicity of the scaffolds decreased with TPP or GN cross linking as the water 
contact angle increased with increasing TPP or GN concentration. As the TPP concentration 
increased from 0.01 % to 0.05, 0.1, 0.15 and 0.2 %, the water contact angle on CS/nano β-
TCP/TPP scaffold surfaces increased from 52.5 ± 0.5° to 53.4 ± 0.9, 54 ± 1.1, 54.6 ± 0.7 and 
54.9±0.6° respectively; whereas the contact angle of CS/nano β-TCP/GN scaffold surfaces 
increased from 54.2 ± 0.4° to 54.7 ± 0.6, 55.1 ± 1, 55.6 ± 0.7 and 56.1 ± 0.5°. The lower 
wettability of GN cross-linked scaffolds compared to TPP is most likely related to the lower 
porosity of GN cross-linked scaffolds (Table 5.3, lower fraction of water-filled pores on the 
surface). It has been established that the prepared scaffolds possess adequate hydrophilicity to 
facilitate hMSCs growth.  
(b) 
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Table 5.3: A comparative table showing the effect of cross-linking on pore size, porosity, 
contact angle, compressive strength, swelling and mass loss of developed scaffolds.  
 
5.3.8 Swelling behaviour 
Figure 5.42 shows the swelling of scaffolds with incubation time. All scaffolds reached 
equilibrium swelling in < 6 hr. CS scaffold without β-TCP and cross-linking showed the 
highest swelling. For CS/β-TCP scaffolds, TPP or GN cross linking reduced swelling but the 
swelling of TPP cross-linked scaffolds was significantly higher than those cross-linked with 
GN. Further, percent swelling inversely varied with cross-linker and decreased with 
increasing TPP or GN concentration. The decrease in swelling of TPP or GN cross-linked 
scaffolds is attributed to their lower porosity (Table 5.2). Similar results in decrease of 
swelling is reported earlier by Han et al. and Pati et al. where they have incorporated nano 
Hap was incorporated  into 3D porous chitosan and cross-linked nanofibrous CS matrices 
with TPP respectively [101, 142].  
Type Sample  Pore size 
(μm) 
Porosity 
(%) 
Swelling 
(%) 
Contact angle  
(
o
) 
Compressive 
strength [Dry] 
(MPa) 
 
Mass 
loss  
(%) 
Compressive 
strength [Wet] 
(MPa)  
CS 61-171 86 ±  3.2 325 51.2 ± 0.8 0.19 ± 0.05 31 NA 
CS/n β-TCP 55-162 80 ±  3.6 275 51.9 ± 1.1 2.67 ± 0.21 18 0.249±0.02 
CS/n β-TCP/TPP 
(0.01%) 
55-168 78 ± 2.9 258 52.5 ± 0.5 2.69 ±  0.17 16 0.257±0.05 
CS/n β-TCP/TPP 
(0.05%) 
57-171 76 ± 1.1 246 53.4 ± 0.9 2.71 ± 0.11  15 0.311±0.01 
CS/n β-TCP/TPP 
(0.10%) 
60-175 75 ± 2.2 240 54.0 ± 1.1 2.72 ± 0.11 13 0.438±0.04 
CS/n β-TCP/TPP 
(0.15%) 
64-179 73 ± 2.1 231 54.6 ± 0.7 2.59 ± 0.19 15 0.214±0.05 
CS/n β-TCP/TPP 
(0.20%) 
68-186 71 ± 1.9 222 54.9 ± 0.6 2.34± 0.15 16 0.341±0.03 
CS/n β-TCP/GN 
(0.01%) 
57-175 76 ± 2.8 231 54.2 ± 0.4 2.69 ± 0.11 14 0.454±0.06 
CS/n β-TCP/GN 
(0.05%) 
59-179 74 ± 1.9 225 54.7± 0.6 2.74 ± 0.13 11 0.492±0.04 
CS/n β-TCP/GN 
(0.10%) 
61-183 73 ± 2.1 214 55.1 ± 1.0 2.78 ± 0.14 8 0.572±0.07 
CS/n β-TCP/GN 
(0.15%) 
66-189 70 ± 1.9 201 55.6 ± 0.7 2.65± 0.17 10 0.389±0.02 
CS/n β-TCP/GN 
(0.20%) 
71-199 68 ± 2.1 189 56.1 ± 0.5 2.49 ± 0.10 12 0.479±0.05 
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Figure 5.42:  Swelling behaviour of CS, CS/nano β-TCP, GN and TPP cross-linked 
CS/nano β-TCP scaffolds for different GN or TPP concentrations with incubation time. 
Decreased swelling rate with increase in cross-linker concentration is observed in the 
developed scaffolds. Initially rapid increase in swelling is noticed (1-2hrs) and equilibrium 
reached in < 6 h for all types of scaffolds. The decrease in swelling of TPP or GN cross-
linked scaffolds compared to pure CS and CS/nano β-TCP scaffolds is shown. The swelling 
of TPP cross-linked scaffolds is significantly higher than GN cross-linked scaffold 
 
5.3.9 In-vitro biodegradation study 
The weight loss of the scaffolds with incubation time is shown in Figure 5.41. All scaffolds 
have degraded to < 20% mass weight after 30 days of incubation. The % weight loss of the 
scaffolds with varied ratios of TPP and GN are depicted in Table 5.3. The weight loss of TPP 
or GN cross-linked scaffolds is generally less than the non cross-linked CS or CS/β-TCP 
scaffolds and shows a bimodal trend with TPP or GN concentration. The scaffold weight loss 
after 30 days of incubation is changed from 14% to 11, 8, 13, 15 and 16% as GN 
concentration increased from zero to 0.01, 0.05, 0.1, 0.15 and 0.2, respectively. The best 
result is achieved with CS/nano β-TCP/GN (0.10 %) scaffold which degraded to 8% of its 
Time (hrs) 
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initial weight, whereas CS/nano β-TCP/TPP (0.10 %) scaffold to 13% and shown in Figure 
5.43. At a given cross-linker concentration, the weight loss between TPP and GN cross-linked 
scaffolds is not significantly different. GN cross linking reduced weigh loss of the scaffolds 
compared to un cross-linked CS/β-TCP scaffolds consistent with previous report  by  Sarem et 
al. where various concentrations of genipin were used to control the rate of degradation of 
gelatin/CS polymer blends [231]. 
 
Figure 5.43:  Degradation pattern of CS, CS/nano β-TCP, GN and TPP (0.1 %) cross-
linked CS/nano β-TCP composite scaffolds. Reduced degradation with change in type of 
cross linking agent is observed. The trend observed is CS > CS/nano β-TCP > CS/nano β-
TCP/TPP > CS/nano β-TCP/GN 
 
Based on the above assays, GN and TPP (0.1 %) cross-linked CS/nano β-TCP composite 
scaffolds were selected for further study because of their superior material property including 
favorable degradation, higher mechanical strength and structural property. 
 
5.3.10 Cell morphology and cell attachment 
In-vitro cell culture studies were performed on GN (0.1 %) and TPP (0.1%) cross-linked 
CS/nano β-TCP composite scaffolds to evaluate their cell supportive property. 
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 The morphology and attachment of the seeded hMSCs on developed composite scaffolds was 
observed by SEM.  Figure 5.44 [i-(a-d)] and Figure 5.44 [(ii-e-h)] show the morphology of 
cells on CS/nano β-TCP/GN and CS/nano β-TCP/TPP scaffolds respectively. After seeding, 
hMSCs were found to be round in shape on 1
st
 and 3
rd
 days of culture. Later on, cells were 
found to cover and spread uniformly on the composite scaffold matrices as shown in Figure 
5.44 (a-d) and Figure 5.45 (e-f). A dense cellular mass of seeded hMSCs is observed on these 
scaffolds with increase in time (7
th
 and 14
th
 day) as shown in Figure 5.44 (c-d) and Figure 
5.44 (g-h). However, the cells were found to be well attached and spread on GN cross-linked 
scaffolds as compared to TPP cross-linked scaffolds. Furthermore, the deposition of extra 
cellular matrix found to be profuse on TPP cross-linked scaffolds which may be due to 
phosphate moiety resulted in enhanced mineral secreting ability of cells as shown in Figure 
5.44 (g-h). These SEM results prove that GN and TPP cross-linked scaffolds are potential 
platforms for growth and proliferation of MSCs. 
 
Figure 5.44 (i): SEM Micrographs of hMSCs cultured on CS/nano β-TCP/GN scaffolds 
upto 14 days of incubation. A dense cellular mass of seeded hMSCs is also observed on 7 
and 14 days of culture. Profuse ECM secretion by the cultured hMSCs on scaffold surface 
is evident as represented by arrow marks 
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Figure 5.44 (ii): SEM Micrographs of hMSCs cultured on CS/nano β-TCP/TPP composite 
scaffolds upto 14 days of incubation. A dense cellular mass of seeded hMSCs is also 
observed on 7 and 14 days of culture. Profuse ECM secretion by the cultured hMSCs on 
scaffold surface is evident as represented by arrow marks 
 
5.3.11 Metabolic activity by MTT assay 
MTT assay was performed to assess metabolic activity of hMSCs cultured on GN and TPP 
cross-linked CS/nano β-TCP composite scaffolds. CS/nano β-TCP, and pure CS scaffolds for 
3, 5, and 7 days and the result is shown in Figure 5.45. The obtained results are compared 
with metabolic activity of cells seeded on CS/nano β-TCP, and pure CS scaffolds.  Metabolic 
activity of hMSCs in all groups increased with time. hMSCs seeded on CS and CS/nano β-
TCP/GN scaffold showed lowest and highest metabolic activity, respectively. The higher 
metabolic activity in terms of absorbance (O.D) value is achieved with CS/nano β-TCP/GN 
(0.742 ± 0.015) scaffolds as compared to CS (0.4 ± 0.018) CS/nano β-TCP (0.614 ± 0.016) and 
CS/nano β-TCP/TPP (0.692 ± 0.011) scaffolds after 7 days of culture. Cells were found to be 
more metabolically active (p < 0.05) on GN/TPP cross-linked scaffolds than on pure CS/nano 
β-TCP scaffold at any point of time. Although GN cross-linked scaffolds had the lower 
porosity and wettability, but hMSCs seeded on CS/nano β-TCP/GN scaffolds showed highest 
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metabolic activity in all time points when compared to CS/nano β-TCP and CS/nano β-
TCP/TPP which was attributed to the less toxic nature of GN as reported previously [202, 
231]. 
 
Figure 5.45: Metabolic activity of hMSCs cultured on CS/nano β-TCP/GN and CS/nano β-
TCP/TPP composite scaffolds upto 7 days of culture. Results are compared with metabolic 
activity of hMSCs seeded on CS/nano β-TCP composite scaffold which was used as control. 
hMSCs seeded on CS/nano β-TCP/GN scaffolds showed highest metabolic activity than 
TPP cross-linked  and non cross-linked CS/nano β-TCP composite scaffolds. Each 
pointrepresents the mean ± SD (n= 3) * and ** shows significant differences between 
groups at p > 0.05 and p < 0.05 respectively 
 
5.3.12 Cell Proliferation  
(i)  Fluorescence microscopy 
The fluorescent images were taken to observe the viability of MSCs cultured on the 
developed scaffolds. Cells are found to increase in number with culture time (as denoted by 
green fluorescence) from 3
rd
 day [Figure 5.46 (a, c)] to 14
th
 day [Figure 5.46 (b, d)]. The 
morphology of the cells is spherical in shape till day 3 and found to spread throughout the 
scaffold matrix at later time points. The cell density of dead cells (as denoted by red 
fluorescence) is also seen on 3
rd
 day and the number is found to decrease with time. Number 
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of dead cells is very few on both the scaffolds indicating excellent viability of seeded hMSCs. 
More number of viable cells is seen upto 14
th
 day indicating excellent biocompatibility of 
developed scaffolds. Furthermore, it is also evident from the figures that, the cell proliferation 
is higher on GN cross-linked scaffold than TPP cross-linked scaffold  
 
 
Figure 5.46 Fluorescent images of hMSCs on CS/nano β-TCP/GN and CS/nano β-
TCP/TPP composite scaffolds upto 14 days of culture.  Scaffolds are stained with calcein 
(green, which transport into cytoplasm of live cells) and ethedium homodimer (red, binds to 
DNA of dead cells).  Number of viable cells is found to increase on both kinds of scaffolds 
from day 3 to 14. However, more number of viable cells on GN cross-linked CS/nano β-
TCP [d] scaffold is seen as compared to TPP cross-linked CS/nano β-TCP [b] scaffold on 
day 14 indicating increased proliferation on GN cross-linked scaffold 
 
(ii) DNA quantification assay 
The proliferation of hMSCs seeded on the developed scaffolds was further assessed by DNA 
quantification assay. An increased DNA content is observed with both GN and TPP cross-
linked scaffolds with culture time as shown in Figure 5.47. However, the DNA content of 
hMSCs on GN cross-linked scaffold is slightly higher (452 ± 22 ng/ml) as compared to TPP 
cross-linked scaffold (376 ± 13 ng/ml) upto 21 days of culture which represents the enhanced 
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proliferation rate on GN cross-linked scaffold, (p>0.05).  Similar trend in increased DNA 
content of osteoblasts was observed earlier on TPP cross-linked CS fibrous mats and TCP 
incorporated PCL 3D porous scaffolds as reported [16, 244].   
 
Figure 5.47: Cell proliferation in terms of DNA quantification on CS/nano β-TCP/GN and 
CS/nano β-TCP/TPP cross-linked composite scaffolds upto 21 days of incubation. Cell 
number (DNA content) increases with incubation time. The highest proliferation is 
observed with GN cross-linked composite scaffolds. Each point represents the mean ± SD 
(n= 3) * and ** denotes significant differences between DNA content with other scaffolds at 
p > 0.05 and p < 0.05 
 
5.3.13 Cytoskeletal organization 
 
Confocal images of hMSCs cultured on CS/nano β-TCP/GN scaffold upto 14 days were 
analyzed for cytoskeletal organization as depicted in Figure 5.48 (i). On day 7, less intensity 
of blue color in the figure denotes minimal growth of cytoskeleton [Figure 5.48 (i-a)]. 
Whereas, on day 14, images show prominent green color confirming the extensive 
development of cytoskeleton as a result of increased cell proliferation as shown in [Figure 
5.48 (i-b)]. 3-dimensional confocal laser scanning microscopic images (Z-stacks) depict cell 
penetration in GN cross-linked composite scaffold matrix upto ~ 50 µm, from the surface of 
CS/n β-TCP/GN(0.1)  
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scaffolds as depicted in Figure 5.48 (ii).  Similar pattern of cell infiltration and uniform 
distribution of fibroblasts were observed earlier by Steward et al on fibronectin fibrils [245].  
 
 
Figure 5.48 (i):  Confocal laser scanning microscopic images of hMSCs cultured on 
CS/nano β-TCP/GN composite scaffolds on day 7 and 14. Images depict the development of 
cytoskeleton with culture time resulting in an extensive cytoskeletal development indicating 
increased cell proliferation and cell-cell interaction on day 14. Nuclei of the cells stained 
with Hoechst 33342 (blue) and actin filaments with phalloidin (green). Bar indicates 
300µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.48 (ii): 3D confocal laser scanning images (Z-stacks) of hMSCs after 14 days of 
culture on CS/nano β-TCP/GN composite scaffolds (c, d) on day 14. Z-stacks rotated in 3D 
space (d) to represent internalization of seeded cells in the porous structure of CS/nano β-
TCP/GN composite scaffolds. Nuclei of the cells stained with Hoechst 33342 (blue) and 
actin filaments with phalloidin (green) 
 Results and Discussion 
    
112 
 
5.3.14 Osteogenic differentiation potential  
(i) Alkaline Phosphatase assay 
Endogenous alkaline phosphatase activity of hMSCs seeded on CS/nano β-TCP/GN and 
CS/nano β-TCP/TPP scaffolds were measured by ALP assay. ALP activity of hMSCs seeded 
on scaffolds is bimodal with respect to incubation time, which increased from day 7 to 14 and 
decreased from day 14 to 21 (Figure 5.49), consistent pattern of ALP activity by MSCs 
undergoing osteogenesis [221, 246]. Figure 5.49 demonstrates an enhanced ALP activity (p < 
0.05) from day 7 to 14 and then a decline in ALP activity is evident for GN and TPP cross-
linked scaffolds. The ALPase activity of GN and TPP cross-linked scaffolds at 7
th 
day is 3.51 
± 0.04 and 3.26 ± 0.036 IU/μg where as at 14th day; the activity is 6.09 ± 0.06 and 5.51 ± 0.07 
IU/μg respectively. This increase in ALPase activity is thus an evident of osteoblast 
differentiation.  The cells cultured on both types of scaffolds show ALPase activity of 5.01 ± 
0.02 and 5.14 ± 0.07 IU/μg respectively on 21st day.  
 
Figure 5.49:Alkaline Phosphatase activity of CS/nano β-TCP/GN and CS/nano β-TCP/TPP 
composite scaffolds. Each point represents the mean ± SD (n= 3) * and ** denotes 
significant differences between groups at p > 0.05 and p < 0.05 respectively. Significant 
increase in ALP is seen on both scaffolds from day 7 to day 14. Highest ALP activity is 
evident on GN cross-linked scaffolds 
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(ii) Total calcium content  
Figure 5.50 depicts the calcium content of hMSCs seeded scaffolds until 21 days of culture. 
The calcium content is found to be increased in logarithmic pattern with time indicating an 
increased degree of mineralization with both GN and TPP cross-linked scaffolds. However, 
GN cross-linked scaffold has expressed higher calcium content (2054 mg/mg DNA) than with 
TPP cross-linked scaffold (1860 mg/mg DNA) as observed for 21 days of incubation, (p < 
0.05). Higher mineralization activity of differentiated MSCs represents the superior 
osteogenic potential of GN cross-linked scaffold compared to TPP cross-linked scaffold. The 
result is in good agreement with published data where fibers were reinforced into hydrogels 
[201]. 
 
 
Figure 5.50: Total calcium content of CS/nano β-TCP/GN and CS/nano β-TCP/TPP cross-
linked CS/β-TCP composite scaffolds. The calcium content increased with culture time. 
Highest calcium content is obtained with GN cross-linked scaffolds representing its higher 
mineralization activity depicting superior osteogenic potentiality. Each point represents the 
mean ± SD (n= 3) ** and *** denotes significant differences between groups at p > 0.05 
and p < 0.05 respectively  
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PART-IV 
Development of Fibrin Coated GN Cross- 
linked CS/nano β-TCP Composite Scaffolds  
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It has already been described that the deficiency of cell affinity of CS scaffold can be 
overcome by the incorporation of bioactive protein molecules like cell binding peptide RGD 
[151]. Because of the presence of a number of cell binding RGD domains, fibrin has been 
reported as a promising bioactive molecule that can used as a surface modifier of scaffold 
thereby improving cell attachment, cell proliferation and extra cellular matrix formation in 
wound healing [158]. In the second phase of our work, improved cell supportive property of 
the CS/nano β-TCP composite scaffold has been achieved by fibrin conjugation. Therefore, in 
this phase of work effort has been given for further improvement of cell affinity of the most 
potential GN cross-linked CS/nano β-TCP/GN composite scaffold developed under this study 
by fibrin coating. The result and discussion of this study is described here. 
 
5.4.1 Morphology and pore size 
 As depicted in SEM micrographs [Figure 5.51 (A)], the pore structure of the developed 
fibrin coated CS/nano β-TCP scaffold matrix is similar to non coated CS/nano β-TCP scaffold 
without any significant change in pore size. The pore size of fibrin coated scaffolds is 
measured as 56-179 μm, whereas uncoated scaffolds show 61-183 µm. Furthermore, fibrin 
coated scaffolds maintained their 3D structure and fibrillar network of fibrin found to deposit 
around the pores of scaffolds is represented in Figure 5.51 (B) with higher magnification. The 
resultant pore size range is sufficient for nesting the seeded cells and sustaining cell adhesion. 
Fibrin enables sufficient diffusion of nutrients to the cells due to its fibrillar network present 
over the scaffold architecture, as reported earlier with fibrin coated PLLA 3D matrices [192]. 
Thus it is concluded that the coating of fibrin does not show any negative impact on the pore 
structure and pore size of the composite scaffold.  
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Figure 5.51 (A): SEM micrographs of fibrin coated GN cross-linked CS/nano β TCP 
composite scaffolds. Fibrillar structures of fibrin are represented with white coloured arrow 
marks. Furthermore, the fibrin coating has added advantage of having fibrillar network 
facilitating transport of nutrients and metabolic waste 
 
 
Figure 5.51 (B): FE-SEM images of fibrilar structures formed by Fibrin on the scaffold 
surface are highlighted using high magnification microscopic images 
5.4.2 Porosity 
There is no significant change in porosity is observed when CS/nano β- TCP/GN scaffold 
(73.4 ± 2.1%) was modified with fibrin and the corresponding % porosity measured as 72.0 ± 
3.8%. The slight decrease in porosity observed with fibrin coated composite scaffolds may be 
because of fibrillar network of fibrin on the surface and inside the porous architecture of 
scaffolds. Similar result of decrease in pore size and porosity has also been reported with 
fibrin coated gelatin/nano HAp scaffolds loaded with bone morphogenic proteins used for 
bone tissue regeneration [236]. 
 
 
 Results and Discussion 
    
116 
 
5.4.3 Functional analysis 
Figure 5.52 shows FT-IR spectra of fibrin coated and uncoated CS/nano β-TCP/GN 
composite scaffolds. Presence of fibrin is confirmed as the FT-IR spectrum shows bands at 
1656 and 1533 cm
-1 
attributed to amide I and amide II of fibrin. Band at 926 cm
-1 
shows 
interactions between COOH group of fibrin and P=O of β-TCP. Furthermore, shift of the OH 
band at 3348 cm-1 represent the interactions between CS and fibrin. Thus, the formation of 
new bands and shifting of bands indicate successful fibrin coating on CS/nano β-TCP/GN 
scaffolds. 
 
 
 
 
 
 
 
 
 
 
Figure 5.52: FT-IR pattern of fibrin coated GN cross-linked CS/nano β TCPcomposite 
scaffolds. Presence of fibrin is confirmed as the FT-IR spectrum shows bands at 1656 and 
1533 cm
-1 
attributed to amide I and amide II of fibrin 
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5.4.4 Compressive strength 
Figure 5.53 depicts that there is no significant change in the compressive strength with fibrin 
coated scaffolds indicating that fibrin does not have any negative effect on the compressive 
strength of CS/nano β-TCP/GN scaffolds. The corresponding compressive strength of 
uncoated and fibrin coated scaffolds are 2.78±0.14 MPa and 2.8±0.13 Mpa respectively. 
 
 
 
 
 
 
 
 
 
Figure 5.53:  Effect of fibrin coating on compressive strength of CS/nano β-TCP/GN 
composite scaffolds. No significant difference is observed in compressive strength of 
CS/nano β-TCP/GN scaffolds with fibrin coating 
 
 
5.4.5 Measured contact angle  
The measured contact angles of CS/nano β-TCP/GN/F and CS/nano β-TCP/GN are 
comparable and the corresponding values of contact angle are 55.4 ± 1.2°and 55.1 ± 1.0° 
respectively. A slight decrease in hydrophilicity is noticed with fibrin coated scaffolds which 
may be attributed to water insoluble nature of fibrin [228]. 
5.4.6 Swelling behaviour 
Figure 5.54 shows the swelling of fibrin coated and uncoated scaffolds. Swelling of fibrin 
coated scaffold is compared to uncoated scaffold. A slight decrease in swelling is observed 
with fibrin coating on GN cross-linked scaffold. It is a well known fact that the hydrophobic 
moieties present in the fibrin protein reduce the swelling of GN cross-linked scaffolds. Both 
the scaffolds showed rapid swelling at initial hours of experiment and reached a state of 
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equilibrium after > 8 hrs. CS/nano β-TCP/GN composite showed slightly higher rate of 
swelling (220 % of initial weight) compared to the scaffolds with fibrin coating (203%). The 
decrease in swelling of fibrin conjugated scaffold may be attributed to the water repelling 
ability of fibrin which restricted the seepage of water into the porous structure of GN cross 
linked scaffold [25]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.54:  Swelling behaviour of CS/nano β-TCP/GN/F and CS/nano β-TCP/GN 
scaffolds decreased swelling rate is observed with fibrin coating. Initially rapid increase in 
swelling is noticed (1-2hrs) and equilibrium reached in > 6 hrs for all types of scaffolds  
 
5.4.7 In-vitro biodegradation study 
The degradation pattern of the developed CS, CS/nano β-TCP/GN/F and CS/nano β-TCP/GN 
scaffolds are shown in Figure 5.55. As observed from figure, no significant difference in 
degradation is noticed between fibrin coated and uncoated scaffolds. However, pure chitosan 
scaffolds have degraded to 31% of their initial weight. A slight lower degradation (7%) of 
fibrin coated GN cross-linked CS/nano β-TCP composite scaffold than uncoated (8%) maybe 
due to the hydrophobic nature of fibrin.  
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Figure 5.55: Biodegradation pattern of CS/nano β-TCP/GN/F composite scaffold in PBS 
for 28 days and its comparison with CS/nano β-TCP/GN scaffold 
 
5.4.8 Cell morphology and cell attachment 
FE-SEM images (Figure 5.56) shows that the seeded MSCs are attached and well spread over 
the scaffolds.  However, the density of cells is found to be higher on CS/nano β-TCP/GN/F 
scaffold than CS/nano β-TCP/GN scaffolds throughout the 14 days of culture period. Initial 
spherical shape (Figure 5.56 a&d) of MSCs is observed to be changed to spindle like 
morphology after 7 days of incubation as revealed by FE-SEM images and shown in Figure 
5.56 (c-g). Excellent cell spreading and cell-material interactions are evident from the 
filopodia like structures formed as depicted in the higher magnification FE-SEM images 
(Figure 5.56-e). Furthermore, the formation of monolayers of seeded cells on CS/nano β-
TCP/GN/F scaffold is also observed indicating the flattened, polygonal morphology and sheet 
like appearance of seeded hMSCs on 14
th
 day of culture as shown in Figure 5.56 (B). All 
together, the developed fibrin coated scaffold has shown enhanced cell supportive property 
providing excellent cell attachment and spreading. 
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Figure 5.56 (A): FE-SEM images showing the morphological changes of hMSCs on 
CS/nano β-TCP/GN (a-c) and CS/nano β-TCP/GN/F composite scaffolds (d-f) upto 14 days of 
culture. Cell -cell and cell-material interactions are represented at higher magnification 
(2000X) in figure 5.57(e-i). Fibrin coated scaffolds have shown more number of cells on 
both the time points (7
th
 and 14
th
 day). Establishment of cell - cell interactions with the help 
of filopodia like structures is represented with white coloured arrow marks figure 5.57 (e-i) 
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Figure 5.56: (B) Cells are highlighted using recolor software 
5.4.9 Metabolic activity by MTT assay 
Figure 5.57 shows an increasing trend of optical density indicating increased cell viability 
with incubation time observed with both fibrin coated and uncoated CS/nano β-TCP/GN 
scaffolds. However, a significant increase in metabolic activity is achieved with CS/nano β-
TCP/GN/F compared to CS/nano β-TCP/GN composite scaffolds with corresponding O.D 
values of  0.931 ± 0.021 and  0.742 ± 0.015 (p ˂ 0.05). This increase in metabolic activity can 
be attributed to the presence of numerous RGD sites in fibrin which favoured more cells to 
attach on fibrin coated scaffolds [25].  The fibrin coated composite scaffold has shown to 
facilitate MSCs to proliferate rapidly in comparison to uncoated composite scaffold.  As it is 
evident from figure, the cell viability is found to be triple from day 3 to day 7. Our results 
matches with previously published data on the role of fibrin in enhancing cellular responses 
on collagen matrices [247].  
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Figure 5.57: Metabolic activity of hMSCs seeded on fibrin coated CS/nano β-TCP/GN 
composite scaffolds upto 7 days of culture.  Uncoated CS/nano β-TCP/GN scaffold was 
used as control.   The metabolic activity is found to be tripled from day 3 to day 7 on both 
types of scaffolds. However, the fibrin coated scaffold has shown highest metabolic activity. 
Each point represents the mean ± SD (n= 3), * and ** represents significant difference 
between the two groups at p>0.05 and p< 0.05 respectively  
 
5.4.10 hMSCs proliferation 
(i) Confocal microscopy 
Proliferation of hMSCs on fibrin coated and uncoated scaffolds were assessed qualitatively by 
confocal images as shown in Figure 5.58.  The number of cells on fibrin coated CS/nano β-
TCP/GN scaffold is higher than CS/nano β-TCP/GN scaffold representing its higher 
metabolic activity of hMSCs. The increased cell proliferation on fibrin coated scaffold may be 
attributed to the presence of fibrin which enhanced the cellular responses by attracting more 
number of cells on scaffold surface and the results are matching with the earlier reports on 
fibrin coated graphene oxide composite scaffolds [228].  
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Figure 5.58 Confocal laser scanning microscopic images of hMSCs cultured on CS/nano 
β-TCP/GN and CS/nano β-TCP/GN/F composite scaffolds on day 7. Images depict the 
increased number of cells on fibrin coated scaffolds compared to uncoated indicating 
increased cell proliferation. Cells are stained with propidium iodide and fluorescein di 
acetate 
 
(ii) hMSCs proliferation by DNA quantification assay 
The proliferation of hMSCs on the scaffolds assessed by DNA quantification is shown in 
Figure 5.59. The rate of proliferation in terms of DNA content is found to increase with time 
and higher rate of proliferation is shown by CS/nano β-TCP/GN/F scaffolds than the scaffolds 
without fibrin. More precisely, DNA content of hMSCs on fibrin coated scaffolds increased 
from 119 ± 16 ng/ml to 612 ± 17 ng/ml which is higher than uncoated scaffolds (100 ± 11 
ng/ml to 452 ± 22 ng/ml,  (p < 0.05). Similar result of increased proliferation rate has been 
reported earlier with fibrin coated graphene oxide scaffolds studied for bone tissue 
regeneration [228]. Thus, the fibrin coated scaffold possesses superior cell supportive 
property achieving higher rate of proliferation than the scaffold without fibrin. 
 
 
 
 
 
 Results and Discussion 
    
124 
 
 
Figure 5.59:  Effect of fibrin coating on the rate of proliferation of hMSCs seeded on 
CS/nano β-TCP/GN composite scaffolds. Uncoated CS/nano β-TCP/GN scaffold was used 
as control. An increase in DNA content with incubation time is observed with both types of 
scaffolds. The higher proliferation is observed with fibrin coated scaffold. Each point 
represents the mean ± SD (n= 3) * and ** shows significant differences between groups at 
p >0.05 and p < 0.05 respectively 
 
5.4.11 Cytoskeletal organization 
Uniform distribution and spreading of hMSCs over the scaffold surface is evident from 
confocal images as depicted in Figure 5.60 [(i) a-b]. 3 dimensional confocal laser scanning 
microscopic images (Z-stacks) shows the cell penetration in CS/nano β-TCP/GN/F composite 
scaffold matrix upto ~ 70 µm, from the surface of scaffolds. The images of 14
th
 day cultured 
sample confirm profuse development of cytoskeleton [Figure 5.60 (ii-a)] on fibrin coated 
scaffolds. The development of cytoskeleton is observed to be less on uncoated scaffolds as 
shown in [Figure 5.60 (ii-b)]. Further, a greater population of cells is found on the fibrin 
coated scaffold when compared to uncoated scaffold. All together, the fibrin coated scaffold is 
superior to the uncoated composite scaffold in terms of cell supportive property. 
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Figure 5.60 (i): 3D Confocal Laser Scanning Microscopy images of hMSCs after 14 days of 
culture on CS/nano β-TCP/GN/F composite scaffolds (a,b). Actin filaments (green) and 
nuclei (blue) were stained Hoechst 33342 and Phalloidin respectively. Cells are found to be 
well distributed and proliferated over the scaffold with high cell viability. Z-stacks rotated 
in 3D space (b) to demonstrate penetration and uniform distribution of seeded hMSCs 
 
 
Figure 5.60 (ii): Confocal Laser Scanning Microscopy images of CS/nano β-TCP/GN/F 
scaffolds (a) and CS/nano β-TCP/GN scaffolds (b) after 14 days of culture. Nuclei of the 
cells stained with Hoechst 33342 (blue) and actin filaments with phalloidin (green). Scale 
bar indicates 300 µm. Extensive development of cytoskeleton is prominent in CS/nano β-
TCP/GN/F when compared to CS/nano β-TCP/GN scaffolds 
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5.4.12 Osteogenic differentiation potential 
(i) ALP assay  
Figure 5.61 shows an increased level of of ALP activity with culture time upto 14days and 
then a decline trend of ALP is observed. The ALPase activity on fibrin coated scaffolds is 
measured as 4.25 ± 0.03 IU/μg and 6.61 ± 0.05 IU/μg on 7th and 14th day respectively. 
However, ALP activity of hMSCs on uncoated scaffold is 3.51 ± 0.04 to 6.09 ± 0.06 on 7 to 
14th day which shows statistical significance with fibrin coated scaffolds (p < 0.05). As ALP 
is an early osteogenic marker, the ALPase activity is higher in the initial days of incubation 
beyond which it found to decrease [201]. The obtained values for fibrin modified and 
unmodified scaffolds on 21
st
 day are 5.1 ± 0.6 and 5.23 ± 0.13. Similar trend is also observed 
with BMP-II derived hydrogel matrix as reported earlier [251]. In addition to β-TCP, the 
presence of fibrin has further enhanced the osteogenic differentiation of seeded hMSCs and 
the results are consistent with previous reports when RGD was conjugated to CS for improved 
cellular responses [155]. 
 
Figure 5.61: Alkaline Phosphatase activity of hMSCs seeded on fibrin coated CS/nano β-
TCP/GN composite scaffolds upto 21 days of culture.  Scaffold without fibrin was used as 
control. Each point represents the mean ± SD (n= 3) * and ** represents significant 
differences between the groups at p>0.05 and p < 0.05 respectively 
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(ii) Total calcium content  
The calcium content of hMSCs seeded scaffolds at different time points is illustrated in 
Figure 5.63. The increase in calcium content is observed to be linear with time representing 
an increased degree of mineralization as observed with fibrin coated and uncoated scaffolds. 
The calcium content of hMSCs cultured on CS/nano β-TCP/GN/F scaffolds upto 21 days is 
2400 ± 59 mg/mg DNA whereas that of CS/nano β-TCP/GN scaffold is 2054 ± 61 mg/mg 
DNA. The osteogenic differentiation of hMSCs on the scaffold may be supported by 
increased number of Ca
+2
 ions generated by TCP dissolution.  Superior mineralization activity 
of MSCs represents the higher osteogenic potential of fibrin coated scaffold when compared 
to its counterpart. A similar trend in increase of Ca content and cell number were 
demonstrated in earlier reports where β-TCP was incorporated in fibrin gels [194]. 
 
Figure 5.62: Total calcium content of CS/nano β-TCP/GN and CS/nano  β-TCP/GN/F 
scaffolds. Calcium content increased linearly with time indicating an increased degree of 
mineralization. The highest calcium content is observed with fibrin coated composite 
matrix. Each point represents the mean ± SD (n= 3) * and ** represents p>0.05 and p<0.05 
respectively  
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(iii) In-vitro biomineralization study 
The Alizarin red assay result reveals the ability of fibrin modified scaffolds to support 
mineralization of hMSCs. The optical microscopic images [Figure 5.63 (i)] of Alizarin Red 
stained cell seeded CS/nano β-TCP/GN and CS/nano β-TCP/GN/F composite scaffolds depict 
an increased mineralization from day 14 to 21. However, a variation in stain intensity (stained 
nodules) is noticed in the form of prominent red stains on 14
th
 and 21
st
 day images with fibrin 
coated scaffolds as compared to uncoated scaffolds. Mineralization was further quantified by 
spectrophotometric measurement of the dye extracted from the obtained stained nodules 
which is shown in Figure 5.63 (ii). Greater absorbance values are obtained from the nodules 
collected from fibrin coated scaffolds indicating the enhanced ability of mineralization by 
fibrin coated scaffolds. Significant difference is observed on day 14 and 21 between the 
samples (p < 0.05) as more number of cells differentiated to osteoblasts on fibrin coated 
scaffolds as compared to other two types of scaffolds. These results are in good agreement 
with previous reports when RGD conjugated CS showed greater mineralization compared to 
unmodified CS scaffolds [155-156]. 
 
 
 
 
 
 
 
 
Figure 5.63 (i) Alizarin red staining images of CS/nano β-TCP/GN (a, b) and CS/nano β-
TCP/GN/F scaffolds (c, d). Number of red stains observed are more prominent with 
CS/nano β-TCP/GN/F scaffold on both 14 and 21 day images (c, d) as compared to 14th and 
21
st
  day images of CS/nano β-TCP/GN (a, b) scaffolds. Intense red stains are observed on 
CS/nano β-TCP/GN/F scaffolds on both 14 and 21 days suggesting elevated levels of 
mineralization 
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Figure 5.63 (ii): Quantitative analysis of mineralization by measuring absorbance of 
extracted alizarin red dye at 540nm using plate reader.  ** denotes differences between 
groups at p < 0.05 
 
(iv) Estimation of GAG 
GAGs are a trivial component of organic bone ECM and its production is an indication of 
differentiation towards a specific lineage [248]. Figure 5.64 shows the GAG content in both 
fibrin coated and uncoated scaffolds. The difference in GAG secretion between CS/nano β-
TCP and CS/nano β-TCP/GN is statistically insignificant. Whereas the amount of GAG 
secreted is significantly higher with fibrin coated scaffolds when compared to other two 
scaffolds (p < 0.05). GAGs are known to bind and accumulate various proteins including 
growth factors and cytokines. Further, they are famous for improving and stabilizing the 
presentation of proteins to their specific receptors thus preventing them from proteolytic 
degradation. GAG of 28 μg/mg scaffold in MSCs seeded scaffolds containing osteo-
differentiation media was higher than that of controls even after 28 days, confirming the 
superior osteogenic potential of fibrin coated scaffold. 
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Figure 5.64: Biochemical analysis of intracellular GAG by hMSCs cultured in the 
osteogenic media for 21 days of incubation. * and ** denotes differences between groups at 
p > 0.05 and p < 0.05 
 
(v) Expression of osteogenic specific genes 
Semi quantitative RT-PCR was performed for analyzing the osteogenic cellular differentiation 
potential of seeded MSCs on CS/nano β-TCP/GN and CS/nano β-TCP/GN/F scaffolds and the 
corresponding gene expression bands obtained are shown in Figure 5.65 (i). Furthermore, the 
bands were semi quantified with band intensity and normalized to β-actin to validate the 
relative expression of osteogenic specific genes as shown in Figure 5.65 (ii). As indicated 
CS/nano β-TCP/GN/F scaffolds exhibits higher levels of osteogenic specific genes when 
compared to CS/nano β-TCP/GN scaffolds. The expression levels of all the genes selected in 
the study is higher (p < 0.05) on fibrin coated scaffolds as compared to uncoated scaffolds. 
All the genes are observed to be up regulated on fibrin coated scaffold which is attributed to 
synergic effects of fibrin and osteoinductive nature of β-TCP [201]. The reason for down 
regulation of osteogenic specific genes on CS/nano β-TCP/GN scaffolds may be attributed to 
insufficient cell adhesion sites which resulted in poor cell cycle progression and thus poor cell 
differentiation as shown in Figure 5.65 (ii). From these results, we conclude that expression 
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of genes related to early (Col-I, BSP) middle (ALP, ON) and late (OC) markers are up 
regulated and thus proved the superiority of fibrin coated scaffolds. Similar results were also 
reported with nanofibrous scaffolds for bone tissue regeneration [249] . 
 
 
 
 
Figure 5.65 (i): Images of amplified cDNA products using specific osteogenic primers 
(BSP, ON, ALP, OC and Col-I) for hMSCs cultured on CS/nano β-TCP/GN and CS/nano 
β-TCP/GN/F scaffolds in osteogenic media for 21 days of incubation. Cell seeded on 
CS/nano/β-TCP/GN/F exhibited lower levels of osteogenic specific genes when compared to 
CS/nano β-TCP/GN scaffolds 
 
 
 
 
 
 
 Results and Discussion 
    
132 
 
 
 
 
Figure 5.65 (ii): Relative Expression of BSP (a), ON (b), ALP (c), OC (d) and Col I (e) 
osteogenic markers on CS/nano β-TCP/GN and CS/nano β-TCP/GN/F. ** Represents a 
statistical difference at p < 0.05. The expression levels of all the genes selected in the study 
is higher on fibrin coated scaffolds when compared to uncoated scaffolds 
 
 
5.4.13 In-vivo biocompatibility  
In-vivo biocompatibility of the most potential CS/nano β-TCP/GN/F scaffold was assessed by 
implanting it subcutaneously as shown in Figure 5.66 (surgically created pouch) in both male 
and female mice for 7 and 28 days.  Tissue responses after implantation of scaffolds are 
shown in Figure 5.67 (i&ii). The mice did not show any wound complications, no 
inflammatory and adverse tissue reactions throughout the experiment. Thus, scaffolds did not 
cause any health complications on the physiology of selected mice. After 7 and 28 days of 
implantation, mice were sacrificed. The host tissue reactions with implanted scaffolds were 
analyzed by H&E staining. On macroscopic observation, all the scaffolds are condensed in a 
thin fibro vascular tissue of mice. During initial days (7
th
 day), we observed the existence of 
few inﬂammatory cells and more number of ﬁbroblasts were grown into the scaffold [(Fig. 
5.67 (i-a)]. However, at later time point (28
th
 day), the number of ﬁbroblast inﬁltration into 
the scaffolds is high owing to the excellent porosity and interconnected porous architecture of 
the scaffold [(Fig. 5.67 (i-b)]. Further, the morphology of scaffold was in pace with the 
neighbouring tissue [Fig. 5.67 (i-b, ii-b)] in both sexes as reported earlier with implantation of 
CS/alginate hybrid scaffolds used for bone tissue engineering applications [30]. Thus, the in-
vivo biocompatibility of CS/nano β-TCP/GN/F composite scaffolds is proved using mice 
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model and thus the scaffolds support attachment, proliferation of cells without causing any 
adverse effects (infection, inflammation and cell death) in the transplanted mice. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.66:  Implantation of CS/nano β-TCP/GN/F composite scaffolds in ICR mice 
strain for in-vivo biocompatibility study, (a) Male & (b) Female mice 
 Results and Discussion 
    
134 
 
 
 
 
Figure 5.67 (i):  Histological sections of subcutaneous skin of ICR mice (male) at the site of 
implanted CS/nano β-TCP/GN/F composite scaffolds after (a) 7 days & (b) 28 days. Bar 
indicates 200µm. I: Implanted scaffold site. S: Subcutaneous connective tissue and I-S: 
The meso-dermal site at the interface of scaffold and tissue during initial days (7
th
 day), 
existence of few inﬂammatory cells is found and more number of ﬁbroblasts was grown 
into the scaffold. However, at later time point (28
th
 day), the number of ﬁbroblast 
inﬁltration into the scaffolds is high 
 Results and Discussion 
    
135 
 
 
 
(ii):  Histological section of subcutaneous skin of ICR mice (Female) at the site of implanted 
CS/nano β-TCP/GN/F composite scaffolds after (a) 7 days & (b) 28 days. Bar indicates 
200µm. I: Implanted scaffold site. S: Subcutaneous connective tissue and I-S: The meso-
dermal site at the interface of scaffold and tissue 
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There is a very few report available in the literature for developing CS reinforced β-TCP 
composite scaffolds (4, 23, 55, 252-54). Most of these works are preliminary study with the 
main aim of improving the mechanical strength of CS scaffold by reinforcing with micro 
sized β-TCP as shown in Table 5.4  To the best of our knowledge, the present work is the 
first report for developing CS composite scaffold using nano sized β-TCP. Further, no 
systematic work has been done so far to address the various lacuna of CS scaffold e.g. cell 
binding ability, degradation to make this potential biopolymer for use as artificial ECM for 
bone tissue regeneration except compressive strength and bioactivity. The novelty of our 
study includes the improvement of cell binding property (with surface modification by fibrin 
conjugation) biodegradation (by the development of cross-linked composite scaffold) along 
with the enhanced bioactivity and mechanical strength using nano β-TCP.   
 
The developed CS/nano β-TCP has shown superior cell supportive property, bioactivity and 
compressive strength than the CS composite scaffold prepared by the widely used micro β-
TCP study by us as well as by other researchers.  Most importantly, the CS/nano β-TCP 
developed by us possess the highest compressive strength (2.67 MPa) among all the CS/β-
TCP composite scaffolds reported so far even the compressive strength reported by Ruiran et 
al reference 10 as specified by the examiner. Besides, mechanical strength the developed 
scaffold has shown desired biocompatibility growth, proliferation and differentiation of 
hMSCs. 
 
Furthermore, the genipin cross-linked CS/β-TCP and fibrin conjugated cross-linked scaffolds 
possess control degradation rate (8% of its initial weight for four weeks of incubation) and an 
improved compressive strength of 2.78 & 2.8MPa respectively.  
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Table 5.4: Comparison of results with the published data 
S.N Scaffold Type & Method Mech.strength 
(MPa) 
Cell study Reference 
1 CS/Gelatin/β-TCP 
(0.8µm)                         
3D Porous, Freeze 
drying 
0.08-0.8 MTT Yuji Yin,2003 
2 CS/invert glass/β-TCP 3D Porous, Freeze 
drying 
0.9-2.19 MTT, SEM Zhang, 2001  
3 CS/gelatin/β-TCP/PLA 
(<26µm) 
3D Porous, Freeze 
drying 
0.2-1.8 RT-PCR,SEM Mohammadi,2004
,  
4 CS/β-TCP 3D Porous, Freeze 
gelation 
0.2-1.75 MTT Ruiran et.al, 2010 
5 CS/β-TCP (82nm) 3D Porous, Freeze 
gelation 
2.67 ± 0.21 MTT, 
Fluorescence  
Siddiqui et.al,  
2014 
6 CS/β-TCP/Fibrin 3D Porous, Freeze 
gelation 
2.71 ± 0.14 MTT, ALP, 
RT-PCR,  
Siddiqui et.al,  
2015  
7 CS/β-TCP/Genipin 3D Porous, Freeze 
gelation 
2.78 ± 0.14 MTT,ALP, 
Confocal 
Under review: 
Siddiqui et.al,  
8 CS/β-TCP/TPP 3D Porous, Freeze 
gelation 
2.72 ± 0.11 MTT, ALP, 
Confocal, Ca 
content 
-do- 
9 CS/βTCP/Genipin/Fibrin 3D Porous, Freeze 
gelation 
2.8±0.13 MTT, 
Osteogenic 
differentiation 
and in-vivo 
Siddiqui et.al, 
Communicated 
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Bone tissue defects and diseases are increasing worldwide due to the shortage of organ donor. 
Allograft bone is used extensively in regeneration of large defects but its use is limited by 
immune rejection and the risk of disease transfer. To overcome these issues, bone tissue 
engineering has emerged as an alternative strategy to repair and/or replace diseased and/or 
damaged bone tissue through the development of  biological substitutes that enable complete 
recovery of the tissue function. However, the development of 3D porous architecture from a 
suitable biopolymer or their composites with a desired set of properties is the key challenge of 
this technique.  Among the various biopolymers explored in the last decade, chitosan is 
considered as one of the potential biomaterials because of its excellent hydrophilicity, 
biocompatibility and wound healing properties. However, chitosan has several limitations 
such as poor mechanical strength, lower bioactivity, fast degradation and low cell binding 
ability that limit its use in bone tissue engineering. Therefore, the present research has 
focussed on the development of novel chitosan based composite porous scaffold by 
addressing various limitations associated with chitosan to make it a potential biomaterial for 
bone tissue regeneration. The most interesting and encouraging results achieved through this 
research work are noted here- 
 
Part I: In the first phase of research work, effort has been given to improve the mechanical 
strength and bioactivity of CS scaffold by reinforcing with bioactive β-TCP ceramic filler. Thus, 
pure CS and CS/β-TCP composite scaffolds using varying ratio of CS and β-TCP in micro and 
nano size were successfully prepared by freeze-gelation method. The scaffolds were characterized 
for morphology, pore size and porosity, compressive strength, swelling, structural, biodegradation 
and bioactivity property. Both pure CS and composite scaffolds exhibited interconnected open 
pore microstructure with a slight decrease in pore size and porosity obtained with composite 
scaffolds. The trend of pore size and porosity follows CS>nano>micro.  The composite scaffolds 
still possess pore size and porosity suitable for bone tissue engineering application.  The 
corresponding pore size and porosity values of CS/micro β-TCP scaffolds are 45-165 µm and 74.2 
± 5.2 to 80.7 ± 2.33% and that of CS/nano β-TCP scaffolds are 51-168 µm and 78.3 ± 2.9 to 84.6 ± 
2.65 % respectively. Within the concentration limit < 50 wt %), the nano β-TCP were also found 
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to disperse more uniformly in the scaffold matrix compared to micro-β-TCP as evident from SEM 
micrographs.   The compressive strength of CS scaffold was remarkably increased by the addition 
of both type of β-TCP.  However, CS scaffold reinforced with nano β-TCP exhibited higher 
compressive strength, the optimum value being 2.67±0.21MPa obtained with the ratio of 60:40 
CS:nano β-TCP as well as improved in vitro bioactivity than other composite matrices developed 
using different ratio and type of fillers. As expected, the degradation rate was slightly decreased 
by the addition of β-TCP and composite scaffold with nano β-TCP offers better degradation 
pattern.   
 
The in-vitro cell culture study using UCB derived MSCs seeded on the composite matrices has 
confirmed the biocompatibility of the freeze-gelled composite scaffolds as assessed by the cell 
attachment and morphology (SEM), cell viability (MTT assay) and proliferation (Fluorescence 
microscopy, Alamar blue assay and DNA quantification). Among the composite scaffolds 
developed, CS/nano β-TCP scaffold (60:40) has shown superior cell supportive property 
achieving better cell attachment, cell proliferation and metabolic activity. Furthermore, higher 
mineralization (total calcium content) and ALP activity of MSCs proves the superior osteogenic 
potential of CS/nano β-TCP scaffold. 
 
All these results suggest that the developed CS/β-TCP can be used as a base polymeric scaffold 
material for various bone tissue engineering application. However, the superior physico-chemical, 
mechanical and in vitro biological properties make CS/nano β-TCP most potential composite 
scaffold for bone tissue regeneration and hence used for further study. 
 
Part II: In the previous section, CS/β-TCP composite scaffolds with improved mechanical 
and bioactive property were developed by freeze-gelation method and CS reinforced with 
nano β-TCP (CS/nano β-TCP) was found to the most potential. CS also lacks cell signalling 
molecules and hence offers less cellular affinity. So in this phase, effort has been given to 
investigate the effect of fibrin as a promising bioactive protein molecule having numerous cell 
binding RGD domains to improve cellular affinity of the   CS/nano β-TCP scaffolds. Fibrin 
conjugated CS/nano β-TCP scaffold (CS/nano β-TCP/F) was prepared by cross-linking with 
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ethyl-3-(3-dimethylaminopropyl) carbodimide. The microstructure of the conjugated scaffold 
possess interconnected open pore and pore network with 49-151 µm pore size and 81.4±4.1% 
porosity suitable for bone tissue regeneration.   
 
 
Further, the in-vitro cell culture study has shown an enhanced cell attachment (FE SEM), cell 
proliferation (Fluorescence microscopy, DNA quantification) and differentiation (ALP, total 
calcium content, alizarin red assay) on fibrin conjugated CS/nano β-TCP scaffold.  The 
uniform cell distribution and cell infiltration throughout the scaffold pores were confirmed by 
confocal laser scanning microscopy (CLSM). Furthermore, higher expression of osteogenic 
specific genes such as Bone sialo protein (BSP), Osteonectin (ON), Alkaline Phosphatase 
(ALP), and Osteocalcin (OC) on fibrin conjugated scaffolds is observed compared to non-
conjugated composite scaffolds.   
 
Thus it has been concluded that the modification of composite scaffold with fibrin is 
beneficial for improving cellular affinity of the scaffold. 
 
Part III: The rapid degradation of CS is another important aspect that needs to be addressed 
to achieve desired degradation rate compatible with the rate of neo tissue formation. Though a 
slight improvement in degradation rate (slow degradation) has been achieved in the first phase 
of research work by incorporating β-TCP, there is need of further controlling high degradation 
of scaffold to a desirable level. Keeping this aspect in view, an effort has been given in this 
part of thesis work for further reduction of degradation by the development of cross-linked 
composite scaffolds. The main aim was to develop genipin (GN) and sodium tripolyphosphate 
(TPP) cross-linked CS/nano β-TCP composite scaffolds with improved degradation 
characteristics along with other physico-chemical, mechanical and in-vitro biological 
property.   
 
The cross-linked CS/nano β-TCP composite scaffolds were successfully developed using 
different concentrations of GN and TPP cross-linking agents.  No significant change in 
scaffold architecture and morphology was observed due to cross-linking. Whereas the 
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degradation rate of the scaffold was significantly decreased by cross-linking and the optimal 
degradation rate was achieved with 0.1w/v% concentration of both GN and TPP.  In 
comparison, GN cross-linked CS/nano β-TCP composite has shown lower degradation rate 
due to its strong cross-linking ability than TPP cross-linked scaffold.  The corresponding 
degradation rates are 8% and 13% respectively. A slight increase in compressive strength is 
also achieved with cross-linked scaffolds; the maximum compressive strength is obtained at a 
concentration of 0.1 w/v% cross-linking agents. The corresponding compressive strength of 
GN and TPP cross-linked scaffolds is 2.78 ± 0.14 MPa and 2.72 ± 0.11 MPa respectively 
which is suitable for cancellous bone tissue regeneration.   
 
Both GN and TPP cross-linked composite scaffolds were also evaluated for their performance 
in in-vitro cell culture study. The study has revealed enhanced cell supportive property of 
cross-linked scaffolds in terms of cell attachment (SEM), cellular metabolic activity (MTT 
assay) cell proliferation (DNA quantification), cytoskeletal organization (confocal laser 
scanning microscopy), total calcium content, and ALP activity.  Furthermore, GN cross-
linked scaffold has shown better performance than TPP cross-linked scaffold. Thus the 
developed CS/nano β-TCP/GN composite scaffold was selected for further study. 
 
Part IV: As in part-II, fibrin has shown a positive impact on the cellular responses of the 
CS/nano β-TCP composite scaffolds. So, in this phase of work, attempt has been made to 
improve the cell binding ability of the most potential CS/nano β-TCP/GN composite scaffold 
by fibrin coating. The developed fibrin modified scaffold (CS/nano β-TCP/GN/F) possesses 
desired interconnected pores and pore network, porosity, hydrophilicity, and favourable 
biodegradation rate. The in-vitro cell culture study has confirmed enhanced cell adhesion 
property in terms of cell (hMSCs) attachment and spreading (FE-SEM study), cell 
proliferation (DNA quantification), cytoskeletal organization and cell infiltration (confocal 
microscopy) and cellular metabolic activity (MTT assay). Higher osteogenic differentiation 
potentiality of the fibrin coated composite scaffold has been proved by  higher ALP activity,  
total calcium and GAG content  and biomineralization  ability of hMSCs seeded on the fibrin 
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coated scaffold than the uncoated one. The higher osteogenic differentiation of hMSCs is also 
evident from the semi quantitative RT-PCR study that revealed higher expression of 
osteogenic specific genes such as Bone sialo protein (BSP), Osteonectin (ON), Alkaline 
Phosphatase (ALP), Collagen I (Col 1) and Osteocalcin (OC) on the fibrin modified scaffolds 
as compared to uncoated scaffold. Finally, in-vivo biocompatibility of these scaffolds was 
proved by animal testing using mice model. All together, the fibrin coating has beneficial 
effect in enhancing various cellular responses of the composite scaffolds. 
 
   Overall, in this study a novel 3D porous composite scaffold has been developed from 
chitosan reinforced with CS/nano β-TCP as filler which can be used as a base polymeric 
scaffold for various bone tissue engineering applications. The property of the CS/nano β-
TCP composite scaffolds was further improved by cross-linking with GN and fibrin coating 
thereby CS/nano β-TCP/GN and CS/nano β-TCP/GN/F scaffolds with favourable 
degradation, enhanced   cellular responses and osteogenic differentiation were developed. It 
has been demonstrated in this dissertation work that the developed CS based composite 
scaffolds in particular CS/nano β-TCP/GN/F can serve as a potential artificial extra cellular 
scaffold matrix for various non load bearing bone tissue regeneration in future.  
 
Suggested Future Work  
The following research work are suggested for future study with the developed composite 
scaffolds- 
i. Three dimensional scaffolds with appropriate design may be fabricated by adopting 
advanced scaffold fabrication technique like electrospinning, rapid protyping 
methods. 
ii. Angiogenesis  study can be performed to confirm the vascularisation aspect of the 
developed scaffold. 
iii. Detail in-vivo animal study can be undertaken for assessing its suitability for possible 
future clinical application. 
 
 Biography 
    
143 
 
BIOGRAPHY 
 
Nadeem Siddiqui is a PhD candidate in the Department of Biotechnology 
and Medical Engineering at National Institute of Technology Rourkela, 
India. He received his B.Tech (Biotechnology) in 2008 from C.M.R 
College of Engineering and Technology, JNTU Hyderabad, Telangana 
(India). He joined NIT Rourkela in the year of 2008 and completed his M.Tech 
(Biotechnology) in 2010. He started his Ph.D in NIT Rourkela in the year of 2010. His 
interests include biomaterials processing and application for bone and cartilage tissue 
engineering, nanotechnology and stem cell research for efficient and improved tissue 
regeneration.  
 
Personal Details: 
Father’s Name   Mr. Late. Saleem Siddiqui  
Mother’s Name  Mrs. Siddiqua Begum  
Date of Birth   15
th
 August, 1985  
Gender    Male 
Nationality    Indian  
Language Known  English, Hindi, Urdu, Telugu and Oriya 
Permanent Address    C/O Waseem Siddiqui 
                                                5
th
 Floor, Flat no: 515 
                                                Tirumala Alluri Nivas Apartments 
    Malakpet, Hyderabad 
                                                Telangana, India-500024 
E.Mail:                                    nadeem.nitian.biotech@gmail.com 
  
JOURNAL PUBLICATIONS  
 
• Published online: Nadeem Siddiqui, Krishna Pramanik*, “Effects of micro and nano 
β-TCP fillers in freeze-gellled chitosan scaffold for bone tissue engineering”. Journal 
of applied polymer science 13
th
 may 2014, Inc. J.App. Polym. Sci. 2014,131,41025, 
[IF:(1.64)]  
• Published online: Nadeem Siddiqui, Krishna Pramanik*, “Development of fibrin 
conjugated chitosan/nano β-TCP composite scaffolds with improved surface property 
for bone tissue regeneration”. Journal of applied polymer science, Inc. J.App. Polym. 
Sci. 2015, 132, DOI: 10.1002/app.41534, [IF:1.64] 
• Under review: Nadeem Siddiqui, Krishna Pramanik and Esmail 
Jabbari*,“Osteogenic Differentiation of Human Mesenchymal Stem Cells in Freeze-
Gelled Chitosan/Nano beta Tricalcium Phosphate Porous Scaffolds Cross-linked with 
Genipin” communicated to Journal of Material science and Engg: C. [IF:3.0]  
• Communicated: Nadeem Siddiqui, Bissoyi Akalabya Krishna Pramanik*, 
manuscript entitled “Enhanced cellular responses on fibrin coated GN cross-linked 
CS/nano β-TCP composite scaffolds”, Journal of Biomedical Nanotechnology [IF:7.5] 
 
 
 
 
 Biography 
    
144 
 
Conference papers 
 
 Nadeem Siddiqui, Krishna Pramanik*, “Development of cross-linked freeze-
gellled chitosan based scaffolds for bone tissue regeneration” Indian Chitin and 
Chitosan society  at Institute for Himalayan Bioresources Technolgy-2013 
organized by IHBT Palampur, Himachal Pradesh, India, June -2013. 
 Nadeem Siddiqui, Krishna Pramanik*, Role of Pluronics in blood vessel 
tissue engineering applications at International Conference on Tissue 
Engineering and Regenerative Medicine (ICTERM-2012), organized by 
NITRKL, India; Sept-2012.  
 Nadeem Siddiqui, Krishna Pramanik*, “Development of freeze-gelled 
chitosan based scaffolds for bone tissue engineering” at NANOBIO-2012 
organized by Amrita institute Kerala, India; Feb-2012. 
 
 Nadeem Siddiqui, Krishna Pramanik*, “Chitosan as an ideal polymer for bone 
tissue engineering” Presented as a poster in National seminar entitled Tissue 
Engineering Prospects and Challenges (TEPC) organized by NIT  Rourkela, 
India; Jan- 2011.  
 
  
 
 
  
  
  
  
  
  
 
 References 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
 
 
 
 
 
 References 
    
145 
 
 
[1] V. C. Mow and R. Huiskers, Basic orthopaedic biomechanics and mechano-biology: 
Lippincott Williams & Wilkins, 2005. 
[2] A. R. Costa-Pinto, et al., "Scaffolds based bone tissue engineering: the role of 
chitosan," Tissue Engineering Part B: Reviews, vol. 17, pp. 331-347, 2011. 
[3] A. M. Martins, et al., "Responsive and in situ-forming chitosan scaffolds for bone 
tissue engineering applications: an overview of the last decade," Journal of Materials 
Chemistry, vol. 20, pp. 1638-1645, 2010. 
[4] Y. Mohammadi, et al., "Osteogenic Differentiation of Mesenchymal Stem Cells on 
Novel Three-Dimensional Poly (L-Lactic Acid)/Chitosan/Gelatin/Beta-Tricalcium 
Phosphate Hybrid Scaffolds," Iranian Polymer Journal, vol. 16, p. 57, 2007. 
[5] M. I. Sabir, et al., "A review on biodegradable polymeric materials for bone tissue 
engineering applications," Journal of Materials Science, vol. 44, pp. 5713-5724, 2009. 
[6] L. Yunfeng, et al., "Review on techniques of design and manufacturing for bone tissue 
engineering scaffold," in Biomedical Engineering and Informatics, 2009. BMEI'09. 
2nd International Conference on, 2009, pp. 1-4. 
[7] J. D. Stroncek and W. M. Reichert, "Overview of wound healing in different tissue 
types," Indwelling Neural Implants: Strategies for contending with the in vivo 
environment, 2008. 
[8] H.I. Chang and Y. Wang, "Cell responses to surface and architecture of tissue 
engineering scaffolds," Regenerative Medicine and Tissue Engineering—Cells and 
Biomaterials, InTech: Rijeka, Croatia, pp. 569-588, 2011. 
[9] J. Venkatesan and S.-K. Kim, "Chitosan composites for bone tissue engineering—An 
overview," Marine drugs, vol. 8, pp. 2252-2266, 2010. 
[10] H. Ruiran, et al., "Preparation of β-calcium phosphate/chitosan composite scaffolds 
and its effect on osteoblasts behaviour," Journal of Functional Materials, vol. 41, pp. 
148-151, 2010. 
[11] A. Di Martino, et al., "Chitosan: a versatile biopolymer for orthopaedic tissue-
engineering," Biomaterials, vol. 26, pp. 5983-5990, 2005. 
[12] T. Jiang, et al., "Fabrication of novel porous chitosan matrices as scaffolds for bone 
tissue engineering," DTIC Document2005. 
[13] M. Yamamoto, et al., "Controlled release by biodegradable hydrogels enhances the 
ectopic bone formation of bone morphogenetic protein," Biomaterials, vol. 24, pp. 
4375-4383, 2003. 
[14] N. Sultana and M. R. A. Kadir, "Study of in vitro degradation of biodegradable 
polymer based thin films and tissue engineering scaffolds," African Journal of 
Biotechnology, vol. 10, pp. 18709-18715, 2013. 
[15] C. E. Orrego and J. S. Valencia, "Preparation and characterization of chitosan 
membranes by using a combined freeze gelation and mild crosslinking method," 
Bioprocess and biosystems engineering, vol. 32, pp. 197-206, 2009. 
[16] F. Pati, et al., "Osteoblastic cellular responses on ionically crosslinked 
chitosan‐tripolyphosphate fibrous 3‐D mesh scaffolds," Journal of Biomedical 
Materials Research Part A, vol. 101, pp. 2526-2537, 2013. 
[17] N. Bhardwaj, et al., "Freeze-gelled silk fibroin protein scaffolds for potential 
applications in soft tissue engineering," International journal of biological 
macromolecules, vol. 49, pp. 260-267, 2011. 
[18] M. Okada and T. Furuzono, "Hydroxylapatite nanoparticles: fabrication methods and 
medical applications," Science and Technology of Advanced Materials, vol. 13, p. 
064103, 2012. 
 References 
    
146 
 
[19] J. R. Porter, et al., "Bone tissue engineering: a review in bone biomimetics and drug 
delivery strategies," Biotechnology Progress, vol. 25, pp. 1539-1560, 2009. 
[20] A. Mol, et al., "Fibrin as a cell carrier in cardiovascular tissue engineering 
applications," Biomaterials, vol. 26, pp. 3113-3121, 2005. 
[21] T. Weigel, et al., "Design and preparation of polymeric scaffolds for tissue 
engineering," 2006. 
[22] S. J. Peter, et al., "In vitro degradation of a poly (propylene fumarate)/β-tricalcium 
phosphate composite orthopaedic scaffold," Tissue engineering, vol. 3, pp. 207-215, 
1997. 
[23] Y. Zhang, et al., "Calcium phosphate-chitosan composite scaffolds for bone tissue 
engineering," Tissue engineering, vol. 9, pp. 337-345, 2003. 
[24] Y.M. Lee, et al., "Tissue engineered bone formation using chitosan/tricalcium 
phosphate sponges," Journal of Periodontology, vol. 71, pp. 410-417, 2000. 
[25] S. Jockenhoevel, et al., "Fibrin gel–advantages of a new scaffold in cardiovascular 
tissue engineering," European journal of cardio-thoracic surgery, vol. 19, pp. 424-
430, 2001. 
[26] E. Gentleman, et al., "Mechanical characterization of collagen fibers and scaffolds for 
tissue engineering," Biomaterials, vol. 24, pp. 3805-3813, 2003. 
[27] S. Sahoo, et al., "A bFGF-releasing silk/PLGA-based biohybrid scaffold for 
ligament/tendon tissue engineering using mesenchymal progenitor cells," 
Biomaterials, vol. 31, pp. 2990-2998, 2010. 
[28] Y. Yang, et al., "Enhancement of mechanical signals for tissue engineering bone," 
Topics in Tissue Engineering, vol. 2, pp. 1-21, 2005. 
[29] T. Jiang, et al., "Chitosan–poly (lactide-co-glycolide) microsphere-based scaffolds for 
bone tissue engineering: In vitro degradation and in vivo bone regeneration studies," 
Acta Biomaterialia, vol. 6, pp. 3457-3470, 2010. 
[30] Z. Li, et al., "Chitosan–alginate hybrid scaffolds for bone tissue engineering," 
Biomaterials, vol. 26, pp. 3919-3928, 2005. 
[31] J. De Groot, et al., "Use of porous polyurethanes for meniscal reconstruction and 
meniscal prostheses," Biomaterials, vol. 17, pp. 163-173, 1996. 
[32] A. J. Salgado, et al., "Bone tissue engineering: state of the art and future trends," 
Macromolecular bioscience, vol. 4, pp. 743-765, 2004. 
[33] M. Barbosa, et al., "Polysaccharides as scaffolds for bone regeneration," Itbm-Rbm, 
vol. 26, pp. 212-217, 2005. 
[34] N. Bhardwaj and S. C. Kundu, "Electrospinning: a fascinating fiber fabrication 
technique," Biotechnology advances, vol. 28, pp. 325-347, 2010. 
[35] M. E. Gomes, et al., "Starch–poly (ε‐caprolactone) and starch–poly (lactic acid) 
fibre‐mesh scaffolds for bone tissue engineering applications: structure, mechanical 
properties and degradation behaviour," Journal of Tissue Engineering and 
Regenerative Medicine, vol. 2, pp. 243-252, 2008. 
[36] G. Marino, et al., "β-Tricalcium phosphate 3D scaffold promote alone osteogenic 
differentiation of human adipose stem cells: in vitro study," Journal of Materials 
Science: Materials in Medicine, vol. 21, pp. 353-363, 2010. 
[37] R. Dorati, et al., "Effect of porogen on the physico-chemical properties and 
degradation performance of PLGA scaffolds," Polymer Degradation and Stability, 
vol. 95, pp. 694-701, 2010. 
[38] W. Thein-Han and R. Misra, "Biomimetic chitosan–nanohydroxyapatite composite 
scaffolds for bone tissue engineering," Acta Biomaterialia, vol. 5, pp. 1182-1197, 
2009. 
 References 
    
147 
 
[39] M. Ngiam, et al., "The fabrication of nano-hydroxyapatite on PLGA and 
PLGA/collagen nanofibrous composite scaffolds and their effects in osteoblastic 
behavior for bone tissue engineering," Bone, vol. 45, pp. 4-16, 2009. 
[40] C. Li, et al., "Bone morphogenetic protein-9 induces osteogenic differentiation of rat 
dental follicle stem cells in P38 and ERK1/2 MAPK dependent manner," International 
journal of medical sciences, vol. 9, pp. 862-871, 2011. 
[41] B. Basu, et al., Advanced biomaterials: fundamentals, processing, and applications: 
John Wiley & Sons, 2010. 
[42] J. M. Dang and K. W. Leong, "Natural polymers for gene delivery and tissue 
engineering," Advanced drug delivery reviews, vol. 58, pp. 487-499, 2006. 
[43] J. Venugopal, et al., "Mineralization of osteoblasts with electrospun 
collagen/hydroxyapatite nanofibers," Journal of Materials Science: Materials in 
Medicine, vol. 19, pp. 2039-2046, 2008. 
[44] R. Pallela, et al., "Biophysicochemical evaluation of chitosan‐hydroxyapatite‐marine 
sponge collagen composite for bone tissue engineering," Journal of Biomedical 
Materials Research Part A, vol. 100, pp. 486-495, 2012. 
[45] S. B. Lee, et al., "Study of gelatin-containing artificial skin V: fabrication of gelatin 
scaffolds using a salt-leaching method," Biomaterials, vol. 26, pp. 1961-1968, 2005. 
[46] Y. Zhang, et al., "The osteogenic properties of CaP/silk composite scaffolds," 
Biomaterials, vol. 31, pp. 2848-2856, 2010. 
[47] H. Ç. Arca and S. Senel, "Chitosan based systems for tissue engineering Part 1: Hard 
tissues," FABAD J. Pharm. Sci, vol. 33, pp. 35-49, 2008. 
[48] X. X. Shao, et al., "Evaluation of a hybrid scaffold/cell construct in repair of high-
load-bearing osteochondral defects in rabbits," Biomaterials, vol. 27, pp. 1071-1080, 
2006. 
[49] Y.-C. Wu, et al., "A comparative study of the physical and mechanical properties of 
three natural corals based on the criteria for bone–tissue engineering scaffolds," 
Journal of Materials Science: Materials in Medicine, vol. 20, pp. 1273-1280, 2009. 
[50] H. Cao and N. Kuboyama, "A biodegradable porous composite scaffold of PGA/β-
TCP for bone tissue engineering," Bone, vol. 46, pp. 386-395, 2010. 
[51] X. Huang, et al., "Peptide interfacial biomaterials improve endothelial cell adhesion 
and spreading on synthetic polyglycolic acid materials," Annals of biomedical 
engineering, vol. 38, pp. 1965-1976, 2010. 
[52] H. Maachou, et al., "Characterization and in vitro bioactivity of 
chitosan/hydroxyapatite composite membrane prepared by freeze-gelation method," 
Trends Biomater Artif Organs, vol. 22, pp. 15-24, 2008. 
[53] Y. Yin, et al., "Preparation and characterization of macroporous chitosan–
gelatin/β‐tricalcium phosphate composite scaffolds for bone tissue engineering," 
Journal of Biomedical Materials Research Part A, vol. 67, pp. 844-855, 2003. 
[54] L. Zhao and J. Chang, "Preparation and characterization of macroporous 
chitosan/wollastonite composite scaffolds for tissue engineering," Journal of 
Materials Science: Materials in Medicine, vol. 15, pp. 625-629, 2004. 
[55] M. Navarro, et al., "Biomaterials in orthopaedics," Journal of the Royal Society 
Interface, vol. 5, pp. 1137-1158, 2008. 
[56] J. Nakamatsu, et al., "Processing and characterization of porous structures from 
chitosan and starch for tissue engineering scaffolds," Biomacromolecules, vol. 7, pp. 
3345-3355, 2006. 
[57] P. K. Dutta, et al., "Chitin and chitosan: Chemistry, properties and applications," 
Journal of Scientific and Industrial Research, vol. 63, pp. 20-31, 2004. 
 References 
    
148 
 
[58] G. Chen, et al., "Development of biodegradable porous scaffolds for tissue 
engineering," Materials Science and Engineering: C, vol. 17, pp. 63-69, 2001. 
[59] Z. Ge, et al., "Manufacture of degradable polymeric scaffolds for bone regeneration," 
Biomedical Materials, vol. 3, p. 022001, 2008. 
[60] A. G. Mikos and J. S. Temenoff, "Formation of highly porous biodegradable scaffolds 
for tissue engineering," Electronic Journal of Biotechnology, vol. 3, pp. 23-24, 2000. 
[61] J. J. Yoon, et al., "Dexamethasone-releasing biodegradable polymer scaffolds 
fabricated by a gas-foaming/salt-leaching method," Biomaterials, vol. 24, pp. 2323-
2329, 2003. 
[62] Q. Hou, et al., "Porous polymeric structures for tissue engineering prepared by a 
coagulation, compression moulding and salt leaching technique," Biomaterials, vol. 
24, pp. 1937-1947, 2003. 
[63] T. Weigel, et al., "Design and preparation of polymeric scaffolds for tissue 
engineering," 2006. 
[64] J. Li and A. F. Mak, "Transfer of collagen coating from porogen to scaffold: Collagen 
coating within poly (DL-lactic-co-glycolic acid) scaffold," Composites Part B: 
Engineering, vol. 38, pp. 317-323, 2007. 
[65] M. T. Gokmen and F. E. Du Prez, "Porous polymer particles—A comprehensive guide 
to synthesis, characterization, functionalization and applications," Progress in 
Polymer Science, vol. 37, pp. 365-405, 2012. 
[66] G. Chen, et al., "Preparation of poly (L-lactic acid) and poly (DL-lactic-co-glycolic 
acid) foams by use of ice microparticulates," Biomaterials, vol. 22, pp. 2563-2567, 
2001. 
[67] A. Bottino, et al., "The formation of microporous polyvinylidene difluoride 
membranes by phase separation," Journal of membrane science, vol. 57, pp. 1-20, 
1991. 
[68] C.Y. Hsieh, et al., "Fabrication and release behavior of a novel freeze-gelled 
chitosan/γ-PGA scaffold as a carrier for rhBMP-2," Dental Materials, vol. 22, pp. 
622-629, 2006. 
[69] P. Van de Witte, et al., "Phase separation processes in polymer solutions in relation to 
membrane formation," Journal of membrane science, vol. 117, pp. 1-31, 1996. 
[70] Z. She, et al., "Preparation and in vitro degradation of porous three-dimensional silk 
fibroin/chitosan scaffold," Polymer Degradation and Stability, vol. 93, pp. 1316-1322, 
2008. 
[71] T.-H. Young, et al., "The formation mechanism of membranes prepared from the 
crystalline EVAL polymer–water (nonsolvent)–2-propanol (nonsolvent) system," 
Journal of membrane science, vol. 159, pp. 21-27, 1999. 
[72] Q. Lv and Q. Feng, "Preparation of 3-D regenerated fibroin scaffolds with freeze 
drying method and freeze drying/foaming technique," Journal of Materials Science: 
Materials in Medicine, vol. 17, pp. 1349-1356, 2006. 
[73] F. J. Hua, et al., "Macroporous poly (L‐lactide) scaffold 1. Preparation of a 
macroporous scaffold by liquid–liquid phase separation of a PLLA–dioxane–water 
system," Journal of biomedical materials research, vol. 63, pp. 161-167, 2002. 
[74] N.-Y. Yuan, et al., "Effects of the cooling mode on the structure and strength of 
porous scaffolds made of chitosan, alginate, and carboxymethyl cellulose by the 
freeze-gelation method," Carbohydrate polymers, vol. 78, pp. 349-356, 2009. 
[75] L. Qian and H. Zhang, "Controlled freezing and freeze drying: a versatile route for 
porous and micro‐/nano‐structured materials," Journal of chemical technology and 
biotechnology, vol. 86, pp. 172-184, 2011. 
 References 
    
149 
 
[76] M.H. Ho, et al., "Preparation of porous scaffolds by using freeze-extraction and 
freeze-gelation methods," Biomaterials, vol. 25, pp. 129-138, 2004. 
[77] M. Statham, et al., "Net-shape manufacture of low-cost ceramic shapes by freeze-
gelation," Journal of sol-gel science and technology, vol. 13, pp. 171-175, 1998. 
[78] C.Y. Hsieh, et al., "Analysis of freeze-gelation and cross-linking processes for 
preparing porous chitosan scaffolds," Carbohydrate polymers, vol. 67, pp. 124-132, 
2007. 
[79] P.-H. Chen, et al., "Novel chitosan–pectin composite membranes with enhanced 
strength, hydrophilicity and controllable disintegration," Carbohydrate Polymers, vol. 
82, pp. 1236-1242, 2010. 
[80] X. Zhu, et al., "Electrospun fibrous mats with high porosity as potential scaffolds for 
skin tissue engineering," Biomacromolecules, vol. 9, pp. 1795-1801, 2008. 
[81] G. Jin, et al., "Stem cell differentiation to epidermal lineages on electrospun 
nanofibrous substrates for skin tissue engineering," Acta biomaterialia, vol. 7, pp. 
3113-3122, 2011. 
[82] A. Subramanian, et al., "Preparation and evaluation of the electrospun chitosan/PEO 
fibers for potential applications in cartilage tissue engineering," Journal of 
Biomaterials Science, Polymer Edition, vol. 16, pp. 861-873, 2005. 
[83] H. S. Yoo, et al., "Surface-functionalized electrospun nanofibers for tissue engineering 
and drug delivery," Advanced drug delivery reviews, vol. 61, pp. 1033-1042, 2009. 
[84] W. Cui, et al., "Electrospun nanofibrous materials for tissue engineering and drug 
delivery," Science and Technology of Advanced Materials, vol. 11, p. 014108, 2010. 
[85] C. Liu, et al., "Novel 3D collagen scaffolds fabricated by indirect printing technique 
for tissue engineering," Journal of Biomedical Materials Research Part B: Applied 
Biomaterials, vol. 85, pp. 519-528, 2008. 
[86] H. Seitz, et al., "Three‐dimensional printing of porous ceramic scaffolds for bone 
tissue engineering," Journal of Biomedical Materials Research Part B: Applied 
Biomaterials, vol. 74, pp. 782-788, 2005. 
[87] D. Han, et al., "Usage of Rapid Prototyping Technique in Customized 
Craniomaxillofacial Bone Tissue Engineering Scaffold,"  vol. 1, ed: InTech, 2011. 
[88] L. Ciocca, et al., "CAD/CAM and rapid prototyped scaffold construction for bone 
regenerative medicine and surgical transfer of virtual planning: a pilot study," 
Computerized Medical Imaging and Graphics, vol. 33, pp. 58-62, 2009. 
[89] W. Sun and P. Lal, "Recent development on computer aided tissue engineering—a 
review," Computer methods and programs in biomedicine, vol. 67, pp. 85-103, 2002. 
[90] A. J. Friedenstein, et al., "Heterotopic transplants of bone marrow," Transplantation, 
vol. 6, pp. 230-247, 1968. 
[91] E. Horwitz, et al., "Clarification of the nomenclature for MSC: The International 
Society for Cellular Therapy position statement," Cytotherapy, vol. 7, pp. 393-395, 
2005. 
[92] A. Erices, et al., "Mesenchymal progenitor cells in human umbilical cord blood," 
British journal of haematology, vol. 109, pp. 235-242, 2000. 
[93] Y. J. Choi, et al., "Determination of osteogenic or adipogenic lineages in muscle-
derived stem cells (MDSCs) by a collagen-binding peptide (CBP) derived from bone 
sialoprotein (BSP)," Biochemical and biophysical research communications, vol. 419, 
pp. 326-332, 2012. 
[94] M. V. Risbud and M. Sittinger, "Tissue engineering: advances in< i> in vitro</i> 
cartilage generation," TRENDS in Biotechnology, vol. 20, pp. 351-356, 2002. 
 References 
    
150 
 
[95] A. Wang, et al., "Porous chitosan tubular scaffolds with knitted outer wall and 
controllable inner structure for nerve tissue engineering," Journal of Biomedical 
Materials Research Part A, vol. 79, pp. 36-46, 2006. 
[96] Z.Q. Feng, et al., "The effect of nanofibrous galactosylated chitosan scaffolds on the 
formation of rat primary hepatocyte aggregates and the maintenance of liver function," 
Biomaterials, vol. 30, pp. 2753-2763, 2009. 
[97] F. Tortelli and R. Cancedda, "Three-dimensional cultures of osteogenic and 
chondrogenic cells: a tissue engineering approach to mimic bone and cartilage in 
vitro," Eur Cell Mater, vol. 17, pp. 1-14, 2009. 
[98] O. F. Zouani, et al., "Differentiation of pre-osteoblast cells on poly (ethylene 
terephthalate) grafted with RGD and/or BMPs mimetic peptides," Biomaterials, vol. 
31, pp. 8245-8253, 2010. 
[99] A. McLaren, "Ethical and social considerations of stem cell research," Nature, vol. 
414, pp. 129-131, 2001. 
[100] K. Tanner, "Bioactive composites for bone tissue engineering," Proceedings of the 
Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, vol. 
224, pp. 1359-1372, 2010. 
[101] G. Han, et al., "Osteogenic differentiation of bone marrow mesenchymal stem cells by 
adenovirus-mediated expression of leptin," Regulatory peptides, vol. 163, pp. 107-
112, 2010. 
[102] T. S. Karande, et al., "Diffusion in musculoskeletal tissue engineering scaffolds: 
design issues related to porosity, permeability, architecture, and nutrient mixing," 
Annals of biomedical engineering, vol. 32, pp. 1728-1743, 2004. 
[103] Y. Yamamoto, et al., "Preparation of artificial skeletal muscle tissues by a magnetic 
force-based tissue engineering technique," Journal of bioscience and bioengineering, 
vol. 108, pp. 538-543, 2009. 
[104] S. K. Nandi, et al., "The repair of segmental bone defects with porous bioglass: an 
experimental study in goat," Research in veterinary science, vol. 86, pp. 162-173, 
2009. 
[105] A. I. Caplan, "Adult mesenchymal stem cells for tissue engineering versus 
regenerative medicine," Journal of cellular physiology, vol. 213, pp. 341-347, 2007. 
[106] R. H. Lee, et al., "Characterization and expression analysis of mesenchymal stem cells 
from human bone marrow and adipose tissue," Cellular Physiology and Biochemistry, 
vol. 14, pp. 311-324, 2004. 
[107] M. Shin, et al., "In vivo bone tissue engineering using mesenchymal stem cells on a 
novel electrospun nanofibrous scaffold," Tissue Engineering, vol. 10, pp. 33-41, 2004. 
[108] W.-J. Li, et al., "A three-dimensional nanofibrous scaffold for cartilage tissue 
engineering using human mesenchymal stem cells," Biomaterials, vol. 26, pp. 599-
609, 2005. 
[109] H. A. Awad, et al., "Autologous mesenchymal stem cell-mediated repair of tendon," 
Tissue Engineering, vol. 5, pp. 267-277, 1999. 
[110] H. Liu, et al., "The interaction between a combined knitted silk scaffold and 
microporous silk sponge with human mesenchymal stem cells for ligament tissue 
engineering," Biomaterials, vol. 29, pp. 662-674, 2008. 
[111] T. N. Vo, et al., "Strategies for controlled delivery of growth factors and cells for bone 
regeneration," Advanced drug delivery reviews, vol. 64, pp. 1292-1309, 2012. 
[112] J. Rossert and B. De Crombrugghe, "Type I collagen: structure, synthesis, and 
regulation," Principles of bone biology, vol. 2, pp. 189-210, 1996. 
[113] D. E. Discher, et al., "Growth factors, matrices, and forces combine and control stem 
cells," Science, vol. 324, pp. 1673-1677, 2009. 
 References 
    
151 
 
[114] J. E. Babensee, et al., "Growth factor delivery for tissue engineering," Pharmaceutical 
research, vol. 17, pp. 497-504, 2000. 
[115] M. Schmidt, et al., "A review of the effects of insulin-like growth factor and platelet 
derived growth factor on  in-vivo cartilage healing and repair," Osteoarthritis and 
cartilage, vol. 14, pp. 403-412, 2006. 
[116] Y. Zhang, et al., "A platelet-derived growth factor releasing chitosan/coral composite 
scaffold for periodontal tissue engineering," Biomaterials, vol. 28, pp. 1515-1522, 
2007. 
[117] P. Yilgor, et al., "Effect of scaffold architecture and BMP-2/BMP-7 delivery on in 
vitro bone regeneration," Journal of Materials Science: Materials in Medicine, vol. 
21, pp. 2999-3008, 2010. 
[118] C. Kaps, et al., "Bone morphogenetic proteins promote cartilage differentiation and 
protect engineered artificial cartilage from fibroblast invasion and destruction," 
Arthritis & Rheumatism, vol. 46, pp. 149-162, 2002. 
[119] B. Chuenjitkuntaworn, et al., "Polycaprolactone/hydroxyapatite composite scaffolds: 
preparation, characterization, and in vitro and in vivo biological responses of human 
primary bone cells," Journal of Biomedical Materials Research Part A, vol. 94, pp. 
241-251, 2010. 
[120] H. Zhou and J. Lee, "Nanoscale hydroxyapatite particles for bone tissue engineering," 
Acta Biomaterialia, vol. 7, pp. 2769-2781, 2011. 
[121] Q. Fu, et al., "Bioactive glass scaffolds for bone tissue engineering: state of the art and 
future perspectives," Materials Science and Engineering: C, vol. 31, pp. 1245-1256, 
2011. 
[122] L. McIntosh, et al., "Impact of bone geometry on effective properties of bone 
scaffolds," Acta Biomaterialia, vol. 5, pp. 680-692, 2009. 
[123] M. M. E. Gomes, "A bone tissue engineering strategy based on starch scaffolds and 
bone marrow cells cultured in a flow perfusion bioreactor," Universidade do Minho, 
2004. 
[124] T. W. Lin, et al., "Biomechanics of tendon injury and repair," Journal of 
biomechanics, vol. 37, pp. 865-877, 2004. 
[125] S. Sangadji and E. Schlangen, "Mimicking Bone Healing Process to Self Repair 
Concrete Structure Novel Approach Using Porous Network Concrete," Procedia 
Engineering, vol. 54, pp. 315-326, 2013. 
[126] E. Margallo Balbás, "Optical techniques for the study of living tissue," 2010. 
[127] A. Subramanian and H. Y. Lin, "Crosslinked chitosan: its physical properties and the 
effects of matrix stiffness on chondrocyte cell morphology and proliferation," Journal 
of Biomedical Materials Research Part A, vol. 75, pp. 742-753, 2005. 
[128] T. Jiang, et al., "In vitro evaluation of chitosan/poly (lactic acid-glycolic acid) sintered 
microsphere scaffolds for bone tissue engineering," Biomaterials, vol. 27, pp. 4894-
4903, 2006. 
[129] N.-C. Cheng, et al., "Genipin-crosslinked cartilage-derived matrix as a scaffold for 
human adipose-derived stem cell chondrogenesis," Tissue Engineering Part A, vol. 19, 
pp. 484-496, 2012. 
[130] G. Wang, et al., "In vitro assessment of the differentiation potential of bone marrow-
derived mesenchymal stem cells on genipin-chitosan conjugation scaffold with surface 
hydroxyapatite nanostructure for bone tissue engineering," Tissue Engineering Part A, 
vol. 17, pp. 1341-1349, 2011. 
[131] Y. Yamada, et al., "Bone regeneration following injection of mesenchymal stem cells 
and fibrin glue with a biodegradable scaffold," Journal of Cranio-Maxillofacial 
Surgery, vol. 31, pp. 27-33, 2003. 
 References 
    
152 
 
[132] M. Saccone and A. K. Jain, "Fracture healing in India: Available therapies, 
indications, and protocols," Indian journal of orthopaedics, vol. 43, p. 175, 2009. 
[133] G. Gururaj, "Injuries in India: A national perspective," Burden of disease in India. 
National Commission on Macroeconomics & Health. Ministry of Health & Family 
Welfare. Government of India, 2005a, pp. 325-347, 2005. 
[134] K. Whang, et al., "Ectopic bone formation via rhBMP‐2 delivery from porous 
bioabsorbable polymer scaffolds," Journal of biomedical materials research, vol. 42, 
pp. 491-499, 1998. 
[135] J. E. Babensee, et al., "Host response to tissue engineered devices," Advanced drug 
delivery reviews, vol. 33, pp. 111-139, 1998. 
[136] M. B. Murphy, et al., "Engineering a better way to heal broken bones," Chemical 
engineering progress, vol. 106, pp. 37-43, 2010. 
[137] L. Y. Z. F. Z. Huiyong, "review on techniques of design and manufacturing for bone 
tissue engineering scaffold," Biomedical Engineering, 2009. 
[138] K. Rezwan, et al., "Biodegradable and bioactive porous polymer/inorganic composite 
scaffolds for bone tissue engineering," Biomaterials, vol. 27, pp. 3413-3431, 2006. 
[139] X. Wang, et al., "Silk nanospheres and microspheres from silk/pva blend films for 
drug delivery," Biomaterials, vol. 31, pp. 1025-1035, 2010. 
[140] M. K. Sah and K. Pramanik, "Soluble‐eggshell‐membrane‐protein‐modified porous 
silk fibroin scaffolds with enhanced cell adhesion and proliferation properties," 
Journal of Applied Polymer Science, vol. 131, 2014. 
[141] B. Stevens, et al., "A review of materials, fabrication methods, and strategies used to 
enhance bone regeneration in engineered bone tissues," Journal of Biomedical 
Materials Research Part B: Applied Biomaterials, vol. 85, pp. 573-582, 2008. 
[142] F. Pati, et al., "Collagen Intermingled Chitosan-Tripolyphosphate Nano/Micro Fibrous 
Scaffolds for Tissue-Engineering Application," Journal of Biomaterials Science, 
Polymer Edition, vol. 23, pp. 1923-1938, 2012. 
[143] B. C. Cho, et al., "The role of hyaluronic acid, chitosan, and calcium sulfate and their 
combined effect on early bony consolidation in distraction osteogenesis of a canine 
model," Journal of Craniofacial Surgery, vol. 13, pp. 783-793, 2002. 
[144] E.-J. Lee, et al., "Membrane of hybrid chitosan–silica xerogel for guided bone 
regeneration," Biomaterials, vol. 30, pp. 743-750, 2009. 
[145] M. E. Frohbergh, et al., "Electrospun hydroxyapatite-containing chitosan nanofibers 
crosslinked with genipin for bone tissue engineering," Biomaterials, vol. 33, pp. 9167-
9178, 2012. 
[146] S. S. Silva, et al., "Novel genipin-cross-linked chitosan/silk fibroin sponges for 
cartilage engineering strategies," Biomacromolecules, vol. 9, pp. 2764-2774, 2008. 
[147] S.-S. Kim, et al., "Poly (lactide-co-glycolide)/hydroxyapatite composite scaffolds for 
bone tissue engineering," Biomaterials, vol. 27, pp. 1399-1409, 2006. 
[148] H. H. Xu and C. G. Simon Jr, "Fast setting calcium phosphate–chitosan scaffold: 
mechanical properties and biocompatibility," Biomaterials, vol. 26, pp. 1337-1348, 
2005. 
[149] P. Weimin, et al., "Tendon-to-bone healing using an injectable calcium phosphate 
cement combined with bone xenograft/BMP composite," Biomaterials, vol. 34, pp. 
9926-9936, 2013. 
[150] S. Bose and S. Tarafder, "Calcium phosphate ceramic systems in growth factor and 
drug delivery for bone tissue engineering: a review," Acta Biomaterialia, vol. 8, pp. 
1401-1421, 2012. 
 References 
    
153 
 
[151] Y. Liu, et al., "Influence of calcium phosphate crystal assemblies on the proliferation 
and osteogenic gene expression of rat bone marrow stromal cells," Biomaterials, vol. 
28, pp. 1393-1403, 2007. 
[152] P. Wongwitwichot, et al., "Comparison of TCP and TCP/HA hybrid scaffolds for 
osteoconductive activity," The open biomedical engineering journal, vol. 4, p. 279, 
2010. 
[153] L. Zhang and T. J. Webster, "Nanotechnology and nanomaterials: promises for 
improved tissue regeneration," Nano Today, vol. 4, pp. 66-80, 2009. 
[154] A. Sendemir‐Urkmez and R. D. Jamison, "The addition of biphasic calcium phosphate 
to porous chitosan scaffolds enhances bone tissue development in vitro," Journal of 
Biomedical Materials Research Part A, vol. 81, pp. 624-633, 2007. 
[155] W.-B. Tsai, et al., "Fabrication of UV-crosslinked chitosan scaffolds with conjugation 
of RGD peptides for bone tissue engineering," Carbohydrate polymers, vol. 85, pp. 
129-137, 2011. 
[156] Y.-Y. Wang, et al., "Introducing RGD peptides on PHBV films through PEG-
containing cross-linkers to improve the biocompatibility," Biomacromolecules, vol. 
12, pp. 551-559, 2011. 
[157] H. Zhou, et al., "Enhanced bioactivity of bone morphogenetic protein-2 with low dose 
of 2 N, 6-sulfated chitosan in vitro andin vivo," Biomaterials, vol. 30, pp. 1715-1724, 
2009. 
[158] F. M. Shaikh, et al., "Fibrin: a natural biodegradable scaffold in vascular tissue 
engineering," Cells Tissues Organs, vol. 188, pp. 333-346, 2008. 
[159] L. He, et al., "A comparative study of platelet-rich fibrin (PRF) and platelet-rich 
plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in 
vitro," Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and 
Endodontology, vol. 108, pp. 707-713, 2009. 
[160] R. J. Gray, et al., "Percutaneous fibrin sheath stripping versus transcatheter urokinase 
infusion for malfunctioning wellpositioned tunneled central venous dialysis catheters: 
a prospective, randomized trial," Journal of Vascular and Interventional Radiology, 
vol. 11, pp. 1121-1129, 2000. 
[161] S. S. Tholpady, et al., "Repair of an Osseous Facial Critical‐Size Defect Using 
Augmented Fibrin Sealant," The Laryngoscope, vol. 109, pp. 1585-1588, 1999. 
[162] Q. Z. Chen, et al., "45S5 Bioglass®derived glass–ceramic scaffolds for bone tissue 
engineering," Biomaterials, vol. 27, pp. 2414-2425, 2006. 
[163] L. Luca, et al., "Injectable rhBMP‐2‐loaded chitosan hydrogel composite: 
Osteoinduction at ectopic site and in segmental long bone defect," Journal of 
Biomedical Materials Research Part A, vol. 96, pp. 66-74, 2011. 
[164] T. Majima, et al., "Alginate and chitosan polyion complex hybrid fibers for scaffolds 
in ligament and tendon tissue engineering," Journal of Orthopaedic Science, vol. 10, 
pp. 302-307, 2005. 
[165] Y. Lin, et al., "Ectopic and in situ bone formation of adipose tissue‐derived stromal 
cells in biphasic calcium phosphate nanocomposite," Journal of Biomedical Materials 
Research Part A, vol. 81, pp. 900-910, 2007. 
[166] S. P. Tsai, et al., "Preparation and cell compatibility evaluation of chitosan/collagen 
composite scaffolds using amino acids as crosslinking bridges," Journal of applied 
polymer science, vol. 105, pp. 1774-1785, 2007. 
[167] D. L. Nettles, et al., "Potential use of chitosan as a cell scaffold material for cartilage 
tissue engineering," Tissue engineering, vol. 8, pp. 1009-1016, 2002. 
 References 
    
154 
 
[168] P. Bagnaninchi, et al., "Chitosan microchannel scaffolds for tendon tissue engineering 
characterized using optical coherence tomography," Tissue engineering, vol. 13, pp. 
323-331, 2007. 
[169] I. Adekogbe and A. Ghanem, "Fabrication and characterization of DTBP-crosslinked 
chitosan scaffolds for skin tissue engineering," Biomaterials, vol. 26, pp. 7241-7250, 
2005. 
[170] T. Funakoshi, et al., "Novel chitosan‐based hyaluronan hybrid polymer fibers as a 
scaffold in ligament tissue engineering," Journal of Biomedical Materials Research 
Part A, vol. 74, pp. 338-346, 2005. 
[171] Y. Zhou, et al., "Electrospun water-soluble carboxyethyl chitosan/poly (vinyl alcohol) 
nanofibrous membrane as potential wound dressing for skin regeneration," 
Biomacromolecules, vol. 9, pp. 349-354, 2007. 
[172] K. Tuzlakoglu and R. Reis, "Formation of bone-like apatite layer on chitosan fiber 
mesh scaffolds by a biomimetic spraying process," Journal of Materials Science: 
Materials in Medicine, vol. 18, pp. 1279-1286, 2007. 
[173] H. Wang, et al., "Biocompatibility and osteogenesis of biomimetic nano-
hydroxyapatite/polyamide composite scaffolds for bone tissue engineering," 
Biomaterials, vol. 28, pp. 3338-3348, 2007. 
[174] J. L. Drury and D. J. Mooney, "Hydrogels for tissue engineering: scaffold design 
variables and applications," Biomaterials, vol. 24, pp. 4337-4351, 2003. 
[175] E. B. Denkbaş, et al., "Norfloxacin-loaded chitosan sponges as wound dressing 
material," Journal of biomaterials applications, vol. 18, pp. 291-303, 2004. 
[176] Y.-J. Seol, et al., "Chitosan sponges as tissue engineering scaffolds for bone 
formation," Biotechnology letters, vol. 26, pp. 1037-1041, 2004. 
[177] M. Krampera, et al., "Mesenchymal stem cells for bone, cartilage, tendon and skeletal 
muscle repair," Bone, vol. 39, pp. 678-683, 2006. 
[178] P. Malafaya, et al., "Chitosan particles agglomerated scaffolds for cartilage and 
osteochondral tissue engineering approaches with adipose tissue derived stem cells," 
Journal of Materials Science: Materials in Medicine, vol. 16, pp. 1077-1085, 2005. 
[179] C.-T. Liao and M.H. Ho, "The fabrication of biomimetic chitosan scaffolds by using 
SBF treatment with different crosslinking agents," Membranes, vol. 1, pp. 3-12, 2010. 
[180] L. Ma, et al., "Collagen/chitosan porous scaffolds with improved biostability for skin 
tissue engineering," Biomaterials, vol. 24, pp. 4833-4841, 2003. 
[181] A. C. Akman, et al., "bFGF‐loaded HA‐chitosan: A promising scaffold for periodontal 
tissue engineering," Journal of Biomedical Materials Research Part A, vol. 92, pp. 
953-962, 2010. 
[182] J. Lu, et al., "Role of interconnections in porous bioceramics on bone recolonization in 
vitro and in vivo," Journal of Materials Science: Materials in Medicine, vol. 10, pp. 
111-120, 1999. 
[183] P. J. VandeVord, et al., "Evaluation of the biocompatibility of a chitosan scaffold in 
mice," Journal of biomedical materials research, vol. 59, pp. 585-590, 2002. 
[184] Z. Zheng, et al., "The behavior of MC3T3‐E1 cells on chitosan/poly‐L‐lysine 
composite films: Effect of nanotopography, surface chemistry, and wettability," 
Journal of Biomedical Materials Research Part A, vol. 89, pp. 453-465, 2009. 
[185] K.-A. Kwak, et al., "Bio-functionalization of polycaprolactone infiltrated BCP 
scaffold with silicon and fibronectin enhances osteoblast activity in-vitro," Applied 
Surface Science, vol. 279, pp. 13-22, 2013. 
 References 
    
155 
 
[186] H. Jiankang, et al., "Preparation of chitosan–gelatin hybrid scaffolds with well-
organized microstructures for hepatic tissue engineering," Acta Biomaterialia, vol. 5, 
pp. 453-461, 2009. 
[187] T. Masuko, et al., "Chitosan–RGDSGGC conjugate as a scaffold material for 
musculoskeletal tissue engineering," Biomaterials, vol. 26, pp. 5339-5347, 2005. 
[188] X. Shao and C. J. Hunter, "Developing an alginate/chitosan hybrid fiber scaffold for 
annulus fibrosus cells," Journal of Biomedical Materials Research Part A, vol. 82, pp. 
701-710, 2007. 
[189] L. Zhao, et al., "Preparation and HL-7702 cell functionality of titania/chitosan 
composite scaffolds," Journal of Materials Science: Materials in Medicine, vol. 20, 
pp. 949-957, 2009. 
[190] C.-m. Han, et al., "Application of collagen-chitosan/fibrin glue asymmetric scaffolds 
in skin tissue engineering," Journal of Zhejiang University SCIENCE B, vol. 11, pp. 
524-530, 2010. 
[191] L. Bi, et al., "Effects of different cross-linking conditions on the properties of genipin-
cross-linked chitosan/collagen scaffolds for cartilage tissue engineering," Journal of 
Materials Science: Materials in Medicine, vol. 22, pp. 51-62, 2011. 
[192] T. Gamboa-Martínez, et al., "Fibrin coating on poly (L-lactide) scaffolds for tissue 
engineering," Journal of Bioactive and Compatible Polymers, vol. 26, pp. 464-477, 
2011. 
[193] C. Bhattacharya, et al., "Development of span 80–tween 80 based fluid-filled 
organogels as a matrix for drug delivery," Journal of pharmacy & bioallied sciences, 
vol. 4, p. 155, 2012. 
[194] H. Zhao, et al., "Fabrication and properties of injectable β-tricalcium phosphate 
particles/fibrin gel composite scaffolds for bone tissue engineering," Materials Science 
and Engineering: C, vol. 29, pp. 836-842, 2009. 
[195] T. Kokubo and H. Takadama, "How useful is SBF in predicting in vivo bone 
bioactivity?," Biomaterials, vol. 27, pp. 2907-2915, 2006. 
[196] I. J. Fuss, et al., "Isolation of whole mononuclear cells from peripheral blood and cord 
blood," Current protocols in immunology, pp. 7.1. 1-7.1. 8, 2009. 
[197] A. Bissoyi and K. Pramanik, "Effects of Non-Toxic Cryoprotective Agents on the 
Viability of Cord Blood Derived MNCs," CryoLetters, vol. 34, pp. 453-465, 2013. 
[198] N. Bhardwaj, et al., "Potential of 3-D tissue constructs engineered from bovine 
chondrocytes/silk fibroin-chitosan for in vitro cartilage tissue engineering," 
Biomaterials, vol. 32, pp. 5773-5781, 2011. 
[199] D. Singh, et al., "Proliferation of myoblast skeletal cells on three-dimensional 
supermacroporous cryogels," International journal of biological sciences, vol. 6, p. 
371, 2010. 
[200] D. Singh, et al., "Proliferation of myoblast skeletal cells on three-dimensional 
supermacroporous cryogels," Int J Biol Sci, vol. 6, pp. 371-381, 2010. 
[201] W. Xu, et al., "Material properties and osteogenic differentiation of marrow stromal 
cells on fiber-reinforced laminated hydrogel nanocomposites," Acta Biomaterialia, 
vol. 6, pp. 1992-2002, 2010. 
[202] J. Qiu, et al., "In vitro investigation on the biodegradability and biocompatibility of 
genipin cross-linked porcine acellular dermal matrix with intrinsic fluorescence," ACS 
applied materials & interfaces, vol. 5, pp. 344-350, 2012. 
[203] C. A. Gregory, et al., "An Alizarin red-based assay of mineralization by adherent cells 
in culture: comparison with cetylpyridinium chloride extraction," Analytical 
biochemistry, vol. 329, pp. 77-84, 2004. 
 References 
    
156 
 
[204] J. De Jong, et al., "Dimethylmethylene blue-based spectrophotometry of 
glycosaminoglycans in untreated urine: a rapid screening procedure for 
mucopolysaccharidoses," Clinical chemistry, vol. 35, pp. 1472-1477, 1989. 
[205] M. Marone, et al., "Semiquantitative RT-PCR analysis to assess the expression levels 
of multiple transcripts from the same sample," Biological procedures online, vol. 3, 
pp. 19-25, 2001. 
[206] J. Eyckmans and F. P. Luyten, "Species specificity of ectopic bone formation using 
periosteum-derived mesenchymal progenitor cells," Tissue engineering, vol. 12, pp. 
2203-2213, 2006. 
[207] S. Otsuru, et al., "Bone marrow-derived osteoblast progenitor cells in circulating 
blood contribute to ectopic bone formation in mice," Biochemical and biophysical 
research communications, vol. 354, pp. 453-458, 2007. 
[208] C. Trojani, et al., "Ectopic bone formation using an injectable biphasic calcium 
phosphate/Si-HPMC hydrogel composite loaded with undifferentiated bone marrow 
stromal cells," Biomaterials, vol. 27, pp. 3256-3264, 2006. 
[209] L. S. Nair and C. T. Laurencin, "Biodegradable polymers as biomaterials," Progress in 
Polymer Science, vol. 32, pp. 762-798, 2007. 
[210] H. Orii, et al., "Beta-tricalcium phosphate (beta-TCP) graft combined with bone 
marrow stromal cells (MSCs) for posterolateral spine fusion," Journal of medical and 
dental sciences, vol. 52, p. 51, 2005. 
[211] M. Spataru, et al., "rheology of tricalcium phosphate (β-TCP) suspensions," Revue 
Roumaine de Chimie, vol. 53, pp. 955-959, 2008. 
[212] F. Causa, et al., "Poly‐ϵ‐caprolactone/hydroxyapatite composites for bone 
regeneration: In vitro characterization and human osteoblast response," Journal of 
Biomedical Materials Research Part A, vol. 76, pp. 151-162, 2006. 
[213] C. Chang, et al., "Fabrication and properties of chitin/hydroxyapatite hybrid hydrogels 
as scaffold nano-materials," Carbohydrate polymers, vol. 91, pp. 7-13, 2013. 
[214] J. S. Temenoff and A. G. Mikos, "Injectable biodegradable materials for orthopedic 
tissue engineering," Biomaterials, vol. 21, pp. 2405-2412, 2000. 
[215] V. Karageorgiou and D. Kaplan, "Porosity of 3D biomaterial scaffolds and 
osteogenesis," Biomaterials, vol. 26, pp. 5474-5491, 2005. 
[216] Y. Cao and B. Wang, "Biodegradation of silk biomaterials," International journal of 
molecular sciences, vol. 10, pp. 1514-1524, 2009. 
[217] C. G. Havens, et al., "Regulation of late G1/S phase transition and APCCdh1 by 
reactive oxygen species," Molecular and cellular biology, vol. 26, pp. 4701-4711, 
2006. 
[218] B. M. Chesnutt, et al., "Design and characterization of a novel 
chitosan/nanocrystalline calcium phosphate composite scaffold for bone regeneration," 
Journal of Biomedical Materials Research Part A, vol. 88, pp. 491-502, 2009. 
[219] S. Chatterjee, et al., "Cryopreservation alters membrane sulfhydryl status of bull 
spermatozoa: protection by oxidized glutathione," Molecular reproduction and 
development, vol. 60, pp. 498-506, 2001. 
[220] W.-J. Li, et al., "Multilineage differentiation of human mesenchymal stem cells in a 
three-dimensional nanofibrous scaffold," Biomaterials, vol. 26, pp. 5158-5166, 2005. 
[221] X. He, et al., "Combined effect of osteopontin and BMP-2 derived peptides grafted to 
an adhesive hydrogel on osteogenic and vasculogenic differentiation of marrow 
stromal cells," Langmuir, vol. 28, pp. 5387-5397, 2012. 
[222] C. Perka, et al., "Segmental bone repair by tissue-engineered periosteal cell transplants 
with bioresorbable fleece and fibrin scaffolds in rabbits," Biomaterials, vol. 21, pp. 
1145-1153, 2000. 
 References 
    
157 
 
[223] T. Gamboa-Martínez, et al., "Fibrin coating on poly (L-lactide) scaffolds for tissue 
engineering," Journal of Bioactive and Compatible Polymers, p. 0883911511419834, 
2011. 
[224] M. Rafat, et al., "PEG-stabilized carbodiimide crosslinked collagen–chitosan 
hydrogels for corneal tissue engineering," Biomaterials, vol. 29, pp. 3960-3972, 2008. 
[225] S.-N. Park, et al., "Characterization of porous collagen/hyaluronic acid scaffold 
modified by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide cross-linking," 
Biomaterials, vol. 23, pp. 1205-1212, 2002. 
[226] S.-M. Lien, et al., "Genipin-crosslinked gelatin scaffolds for articular cartilage tissue 
engineering with a novel crosslinking method," Materials Science and Engineering: 
C, vol. 28, pp. 36-43, 2008. 
[227] K. Madhumathi, et al., "Development of novel chitin/nanosilver composite scaffolds 
for wound dressing applications," Journal of Materials Science: Materials in 
Medicine, vol. 21, pp. 807-813, 2010. 
[228] R. Deepachitra, et al., "Osteo mineralization of fibrin-decorated graphene oxide," 
Carbon, vol. 56, pp. 64-76, 2013. 
[229] R. Landers, et al., "Rapid prototyping of scaffolds derived from thermoreversible 
hydrogels and tailored for applications in tissue engineering," Biomaterials, vol. 23, 
pp. 4437-4447, 2002. 
[230] T. A. Ahmed, et al., "Characterization and inhibition of fibrin hydrogel-degrading 
enzymes during development of tissue engineering scaffolds," Tissue engineering, vol. 
13, pp. 1469-1477, 2007. 
[231] M. Sarem, et al., "How can genipin assist gelatin/carbohydrate chitosan scaffolds to 
act as replacements of load-bearing soft tissues?," Carbohydrate polymers, vol. 93, pp. 
635-643, 2013. 
[232] D. Le Nihouannen, et al., "Micro-architecture of calcium phosphate granules and 
fibrin glue composites for bone tissue engineering," Biomaterials, vol. 27, pp. 2716-
2722, 2006. 
[233] S.-R. Son, et al., "In vitro and in vivo evaluation of electrospun PCL/PMMA fibrous 
scaffolds for bone regeneration," Science and Technology of Advanced Materials, vol. 
14, p. 015009, 2013. 
[234] G. Diogo, et al., "Manufacture of β-TCP/alginate scaffolds through a Fab@ home 
model for application in bone tissue engineering," Biofabrication, vol. 6, p. 025001, 
2014. 
[235] S.-W. Kang, et al., "Surface modification with fibrin/hyaluronic acid hydrogel on 
solid-free form-based scaffolds followed by BMP-2 loading to enhance bone 
regeneration," Bone, vol. 48, pp. 298-306, 2011. 
[236] Y. Liu, et al., "Segmental bone regeneration using an rhBMP-2-loaded 
gelatin/nanohydroxyapatite/fibrin scaffold in a rabbit model," Biomaterials, vol. 30, 
pp. 6276-6285, 2009. 
[237] Q. Liu, et al., "A comparative study of proliferation and osteogenic differentiation of 
adipose-derived stem cells on akermanite and β-TCP ceramics," Biomaterials, vol. 29, 
pp. 4792-4799, 2008. 
[238] H. W. Sung, et al., "Crosslinking of biological tissues using genipin and/or 
carbodiimide," Journal of Biomedical Materials Research Part A, vol. 64, pp. 427-
438, 2003. 
[239] H. W. Sung, et al., "Stability of a biological tissue fixed with a naturally occurring 
crosslinking agent (genipin)," Journal of biomedical materials research, vol. 55, pp. 
538-546, 2001. 
 References 
    
158 
 
[240] F.-M. Hsieh, et al., "Study of sodium tripolyphosphate-crosslinked chitosan beads 
entrapped with Pseudomonas putida for phenol degradation," Process Biochemistry, 
vol. 43, pp. 83-92, 2008. 
[241] F. Pati, et al., "Development of chitosan–tripolyphosphate fibers through pH 
dependent ionotropic gelation," Carbohydrate research, vol. 346, pp. 2582-2588, 
2011. 
[242] Y.-L. Si, et al., "MSCs: biological characteristics, clinical applications and their 
outstanding concerns," Ageing research reviews, vol. 10, pp. 93-103, 2011. 
[243] L. P. Yan, et al., "Genipin‐cross‐linked collagen/chitosan biomimetic scaffolds for 
articular cartilage tissue engineering applications," Journal of Biomedical Materials 
Research Part A, vol. 95, pp. 465-475, 2010. 
[244] B. Rai, et al., "Differences betweenin vitro viability and differentiation and in vivo 
bone-forming efficacy of human mesenchymal stem cells cultured on PCL–TCP 
scaffolds," Biomaterials, vol. 31, pp. 7960-7970, 2010. 
[245] R. L. Steward, et al., "Mechanical stretch and shear flow induced reorganization and 
recruitment of fibronectin in fibroblasts," Scientific reports, vol. 1, 2011. 
[246] X. He, et al., "Effect of grafting RGD and BMP-2 protein-derived peptides to a 
hydrogel substrate on osteogenic differentiation of marrow stromal cells," Langmuir, 
vol. 24, pp. 12508-12516, 2008. 
[247] P. de la Puente and D. Ludeña, "Cell culture in autologous fibrin scaffolds for 
applications in tissue engineering," Experimental cell research, 2013. 
[248] K.-H. Choi, et al., "The chondrogenic differentiation of mesenchymal stem cells on an 
extracellular matrix scaffold derived from porcine chondrocytes," Biomaterials, vol. 
31, pp. 5355-5365, 2010. 
[249] J. M. Grasman, et al., "Crosslinking strategies facilitate tunable structural properties of 
fibrin microthreads," Acta biomaterialia, vol. 8, pp. 4020-4030, 2012. 
[250]  K. H. Gudmundasson, et al., "An experimental investigation into the off-statae 
viscosity of MR Fluids," procedings of 12
th
 International conference on Electro 
Rheological fluids and Magneto rheological suspensions, pp. 679-690, 2011. 
 [251]  S. Moeinzadeh, et.al., "Experimental and Computational Investigation of the Effect of 
Hydrophobicity on Aggregation and Osteoinductive Potential of BMP-2-Derived 
Peptide in a Hydrogel Matrix" . Tissue Engineering Part A, 2014.  
 [252] Zhang, et.al, "Three‐dimensional macroporous calcium phosphate bioceramics with 
nested chitosan sponges for load‐bearing bone implants." Journal of biomedical 
materials research Vol 61, pp. 1-8 2002. 
[253]  Y. Shu, et al. "Synthesis and sintering of nanocrystalline hydroxyapatite powders by 
gelatin-based precipitation method." Ceramics international Vol. 33.  pp. 193-196, 
(2007). 
[254]  W.Christian, et al. "Hydrogel-β-TCP scaffolds and stem cells for tissue engineering 
bone." Bone Vol. 4, pp. 555-563, 2006. 
[255]  Lindahl, et.al. "Mechanical property of dried defatted spongy bone" Acta Orthopaedica 
stand. Vol 47 (1); pp. 11-19, 1976. 
 
 
 
